Dr. Zhigang Tian’s laboratory is credited with seminal discoveries regarding basic knowledge of natural killer (NK) cells and NK cell-based immunotherapy. In 2008 and 2019, he won National Natural Science Award, and in 2011, he won National Scientific and Technological Progress Award. Since the outstanding contributions in the field of NK cell research, Dr. Tian was elected as a member of the Chinese Academy of Engineering in 2017 and a member of the Academia Europaea in 2022.
Dr. Tian is currently professor at University of Science and Technology of China (USTC) in Hefei, China, where he also served as a Deputy Director of the Academic Committee of USTC, Director of Institute of Immunology, Director of The Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science (CAS), and President of the Institute of Health and Medicine, Hefei Comprehensive National Science Center.
Dr. Tian is the former President of Chinese Society of Immunology, and the former Council member of International Union of Immunological Societies (IUIS).

Dr. Ho is a Senior Investigator, the Deputy Chief of the Laboratory of Molecular Biology, the Head of the Antibody Therapy Section, and the Director of the Antibody Engineering Program at the National Cancer Institute (NCI), National Institutes of Health (NIH). He received his Ph.D. from the University of Illinois at Urbana-Champaign, where he generated anti-idiotypic antibodies as cocaine antagonists. He completed a postdoctoral fellowship at the NIH, where he engineered immunotoxins targeting CD22 and mesothelin for the treatment of B cell leukemias and mesothelioma. Dr. Ho has pioneered the generation of therapeutic antibodies that target cancer-associated heparan sulfate proteoglycans. A focus of his laboratory work is on the validation of cell surface glypicans such as GPC3, GPC2 and GPC1 as new therapeutic targets in cancer. This area of research ranges from investigation of the fundamental mechanisms by which glypicans regulate Wnt, Yap and other signaling molecules to the design of antibody-based cancer therapeutics. His laboratory also established mammalian cell surface display, developed rabbit monoclonal antibodies, and built shark and camel single domain antibody phage libraries as new tools to advance antibody engineering and drug discovery. The immune therapeutics such as CAR-T cells based on his research are being tested at clinical stages for treating liver cancer, neuroblastoma, mesothelioma and other cancers.
Dr. Ho is was elected to the Board of Directors for the Antibody Society and to the Board of Directors for the Foundation for Advanced Education in the Sciences (FAES). Dr. Ho received many awards including the Asian & Pacific Islander American Organization (APAO) Scientific Achievement Award, Dr. Francisco S. Sy Award for Excellence in Mentorship at HHS, NIH Deputy Director for Intramural Research (DDIR) Innovation Award, and NCI Director’s Innovation Award.

许田教授在1993到2018年历任耶鲁大学遗传学和神经生物学助理教授、副教授、终身教授、C.N.H. Long讲席教授，及耶鲁大学遗传学系副系主任、耶鲁大学校长顾问，1996-2018年历任复旦大学兼职教授、长江讲座教授、发育生物学研究所所长、国家发育与疾病国际合作研究中心主任。许田教授长期担任Cell、Annual Review of Genetics、Molecular CancerResearch、Integrative Biology、The International Journal of Biological Sciences等杂志编委，Disease Models and Mechanisms创刊编委。许田教授曾任华人生物学家协会主席，获美国优秀博士后奖(Whitney)、美国优秀青年科学家学者(Pew)、霍华德休斯研究员、结节性硬化症协会创新奖和杰出贡献奖、美国科学促进会成员(AAAS Fellow)等奖项。许田教授不仅是LAM、Drug Farm、Double Rainbow、FosunLead、GeCell等科技公司的创始人，也是CuraGen、Butterfly、Hyperfine、Quantum-Si等公司顾问。
From 1993 to 2018, Prof. Tian Xu served as an assistant professor, associate professor, tenured professor, CNH Long Chair Professor, associate dean of the Department of Genetics and Neurobiology and advisor to President at Yale University. From 1996 to 2018, Prof. Xu served as adjunct professor at Fudan University, Chair Professor of the Yangtze River, Director of the Institute of Developmental Biology, and Director of the International Cooperation Research Centre for National Development and Disease. Prof. Xu has been a long-term editorial board member of the magazines, Annual Review of Genetics, Molecular Cancer Research, Integrative Biology, The International Journal of Biological Sciences, and the editorial board of Disease Models and Mechanisms. He has served as chairman of Chinese Association of Biologists. He was awarded the American Outstanding Postdoctoral Award (Whitney), American Outstanding Young Scientists Scholar (Pew), Howard Hughes Fellow, Tuberculosis Sclerosis Association Innovation Award and Outstanding Contribution Award, and the American Association for the Advancement of Science (AAAS Fellow) and other awards. Prof. Xu is not only the founder of LAM, Drug Farm, Double Rainbow, Fosun Lead, GeCell and other technology companies, but also an advisor of companies such as CuraGen, Butterfly, Hyperfine, Quantum-Si, etc.

陈功教授是国家特聘专家，暨南大学粤港澳中枢神经再生研究院大脑修复中心主任。复旦大学毕业，中科院上海生理所神经生物学博士。美国耶鲁大学和斯坦福大学博士后。曾任宾夕法尼亚州立大学终身教授和冠名主任教授（Endowed Chair Professor， 讲席教授）。陈功教授领导的团队在国际上首次报导了用神经转录因子NeuroD1将大脑内源性星形胶质细胞原位高效地转化为功能性神经元这一里程碑工作，被干细胞顶尖杂志Cell Stem Cell评为2014年度最佳论文，为大脑修复开辟了全新的神经再生型基因疗法。2015年再次在Cell Stem Cell上发表小分子化合物诱导培养的人源胶质细胞高效转化为功能性神经元的工作，为开发利用脑内胶质细胞再生神经元的药物疗法奠定了基础。2020年又在国际上首次发表灵长类大脑原位神经再生的里程碑工作。陈功教授有一百多项发明专利申请，已经获得国际范围内的45项专利授权，涵盖中国，美国，欧盟，日本等国家。陈功教授是NeuExcell 神曦集团的科学创始人。NeuExcell 致力于运用神经再生型基因疗法治疗神经损伤和退行性疾病。2021年，NeuExcell与罗氏制药旗下的Spark达成了1.9亿美金的合作协议，共同开发治疗亨廷顿舞蹈症的基因治疗药物。NeuExcell 在2022年被著名生物技术杂志GEN评选为亚洲5大极具潜力的基因治疗公司。

合源生物科技（天津）有限公司 CEO
临床医学博士学位（内科血液病学），在肿瘤生物科学研究、创新药研发与商业化领域拥有超过20年经验。
2018年参与创立合源生物并担任首席执行官。凭借对细胞基因前沿创新技术发展和创新药研发及商业化路径的深刻洞见，搭建了具有国际竞争力的多疾病领域的细胞治疗产品管线和专业团队，以临床价值为导，向带领公司稳步实现从细胞药物研发到商业化、并逐步实现全球化的战略布局，致力于将公司打造成为全球领先的专注于细胞基因领域的生物制药企业。
在吕璐璐博士的带领下，公司首个具有完全中国自主知识产权的核心产品，纳基奥仑赛注射液（CNCT19细胞注射液）获得国家药品监督管理局“突破性治疗药物”（2020）认定和美国FDA“孤儿药”（2022）认定，其新药上市申请（NDA）于2022年12月获得国家药品监督管理局正式受理并纳入优先审评，该产品是中国白血病治疗领域首个获得NDA受理并有望首个获批的CAR-T细胞治疗产品，也是有望首个获批的中国全自主研发的靶向CD19 CAR-T细胞治疗产品。
2007年以前，主要从事造血干细胞和间充质干细胞临床和科研工作。
2007年~2018年，在诺华、健赞、罗氏、阿斯利康和默沙东等跨国公司关键岗位任职，从事血液和肿瘤领域创新药物研发和产品商业化工作。

Dr. Bose Kalampanayil is Chief Technology Officer at Neurophth Therapeutics since 2019. Dr. Kalampanayil has over 20 years of experience in the biopharmaceutical industry, including CMC experience in cell and gene therapy and vaccine manufacturing. Most recent cell/gene therapy experience and consultations include, GMP Plasmid Productions, GMP Upstream and Downstream Productions for various AAVs (AAV2, 5, 6, 8 & 9). Served as a “Subject Matter Expert” in process engineering, process development and CDMO selection processes for GMP Manufacturing. Held management positions in several biotechnology companies and CDMOs in USA, including Vigene Biosciences, Therabron Therapeutics, AERAS, Iomai (Intercell) and Charles River Laboratories. Dr. Kalampanayil has a PhD in Biochemistry from University of Maryland and hold American Board certification in Clinical Chemistry.

张春博士毕业于美国佛罗里达大学，在世界腺相关病毒（AAV）载体，基因治疗奠基人的实验室工作学习多年，至今已有20年的AAV研究开发经历。目前，在中国科学院苏州生物医学工程技术研究所担任研究员，博士生导师。张春博士创立了苏州吉恒基因科技有限公司。近年来，重点研究创新了高效安全AAV载体包装生产，大基因AAV基因治疗，有效AAV基因编辑领域里的多个重要技术。张春博士聚焦解决AAV基因治疗的根本问题，立足AAV基因治疗的长期发展，努力将AAV载体发展成为人类健康长寿载体。
Dr. Zhang earned his Ph.D. from University of Florida. He was a faculty member in Dr. Berns’ lab and studied AAV gene therapy. Now, Dr. Zhang is a professor at Suzhou Institute of Biomedical Engineering and Technology, CAS. For 20 years, Dr. Zhang has focused on research and product development of rAAV vector, AAV gene therapy and AAV gene editing. Significant breakthroughs have been made and innovative rAAV technologies have been developed, which will greatly facilitate the success of AAV gene therapy. Dr. Zhang has a vision of developing AAV vector into a human health vector.

张雷博士于中科院生化细胞所获得博士学位后，前往瑞士的弗雷德里希.米歇尔生物医学研究所从事博士后研究工作，长期深耕于炎症反应，肿瘤新生血管生成，肿瘤形成的分子生物学机制；着重研究了淋巴瘤和结肠癌过程中Hippo pathway的影响。
回国后，张雷博士一直致力于细胞治疗药物的研究开发，主管了中国第一款获批上市的CAR-T药物：Yescarta ，“奕凯达”的技术转移落地，并主持了多项创新性实体瘤治疗CAR-T细胞的早期研发工作，申请了多项专利。目前，张雷博士就职于星奕昂生物科技有限公司，主管研发工作。

Founder of Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd
Director of the Institute of Biomedical Engineering and Technology at East China Normal University
Member of the Cell Therapy Professional Committee of China Research-oriented Society
· Medical: Graduated from Fudan University Medical School，6 years of experience as a cardiac surgeon at Zhongshan Hospital.
· Basic research: Ph.D., Department of Medical Microbiology and Immunology, University of Alberta, Canada, and Division of Pediatric Molecular Genetics Center, University of California, San Diego, studied gene therapy under Professor Theodore Friedmann, the father of American "gene therapy".
· Pharmaceutical: Formerly an associate professor of Pharmaceutical Chemistry and Pharmaceutical Sciences at the University of Utah, USA.
· Entrepreneurship: Co-founded Nisshin Electric Technical Corporation, a US-Japan joint venture, and served as Vice President.
· Academic: "Zijiang Distinguished Professor" of East China Normal University, set up pharmacy specialty, and set up biomedical engineering and technology research institute.
· Domestic Entrepreneurship: Established Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd, which is the leading enterprise of CAR-T technology innovation in China, and has successfully carried out CAR-T clinical research on more than 1,000 patients with hematological tumors and solid tumors.

Dr. Yuxuan Wu, Founder and CEO of YolTech Therapeutics, Professor at East China Normal University. Dr. Wu developed CRISPR/Cas9 based Gene Editing system in hematopoietic stem cells and led the first CRISPR/Cas9 Gene editing treatment for patients with β0/β0 thalassemia, achieving great clinical outcome with patients’ Long term recovery of hemoglobin (Published in Nature, Aug.2022). With more than ten years’ expertise and practice in Gene Editing, Dr. Wu founded YolTech Thepapeutics in 2021 in Shanghai, devoted to advancing in vivo Gene Therapy in treating patients suffering serious diseases with feasible therapeutic solutions.

Juventas Cell Therapy， CTO
Novartis, Global Quality Auditor
MSKCC, Quality & Operations Manager
Vivaldi Biosciences, GMP Production Manager
Hebrew University of Jerusalem, PhD
Cornell University and Iowa State University, Postdoc
15 years hands-on experiences in CAR-T cell therapy，including clinical research & development, GMP manufacturing, vein-to-vein quality management, product launch & commercialization.

2003-2004 新加坡生物医药公司 新加坡 研究助理
从事小分子抗癌药物研发，参与发表美国专利一项
SBIO Pte. Ltd., Singapore, Research Associate
Focusing on novel anti-cancer drug R&D, and published one US patent as one of the six inventors.
2007-2015 北京科兴生物制品有限公司 中国 质量总监
全面负责QA和QC工作；引进了质量风险管理、CAPA、变更等质量管理工具；重建了公司的确认和验证体系；
参与了新疫苗生产基地的设计、建设、验证等全部工作；在无菌工艺环节引进了一次性系统；先后多次通过墨西哥、土耳其、WHO等国家的GMP认证；多次配合国家局迎接WHO的GMP检查；将GMP体系逐渐扩展为QMS体系。
Sinovac Biotech Ltd., China, Quality director
In charge of both QA and QC departments. Set-up several quality management tools, such as QRM, CAPA, change control. Reconstructed the qualification and validation system. Engaged in design, construction and qualification of new vaccine production site. Introduced single-use technology into the aseptic process. Obtained different international GMP certifications, including Mexico and Turkey. Passed WHO GMP mock-up inspection several times.
Expanded the GMP system to QMS, which includes GLP, GCP, GSP and GVP and covers the whole life cycle of vaccines.
2015-2017 独立顾问
为制药及诊断试剂企业提供欧盟水平的咨询服务，主要涵盖厂房设计、确认 与验证、质量管理体系搭建、GMP相关培训等。
Independent Consultant
Provide consultant services to pharmaceutical companies, including facility design, qualification & validation, quality management system, GMP trainings, etc.
2017.4-今 北京市食品药品监督管理局认证中心 中国 外聘GMP专家
为北京局认证中心提供GMP咨询服务，培训北京局GMP检查员等。
Provide GMP consultant service to Beijing CFDA, and training GMP inspectors from Beijing CFDA.
2017.6-今 南京驯鹿医疗技术有限公司 董事、CMC VP
为公司CAR-T产品提供厂房设计、药学研究、注册申报等提供顾问服务。
Nanjing IASO Biotherapeutics Co., Ltd. Director of Board, Consultant Support to facility design, CMC, registration, etc. for CAR-T pipelines.

• 2020 to Present: UTC Therapeutics Inc., Co-founder, Chairman and Chief Scientific Officer
• From 2009 to 2019: Served as the director of the T cell engineering laboratory and an associate professor of the Department of Pathology at the Center for Cellular Immunotherapy at the University of Pennsylvania.
• Participated in the development and commercialization of Kymriah, the world's first CAR T cell product.
• led the research and development of RNA CART cell technology and carried out the world's first RNA CAR T cell treatment of cancer patients in 2010.
• led the R&D and process development of the world's first (US) regulatory-approved CRISPR gene editing clinical trial, and the clinical research results have been published in Science.
• Published more than 50 research papers, including in Science, Nature, Clinical Cancer Research, Molecular Therapy, Cancer Immunology Research, Protein Cell, Cancer Research and other journals.
• Filed More than 130 patents, ranking 7th in the global CAR T patent ranking according to the statistics of Nature Biotechnology in 2019.
• In 2015, co-founded Tmunity Therapeutics and was the founder of the company's core technology.
• From 2003 to 2008, As a Senior Research Fellow in Rosenberg Laboratory at National Cancer Institute (NCI), engaged in the research of TCR-T and CAR T. Guided and participated in the research and development of Yescarta CD19 CAR T. Published a total of 17 articles, 6 of which were the first author and participated in the research and development of 5 clinical trials.
• From 2000 to 2002, worked as a research assistant in the Department of Surgery of Duke University in the United States, and was engaged in tumor immunotherapy by RNA electroporation of dendritic cells.
• From 1996 to 2000, Worked at the Department of Immunology of the Weizmann Institute of Science in Israel as a postdoctoral researcher on bone marrow allograft transplant immune tolerance.
• In 1994, received a Ph.D. in Transplantation Immunology from the Third Military Medical University

Dr. Zhang Hongbing is an experienced scientist with over 20 years of expertise in drug research and development, particularly in the field of cancer immunotherapy. As the Vice President of Research at Eureka Therapeutics Inc., he oversees the company's antibody and cellular immunotherapy drug research and development, as well as strategic external R&D collaborations.
Throughout his career, Dr. Zhang has led the development of several macromolecular drugs and cell therapy drugs from early discovery to preclinical/translational product development and hold many international patents. He has worked in various biotechnology companies from start-up to publicly traded, including Xenogen Corporation, Chiron Corporation and Five Prime Therapeutics Inc. The macromolecular and cell therapy drug projects he has led have turned into strategic collaborations with large pharmaceutical companies for various start-up companies.
Dr. Zhang received his bachelor's degree from the Department of Biology (now the School of Life Sciences) of Peking University in 1988, and his Ph.D. in Molecular Genetics from Baylor College of Medicine, Texas, USA in 1995.

Dr. Wenbo Wang was trained in Shanghai Institute of Materia Medica, CAS as a master student and obtained his PhD degree from DKFZ (German cancer research center) and Heidelberg University in 2015. He worked as a postdoc. associate in the Jackson laboratory and the University of Pennsylvania. In Upenn, he worked under the supervision of Prof. Yangbing Zhao and Prof. Carl June studying novel TCRs, novel aAPCs model generation and T cell genome editing. He then joined National Research Center for Translational Medicine, Shanghai Ruijin Hospital as a Co-PI and led the study of combination therapy with TCR-T and NK cells and adverse effects of CAR-T cell therapy. In 2018, he joined Curegenetics as VP of translational medicine and led a group focusing on TCR engineering and novel CAR-T cell therapies. In 2021, he founded LeaLing Biopharma and serves as CEO. He has years of experiences in TCR based therapies and other cellular therapies. He invented fast cloning technologies of TCR full length which facilitates the R&D of personalized TCR-T and other TCR based therapies. He also filed over 20 patents focusing on novel TCRs and CARs, TCR cloning and sequencing, T cell engineering and other novel cellular therapies and published over 10 papers in famed biomedical journals.

周鹏辉，广州泛恩生物创始人、董事长，密西根大学免疫学博士，哈佛大学医学院博士后，中山大学肿瘤防治中心、华南肿瘤学国家重点实验室教授、博士生导师。入选国家“万人计划”领军人才、国家“海外高层次人才引进计划”、广东省“珠江人才计划”领军人才、广州市开发区“创业领军人才”。长期从事实体肿瘤免疫治疗药物开发与临床应用，鉴定了肿瘤微环境抑制T细胞的关键信号通路与基因，为逆转实体肿瘤微环境提供了高效的解决方案；发现了肿瘤抗原特异T细胞的分子标志物，建立了快速获取自体抗肿瘤T细胞与TCR的核心技术；多项专利转化为产品。开发了准确筛选免疫治疗有效患者的诊断试剂盒；研制了“个体化TCR-T细胞治疗”、“逆转实体肿瘤微环境的TCR-T细胞治疗”、“TAL-T细胞治疗”等新型免疫治疗方法与药物，进入了Ⅰ期临床试验。研究成果发表于Nature、Cell、Nature Medicine、Cell Research、JCI、PNAS等高水平国际学术期刊。

Dr Yi Li graduated from XiangYa School of Medicine, CSU and gained his Ph.D at University of Leicester, UK, has served as Chairman and CSO at TIOC therapeutics Ltd, Principle Investigator at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. Dr Li’s main research interest is immunotherapy, especially focus on optimizing T cell receptors and manipulating immune microenvironment for advanced therapeutic strategies. Represented studies of Dr Li were published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy and Immunology etc. Dr Li provided major contributions to the world first TCR based drug Kimmtrak approved by FDA, USA, and the first TCR-T IND TAEST16001 approved by NMPA, China.

韩研妍，博士，恒瑞源正生物科技有限公司 首席科学家
德国慕尼黑大学医学院人类生物学博士，慕尼黑工业大学肿瘤免疫学博士后，中欧EMBA。深圳市领军人才，深圳市孔雀计划人才。国家科技部重大专项，973重大项目的主要承担者，国家面上项目，深圳科创项目等产业项目的负责人。
恒瑞源正生物科技有限公司成立于2015年，是一家专注于实体瘤的免疫疗法的生物制药公司。恒瑞源正由恒瑞集团和深圳源正细胞合资成立，公司总部位于上海，在广州和深圳设有全资子公司，拥有研发中心和GMP级细胞制备车间，总面积近13000平方米。恒瑞源正已在中国、美国、日本和欧盟等国家或地区申请了多项发明专利并获得授权。公司拥有自主知识产权的实体瘤免疫细胞疗法 MASCT-I 已经完成了注册一期临床试验，目前已经进入注册二期临床试验阶段。该公司首款具有自主知识产权的TCR-T产品HRYZ-T101注射液已经向CDE提交IND申请并获得受理。

何霆 艺妙神州创始人兼CEO
何霆，清华大学生物学博士，高级职称，2015年创办北京艺妙神州医药科技有限公司，专注基因细胞药物的研制，坚持以“让癌症不再是绝症”为使命，从0到1打造一支一流的基因细胞药物研发团队，构建了领先的基因细胞药物一站式技术平台；带领团队取得了北京市首张 CAR-T 药品生产许可证，自主研发的1类抗肿瘤新药 IM19 CAR-T 细胞注射液，获得国家药监局颁发的3个临床试验批件，有望成为同类首款自主原研的CAR-T药物。艺妙神州获得多家知名投资机构青睐，累计完成9轮超10亿元的融资，股东包括中国人寿、中国太平、国投创业、龙门基金、中关村科学城基金、首钢基金、北创投、首都科技发展集团、同创伟业、夏尔巴投资、盛景嘉成、广发乾和等。
作为项目负责人，承担了国家科技部-重点研发计划专项、北京市科委-G20工程重大新药创制项目、北京市科委-医药创新品种及平台培育项目、北京市经信局-高精尖产业项目、北京市科技新星计划、中关村前沿企业支持项目和北京市科技型中小企业促进专项等政府科研项目。
曾获中关村高端领军人才、北京市科技新星、北京市海英人才、北京市雏鹰人才、北京市青年人才、麻省理工科技评论“35岁以下科技创新35人”、《财富》“中国40位40岁以下商界精英”、全国颠覆性技术创新大赛优胜奖、清华大学校长杯金奖等荣誉。
作为研发和技术带头人，获得30多项技术专利授权，自主研发整套基因细胞药物技术平台，支撑起多种主流基因细胞药物的创新开发；在国际学术期刊发表十数篇该领域的SCI研究论文，受邀出席多个国际顶尖学术和产业会议并做主题演讲，包括美国临床肿瘤学会年会（ASCO）、美国血液学会年会（ASH）、亚洲细胞疗法制造学会年会、CAR-TCR亚洲峰会等。

高晓飞博士是西湖生物医药科技（杭州）有限公司（Westlake Therapeutics，以下简称“西湖生物医药”）的创始人，于2017年回国加入西湖大学组建自己的团队，基于以填补国内未被满足临床需求为目标，并借助于在打造工程化红细胞药物技术平台REDx上取得的突破，高博士和创业团队于2019年1月创立了西湖生物医药，西湖生物医药专注于将在研阶段的创新红细胞疗法推向临床开发，产品布局以靶向免疫代谢、癌症治疗为主线，以提高患者生存及生活质量为目的，开发疗效显著且安全可靠价优的新药治疗方案。
高博士拥有20年以上在中国和美国顶尖科研院所从事学术科研及生物创新药研发的经验，且科研成果成功获得产业转化应用。高博士在美国堪萨斯大学获得博士学位、于美国麻省理工学院完成博士后研究。

浙江大学/第二军医大学医学免疫学国家重点实验室博士，讲师。十五年从事CAR-T、NK、TIL、DC、TCR-T等多种细胞肿瘤治疗从研发到临床的经验。曾负责中国首个CAR-T细胞治疗恶性血液肿瘤I/II期注册临床启动并推进至II期，同时负责推进三个CAR-T细胞治疗的注册临床及TCR-T及TIL细胞治疗实体瘤IIT临床研究。参与了中国首个获取CFDA批准的细胞治疗产品“抗原致敏的树突状细胞治疗转移性大肠癌”Ⅱ/Ⅲ期临床试验（2006 -2018）。在高企及CRO公司负责在整个细胞治疗临床试验周期前期研发，IND申报，医学研究、临床运营、及药物警戒等方面管理。作为主要负责人员参与科技部863重大专项 “细胞治疗关键技术及产品研发”主题项目、科技部重大新药创制“大肠癌树突状细胞治疗性疫苗的临床研究”、承担并参与多项国家自然科学基金、上海市科委重点攻关等多项与细胞免疫治疗肿瘤的项目研究。以第一作者在Biomaterials、 Cell Mol Immunol、J Biol Chem、Mol Ther. 等杂志发表多篇论文，申请免疫治疗相关专利多项。

Dr. Chen got his bachelor and Ph.D degrees from Wuhan University. He went on and did postdoctoral work on tumor immunotherapy at Duke University. Dr. Chen co-founded Hervor Therapeutics in 2021 as VP of R&D. Before that he was at TCRCure and led TCRCure US R&D department.
Dr. Chen has extensive experience in cell therapy drug development, he led the development of a global FIC CAR-T product for Ovarian and Endometrial Cancer, a FIC anti-PD1-armored TCR-T product and many other CGT platforms.

李志远，博士，高级工程师，毕业于中国科学院大学上海巴斯德研究所。曾先后在西比曼生物科技（上海）有限公司、信达生物（苏州）有限公司担任高级研发经理、功能生物学副总监等职务，现任普米斯生物功能生物学与细胞治疗总监。在免疫及细胞治疗领域拥有近15年的研究经验，在靶向CD19、CD20、BCMA、MSLN、CLDN 18.2等众多血液肿瘤与实体肿瘤相关靶点的细胞治疗产品开发方面拥有丰富经验。在信达生物工作期间，领导了细胞治疗相关项目抗BCMA全人源单链抗体筛选工作；目前，该项目相关CAR-T产品处于NDA阶段。入职普米斯后，领导开发了可应用于实体肿瘤临床治疗的CAB-T细胞治疗平台，基于此平台开发的多个细胞治疗产品已进入非注册临床研究（IIT）阶段。

Chelsie He, the Founder and CEO of Suzhou GenAssist, is an expert in drug discovery and a veteran in healthcare investment and incubation. Dr. He received her Ph.D degree in immunology, Shanghai Jiao Tong University and MBA from the Alian Manchester Business School. She has won Entrepreneurship Leading Talents of Suzhou Industrial Park and Gusu Talents. GenAssist is the first Chinese company dedicated to the development of base editing gene therapy drugs against rare diseases. Chelsie He is currently leading GenAssist to develop various first-in-class base editing gene therapy drugs. The first indication of Duchenne muscular dystrophy (DMD) has entered the IND enabling stage, which is currently the latest DMD base editor drug in the world. Dr. He has more than ten years’ experience in drug R&D and production, and eight years’ experience in Investment and Business Development. She served as the Managing Director in Fosun Innovation Center, Investment director in Sunshine Insurance Co., Ltd and Product Planning director in Tasly Group. By leveraging her expertise both in academia and industry, she successfully led more than 10 licensing deals and M&A projects.

Dr. Jingmin Zhou is the CEO & Co-Founder of Genemagic Biosciences, a startup focuses on neuro regeneration to cure patients with CNS diseases. Before he joined Genemagic, he served as Senior Director of Process & Analytical Development at Prevail therapeutics, a wholly Eli Lilly owned subsidiary, he also served different CMC roles at Axovant, Spark & Intrexon. With 17 years of CMC experience on AAV, he has contributed more than 10 approved INDs and 1 successful BLA (Luxturna) by FDA & EMA. Jingmin is a member of USP’s AAV Gene Therapy Expert Panel (2021-2025), responsible for developing best-practice guidelines on AAV vector design, manufacturing, quality control and regulatory considerations.

马一介博士是北海康成的高级总监，商务拓展和战略合作主管。他领导和管理公司的全球合作与交易。他同时还负责公司的基因疗法战略。他在生命科学领域的基础研究、创业、投资、战略咨询和商务拓展方面拥有超过 20 年的综合经验。此前，他曾在全球战略咨询公司 Trinity Life Sciences 工作，为各阶段生物制药企业，包括赛诺菲、强生、渤健、福泰制药等在内的世界财富 500 强公司提供战略咨询，并为价值从 5亿到 10 亿美元以上的投资和交易机会提供评估与建议。在此之前，他曾在波士顿的一家生物科技投资基金工作，并与他人共同创立了一家聚焦精准医疗的初创公司，并获得风险投资。他曾是病毒免疫学科学家，在美国伊利诺伊大学医学院完成了博士学位，并师从于国际著名病毒学家Elliott Kieff教授在哈佛大学医学院及布莱根和妇女医院完成了博士后研究。曾在Cell Host&Microbe、Cell Metabolism、美国国家科学院院刊等国际知名期刊发表科学论文30余篇，全球引用2000余次。
Dr. Yijie Ma is the Senior Director, Head of Business Development - Strategic Partnerships at CANbridge Pharmaceuticals, where he leads and manages global partnerships and transactions. He is also responsible for driving the gene therapy strategy of the company. He has more than 20 years of combined experiences in research, entrepreneurship, investing, strategy consulting and business development in the life sciences field. Previously, he worked at Trinity Life Sciences, a global life sciences strategy consulting firm, and provided strategic advice to clients ranging from startups to Fortune 500 biopharma companies across a wide range of therapeutic areas including Sanofi, Johnson & Johnson, Biogen, Vertex etc. He advised on investment and BD&licensing opportunities valued from $500M to $1B+ USD. Prior to that, he worked in a biotech investment fund in Boston and had co-founded a venture-backed precision medicine startup. He was trained as a viral immunologist and completed his PhD at the University of Illinois College of Medicine and postdoc research under the mentorship of Dr. Elliott Kieff, a world-renowned expert in Epstein-Barr virus, at the Harvard Medical School and Brigham and Women’s Hospital. He has authored more than 30 scientific publications in internationally renowned journals such as Cell Host&Microbe, Cell Metabolism, PNAS and so on with more than 2000 worldwide citations

Dr. Riguo Fang is currently the R&D Vice President at EdiGene. He is the leader of EdiGene’s stem cell platform. Dr. Fang holds a doctorate degree from Peking University and a bachelor’s degree from Shanghai Jiao Tong University; During his Ph.D. and post-doctoral studies, he studied under Professor Hongkui Deng, an internationally renowned stem cell expert. Dr. Fang is also a leading talent in Guangzhou and an Associate Researcher in the Beijing Municipal Nature Science Research Series. His research interests are in stem cell and regenerative medicine. Dr. Fang has nearly 15 years of experience in stem cell research and technology translation, with a cumulative publication impact factor of over 76 and more than 15 patent applications. His main focus is on stem cell and genetically-modified stem cell therapeutics development, stem cell biology study, iPSC generation and downstream differentiation.
As project leader of the company’s leading investigational therapy ET-01, Dr. Fang led the team to complete early-stage scientific research, process development and manufacturing as well as non-clinical safety and efficacy evaluation of ET-01, and successfully advanced the product into clinical stage. He is currently responsible for the strategy development, team management and project advancement of ET-01, including Research, CMC, regulatory affairs and clinical development.

赵春林 博士，安龙基金创始合伙人，安龙生物创始人，为清华大学生物系首届毕业生，获得美国匹兹堡医学院分子生物学博士和芝加哥大学工商管理硕士，曾任美国辉瑞制药资深经理，国科嘉和及康桥资本董事总经理，拥有三十多年生命科学及医疗健康领域的创业和投资经验，投资过信达生物，贝瑞合康，天镜生物，歌礼药业，莱凯医药，创响生物及国科恒泰等杰出企业。赵春林博士曾任清华大学生命科学院，医学院及药学院首届校友会主席，为百华协会资深会员。 安龙基金是一只专注于国内早期生命科学与医疗健康领域的基金，投资领域横跨生命科学，医药研发，医疗器械，医疗服务及相关领域。 安龙生物是国内核酸药物领先企业，专注基因治疗，RNA，基因编辑等核酸药物的新药研发。专业之外，赵春林博士喜欢足球，滑雪，曾做过DJ，拥有三个漂亮可爱的女儿。
Chunlin Zhao, Ph.D
Founder of the AnlongMed/AnlongBio. Dr. Zhao is among the first class graduated from Biological Science and Technology department at Tsinghua University in 1990. Then, he received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China, he founded Beijing LongMed biological technology co., LTD and then became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, GKHT and Imagine. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association of School of Life Sciences，School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading fund in Chinese life sciences and health care, focusing on biotech & pharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.

李斌 二级研究员、余㵑学者、上海交大特聘教授、国家基金委免疫学杰青、上海市领军人才、上海市优秀学科带头人，上海市免疫学研究所科研副所长&课题组长、中国细胞生物学学会常务理事、上海市欧美同学会生物医药分会会长、PENN Medicine China Club 副会长；European Journal of Immunology 执行副主编（2020）
主要研究方向：FOXP3+调节性T细胞及其临床应用。先后承担国家基金委杰出青年基金、重点项目（3项) 、移植免疫专项、中美及中波国际合作项目等；2009年回国以来，在国际一流学术刊物如 IMMUNITY、NAT IMMUNOL等发表FOXP3+Treg领域相关通讯及共同通讯作者论文一百余篇。
Bin Li, Ph.D. Yu He Scholar; Distinguished Professor of SJTU
Senior Investigator & Associate Director, Shanghai Institute of Immunology, Adjunct “Guangci” Professor, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University; President of the Biomedical Branch of the Shanghai Overseas Returned Scholars Association; Vice-President of PENN Medicine China Club;

沈海法博士是斯微（上海）生物科技股份有限公司的联合创始人，并担任该公司的CTO。沈海法博士具有丰富的学术界和工业界的经验。他于1997年在美国德克萨斯大学休斯敦安德森肿瘤中心研究生院获得博士学位，并于2001年在美国国立肿瘤研究院完成博士后训练，随后进入生物制药行业，投身于抗肿瘤新药的研发，并在工业界工作了8年。沈博士于2009年回到学术界，专注于新药设计和新型药物递送技术的研究，并担任美国康奈尔大学医学院教授和康奈尔大学医学院附属休斯敦卫理公会医院肿瘤中心转化医学首任主任。沈海法博士和他的小组发表了110多篇研究论文，其中多篇刊登在Nature 和Nature Biotechnology等杂志，并获得了10多项专利技术的申请和授权。

胡荣宽，星锐医药创始人、董事长兼首席执行官。胡博士在核酸技术和药物研发方面拥有十余年的经验。在创立星锐医药之前，曾任职于石药集团、吉玛生物、中科院和诺和诺德，领导和参与了多个mRNA及siRNA药物研发项目，助推了国产第一款mRNA疫苗的获批上市。胡博士是50多项发明专利、研究论文的发明人和作者，荣获江苏省双创人才、姑苏领军人才、苏州园区科技领军人才等称号。他在中国科学技术大学获得博士学位，中欧国际工商学院EMBA，并曾于德克萨斯大学西南医学中心从事博士后研究。

Dr. Peter Xiaowen He has worked on R&D in the fields of immunotherapeutics, vaccine and cell-based products for more than twenty years with 25 patents and over 30 SCI published articles. Dr. He developed the therapeutic Serratia Marcescens formula approved by cFDA as Class I biological product and won the second prize of Science and Technology Progress Award for his development of therapeutic vaccine against hepatocellular carcinoma. Dr. He has been research professor and PIs in Stem Cell Center of New Jersey and Merck USA. Dr. He got a lot of funding from NIH and National Natural Science Foundation of China and led the teams to establish the key manufactory and quality control systems for cell-based therapeutics. Currently Dr. He worked as Co-founder and CSO in Origincell.

· Twenty-five years of experience in drug R&D，involved areas of small molecule drugs, antibodies, and cell therapy
· Serve as CEO of BriSTAR Immunotech, a clinical company focused on the development of innovative cell immunotherapy products for solid tumor and blood tumor
· Co-founded several startups, including Exacis Biotherapeutics, a company that uses mRNA technology to prepare engineered iPSC, and then differentiate it into iNK cells for the treatment of malignant tumors
· Joined the Antibody and Biologics Industrialization Center in Toronto, Canada, where he held the position of Vice President
· Joined the Campbell family Institute for Breast Cancer Research, Princess Margaret Hospital (UHN), a division of Toronto General Hospital, as Director of Drug Development
· Joined Genentech as a researcher in oncology and Affinium Pharmaceuticals as Head of Drug Development
· Participated in a number of financing activities involving angel investment, venture capital and corporate investment
· Received a PhD in Molecular and medical Genetics from the University of Toronto and conducted postdoctoral research at the University of Toronto and the University of Michigan
· Has published more than 50 scientific papers in the journals Science, Nature, EMBO, Genes and Development, Cancer Cell, Cell Stem Cell, and others, with over 10,000 citations. Inventor and co-inventor of more than 60 patents and patent applications.
· 拥有超过25年的研发和管理经验，覆盖小分子药物，抗体和细胞治疗领域。现任华夏英泰（北京）生物技术有限公司CEO一职，这是一家处于临床阶段的，专注于研发创新型肿瘤细胞免疫治疗产品的公司。
· 曾联合创始多家初创公司，包括新型细胞治疗研发公司Exacis Biotherapeutics 并任研发负责人。
· 曾任加拿大Centre for Commercialization of Antibodies and Biologics（CCAB）副总裁，以及Toronto Recombinant Antibody Centre（TRAC）科学领袖。
· 曾担任Campbell家庭乳腺癌研究所、大学健康网络药物发现和治疗的负责人。
· 在Affinium Pharmaceuticals 和Genentech Inc. 担任过各种科学研究及管理职务。
· 曾参与多个授权交易和融资活动，涉及天使投资、风险投资和企业投资。
· 多伦多大学分子和医学遗传学博士，多伦多大学和密歇根大学进行博士后研究。
· 在《科学》、《自然》、《EMBO》、《基因与发展》、《癌细胞》、《细胞干细胞》等杂志上发表超过50篇科学论文，被引超过1万次。60多项专利和专利申请的发明人和共同发明人。

鼎新基因总经理，北京大学生理学博士。曾作为总裁参与基因治疗公司华毅乐健的孵化，主导了血友病A的AAV基因治疗项目的早期临床转化。 2020年联合创立上海鼎新基因科技有限公司，致力于递送技术驱动的创新基因治疗管线的开发，布局眼科、耳科、代谢等领域疾病。
General Manager of Shanghai Refreshgene Therapeutics, Ph.D. in Physiology from Peking University. As president, he participated in the incubation of gene therapy company Gritgen Therapeutics, and led the early clinical transformation of the AAV gene therapy program for hemophilia A. In 2020, he co-founded Refreshgene, which is committed to the development of innovative gene therapy pipelines driven by gene delivery technology in the fields of ophthalmologic, otologic, and metabolic diseases.

深圳市济因生物科技有限公司创始人、董事长兼CEO。
中国科学院大学博士。专注于通用型细胞与基因治疗产品开发，包括体内CAR-T与iPS来源NK细胞（CAR-iNK）制备技术研发。

陆道培医院医疗执行院长，北京陆道培血液病研究院院长
毕业于北京大学医学院，在美国内布拉斯加医学中心完成住院医，毕业于美国斯坦福大学血液及肿瘤专科
美国肿瘤以及血液病专科协会认证的血液及肿瘤专家，具有美国血液病专科医生，肿瘤专科医生执照以及中国行医执照
首都医科大学肿瘤学系第四届系务委员会委员
中国非公医疗机构协会第一届常务理事
中国非公立医疗机构协会血液病专业委员会主任委员
中国非公立医疗机构协会生物技术与细胞应用专业委员会常务委员
中国造血干细胞捐献者资料库专家委员会委员
中国临床肿瘤学会（CSCO）抗白血病联盟专家委员会常务委员
中国抗癌协会第一届血液病转化医学专业委员会常务委员
北京医学教育协会第七届理事会理事
医学界价值医疗泰山奖2021年度医疗管理奖获得者

Zhao Wei-Li, M.D., PhD, Professor of Hematology, First Deputy Director of Shanghai Institute of Hematology and Vice President of Shanghai Ruijin Hospital. She is the doctoral supervisor of both Shanghai Jiao Tong University and University Paris VII, foreign member of American Society of Hematology, Vice President of Chinese Association of Hematology, Secretary General of Chinese Society of Experimental Hematology, and member of the editorial committee of Pathobiology, Biomarker Research, Chinese Journal of Hematology, Chinese Journal of Leukemia & Lymphoma, and Clinical Hematology Journal. She mainly focuses on the clinical and basic research of hematological malignancies, especially the molecular mechanism and targeted therapy of malignant lymphoma. She innovatively proposed the molecular pathways of apoptosis, angiogenesis and cell differentiation involved in lymphoma progression and the availability of targeted agents for treatment. She has been awarded National Award for Science and Technology Progress and Outstanding Achievement Award of Scientific Research from National Ministry of Education and HUA XIA Award of Medicine and Technology from National Ministry of Science and Technology for her research progress and is now leading projects granted by National High Technology Research and Development Program of China, by National Natural Science Foundation of China and several other events on provincial level. She has been honored New Century Excellent Talents in University by State Ministry of Education, Rising-Star by Shanghai Committee of Science and Technology, Shu Guang Scholar by Shanghai Municipal Educational Committee. She has published over 108 articles including those on leading hematology journals like《CANCER CELL》、《NATURE GENETICS》、《BLOOD》、《MOLECULAR CANCER》、《SIGNAL TRANSDUCT TARGET THER》、《J HEMATOL ONCOL》、《LANCET HAEMATOL》、《CLIN CANCER RES》with total impact factors over 1200.

陈有海，免疫学博士，欧洲科学院（Academia Europaea）院士，美国医学与生物工程院（AIMBE）Fellow，国家特聘教授，教育部长江学者，基金委杰出青年学者。现任中科院深圳理工大学药学院讲席教授、院长。曾任美国宾夕法尼亚大学病理学和实验医学系终身教授，宾夕法尼亚大学医学院教学委员会主席，美国多发神经硬化基金会科学委员会主席等职务。主要从事癌症、炎症机制和治疗的研究，在免疫应答的调节、免疫性疾病的发病机制及治疗、新免疫检查点药物在癌症治疗中的应用等诸多领域取得显著的成就。在《Science》、《Cell》、《Nature》、《Nature Immunology》、《Nature Cancer》等国际权威杂志发表学术论文150余篇（截止到2022年H因子68； i10因子135；文章总引用次数～19000）。入选全球前1%顶尖科学家终身影响力榜单，是美国Kunkel学会会士（Elected Member），雷顿奖（Colyton Prize）获奖人。

He Huang, M.D., Ph.D., president of the First Affiliated Hospital, Zhejiang University School of Medicine; Director of Hematology Institution of Zhejiang University. Prof. Huang is also actively involved in and holds key positions in a number of professional organizations and scientific committees, including being Vice Chairman of Experts Committee of Chinese Marrow Donor Program; Executive Committee Member of Asia-Pacific Bone Marrow Transplantation Group (APBMT); Committee member of European Society of Hematology (EBMT); Committee member of Asian Cellular Therapy Organization(ACTO).
Prof. Huang specializes in clinical and basic research on hematopoietic stem cell transplantation, cellular immunotherapy and stem cell biology research. As corresponding author, he has published 213 original papers in SCI-cited journals including Nature, Blood etc. He has been awarded 19 national invention patents. He also organized APBMT annual meetings in 2005 and 2014 in Hangzhou, China as the chairman of the conferences. For his outstanding achievement on hematopoietic stem cell transplantation, Prof. Huang was awarded the national prizes by State Council twice in 2003 and 2015, respectively.

刘明耀，华东师范大学生命医学研究所所长，上海市调控生物学重点实验室主任。
1992 年，获美国马里兰大学(University of Maryland, College Park)细胞生物学博士 学位；1993 年到 1998 年，先后在美国约翰-霍普金斯大学医学院(Johns Hopkins University School of Medicine)和加州理工学院(California Institute of Technology)生 物学部做博士后研究。
1999 至 2007 年，先后在美国德克萨斯农工大学生命科学与技术研究所(Texas A&M University Institutes of Biosciences and Technology)任助理教授、副教授及终身正教授、 博士生导师；美国德州大学休斯顿医学院(UT Houston Medical School)，德州大学MD Anderson肿瘤中心(University of Texas MD Anderson Cancer Center)博士生导师。
2007 年，受聘回国加入华东师范大学，组建生命医学研究所并任所长；2011 年，组建上海市调控生物学重点实验室并任主任，同年起担任教育部创新团队带头人、国家重大科学研究计划（973 项目）首席科学家。2017 年起担任中国细胞生物学会肿瘤细胞分会会长，2020 年起任教育部科技委员会委员。
2012 年至 2020 年，担任华东师范大学生命科学学院院长，华师大-以色列海发大学科学与技术转化研究院院长。 刘明耀教授致力于 G 蛋白偶联受体（GPCR）在个体发育和重大疾病发生发展中的功能、机理及靶向药物研发，同时在基因编辑和细胞治疗的技术应用转化中做出卓越研究。回国后作为首席科学家先后主持国家973和重大科学研究计划（2 项）、国家自然科学基金重点项目（5项）、国家重大新药创制课题等。已在 Science、Nature、Nature Medicine、Nature Biotechnology、Nature Cell Biology、PNAS 等国际知名学术刊物上发表 SCI 论文 400 多篇，论文引用 2 万5千多次，H-Index 81，连续多年被评为高被引学者，申请专利 200 多项，授权 80 余项。
2012 年和 2017 年，分别获得国家科学技术进步一等奖和上海市科技进步一等奖，2014 年获得上海市白玉兰纪念奖，2021年获得华东师范大学首届杰出成就奖。

Dr. Que serves as CEO at Ascle Therapeutics, responsible for the Pipeline Development of CAR-NK Cell Therapeutics, Technology Platform Advancement, Team Building and Management, and Routine Operation of the Company.
Dr. Que is specialized at Analytical Development and Quality Control, and She has extensive experience in leading projects through CMC development, IND filing (~20), clinical development, BLA/NDA filing, GMP/PAI inspection towards BLA approval (~6), product launch and commercialization.
Previously, Dr. Que worked as Chief Technology Officer at Harbour BioMed, responsible for CMC and cGMP manufacturing of antibody therapeutics; Senior VP of Quality for Innovent Biologics, Executive Director of Protein Analytical Science for WuXi Biologics, Genentech and Pfizer Global Biologics in the area of protein analytical chemistry of protein drug development.
Dr. Que obtained PhD in Bioanalytical Chemistry from Chemistry Department, Indiana University.

- Founder, Chairman and CEO, Neukio Biotherapeutics
- VP & CTO, Fosun Pharma
- Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years
- COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies.
- Head of Operations, GSK R&D Center in China
- Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China
- Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA
- Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA
Richard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.

姚璇博士为辉大基因创始人&CEO，负责公司战略布局、团队组建、项目推进与体系建设。本科毕业于哈尔滨工业大学，并在中科院神经科学研究所获得神经生物学博士学位，创立辉大前曾担任中科院神经科学研究所副高级研究员。期间专注于新型基因编辑技术、动物模型建立及疾病治疗应用等多个领域的研究开发，在国际高水平期刊发表多项成果并申请多项发明专利。

刘冬琴，华东理工大学生物工程专业硕士，拥有9年基因及细胞治疗行业工作经验，熟悉多种病毒载体上游生产及下游纯化工艺开发，于2021年2月加入颇尔公司，担任颇尔上海工艺开发中心经理一职。负责基因及细胞治疗等生物制药领域产品的工艺开发项目管理及工艺开发中心实验室运营管理等工作。

金毅，本科毕业于武汉大学，生物技术专业；博士毕业于University of Glasgow，病毒学专业。
加入Cytiva后先后担任高级技术支持和产品经理。

生物化学工程博士，毕业于华东理工大学。上海交通大学安泰管理学院MBA。拥有近20年生物药物研发和产业化经验。历任CAR-T公司生产总监。上市血液制品公司经理、总监，负责研发、法规注册事务、质量管理等。熟悉质粒、慢病毒、CAR-T细胞制备工艺及质量质控。熟悉哺乳动物细胞平台工艺开发。熟悉病毒载体制备上游工艺开发和GMP生产。负责的多个CGT项目获得IND批准。具有丰富的团队管理经验。

汪溪洁，毒理学博士，研究员，博士生导师，中国毒理学会认证学家（DCST），中国药理学会安全药理专业委员会委员，上海市毒理学会理事。毕业于南京医科大学卫生毒理学专业，现任上海益诺思生物技术股份有限公司技术创新中心负责人、毒理事业部高级总监，14+年新药非临床评价工作经验，熟悉国内外非临床安全性评价研究指导原则要求，负责200+个新药非临床安全性评价试验，包括化学药、生物大分子药物、细胞和基因治疗、中药等。主持上海市科委科技创新行动项目3项，参与国家科技重大专项等项目10多项，发表论文40余篇，参编专著3部；作为主要完成人曾获上海市科技进步奖二等奖和中国药学会科学技术奖二等奖。

Dr. Wen (Maxwell) Wang currently is the Chief Executive Officer in IASO Biotherapeutics Co., Ltd. He obtained his M.D. degree in Wuerzburg University in Germany and Ph.D. degree from University of Aberdeen in UK and then did his postdoctoral training in at UConn Health Center in USA.
Dr. Wang has over 7 years of experience in Chinese Leading cell therapy companies including JW Therapeutics, Cellular Biomedicine Group (Nasdaq: CBMG) in clinical, preclinical, and translational development including CART cell and stem cell therapy. He held one of leading position in the 1st Chinese CD19-targeted CART cell and Mesenchymal Stem Cell INDs.
Before industry career, Dr. Wang worked as a Resident and Attending in Orthopedic Department in Shanghai TCM Hospital for 5 years.

Tongcun Zhang,PhD, Professor,Dean of College of Life Sciences and Health, Wuhan University of Science and Technology, Founder of Wuhan Bio-Raid Biotechnology Co., Ltd, was appointed as Distinguished Professor of "Chutian Scholar" and "100 Talents Program" in Hubei Province and Tianjin, "Yellow Crane Talent" and "3551" Talent Program of Optics Valley inWuhan Municipality.
Dr. Zhang actively contributes to a number of professional organizations and academic committees, including the senior member of the American Cancer Society, American Heart Association, and China Fermentation Industry Association, the Director of the Institute of Biochemistry and Molecular Biology in China, Distinguished expert of the Chinese Academy of Health Products, the permanent member of Biophysical Society in Hubei province, Director of the Institute of Biochemistry and Molecular Biology in Hubei province.
Dr. Zhang’s research focuses on molecular mechanisms of cardiovascular disease and CAR-T cell immunotherapy. He has hosted over 10 national, provincial, and ministerial projects, e.g. the National Major Research Program, the 863 Program, the 973 Program, and the National Natural Science Foundation of China, published over 150 papers in Nature, Blood,etc.,and been awarded 32 patents.

加拿大达尔豪斯大学访问学者
信达细胞制药（苏州）有限公司
CAR-NK研发负责人
外科学博士
归国后一直从事下一代CAR-NK细胞相关技术的开发，带领CARNK团队发明多种基因编辑技术，并通过专利技术解决干细胞向NK 分化瓶颈。着力推动国内基于流式细胞术的抗体展示技术，为下一代CAR-T与CAR-NK技术赋能

杨林博士, 博生吉医药科技（苏州）有限公司创始人/董事长/CEO、博生吉安科细胞技术有限公司董事长兼CEO、兼职苏州大学唐仲英血液学研究中心特聘教授/博士生导师；苏州肿瘤免疫诊疗工程技术研究中心主任；曾兼任美国MD安德森癌症研究中心淋巴瘤/骨髓瘤系兼职教授。拥有20余年全球顶级癌症研究中心研发经验，是肿瘤生物学和免疫治疗领域的专家。荣获江苏省高层次创新创业领军人才、江苏省六大高峰人才团队、安徽省战略性新兴产业技术领军人才、中国创新创业大赛二等奖、创响中国安徽赛区第一名、庐州产业创新团队、合肥市创业领军人才等多项荣誉。在《Cancer Cell》、《Cancer Research》、《Oncogene》、《JBC》、《Cancer Science》等学术杂志发表论文80余篇。主持国家自然科学基金、科技部重大专项子课题、美国NIH SPORE子课题等项目。杨林博士致力于突破性 CAR-T细胞和CAR-NK细胞新药的研发以及肿瘤免疫细胞治疗技术的转化医学研究和产业化，率先在中国建设了以全自动CART细胞生产工艺为基础的、具有国际先进水平的产业化基地，并带领团队研发多个first-in-class 潜力的CAR-T细胞药物，包括已获批IND和美国FDA孤儿药认定的全球领先的CD7-CAR-T细胞、以及针对儿童实体肿瘤的、获得IND受理以及美国FDA孤儿药以及罕见病认定的B7-H3-CAR-T.
Lin Yang, Ph.D., the Founder and Chairman of PersonGen BioTherapeutics (Suzhou) Co., Ltd. Dr. Yang has more than 20 years of R&D experience in the world's top cancer research center, and is an expert in the field of tumor biology and immunotherapy. He has won many honors, including Innovation and Entrepreneurship Talents of Jiangsu Province, Six Peak Talent (Groups) of Jiangsu Province, Technical Talents of Anhui Province, Entrepreneurship Talents of Hefei, Luzhou Industrial Innovation Talent(Groups), Second Prize of China Innovation and Entrepreneurship Competition (2017), First Prize of Anhui Innovation and Entrepreneurship Competition(2017), etc. He has published more than 80 research articles in academic journals, including Cancer Cell, Cancer Research, Oncogene, JBC and Cancer Science, etc. Dr. Yang is committed to developing advanced cellular immunotherapeutics for aggressive cancers, especially for which with few effective therapies. By leveraging his expertise both in academia and industry, he significantly facilitates translational research and commercialization of the developed products. He is a pioneer of establishing a fully-automatic CAR-T cell manufacturing facility with the world’s cutting-edge platform in China. Hi is currently leading PersonGen to develop various first-in-class CAR-T cell therapeutics for treating hematologic malignancies and solid tumors.

正序生物专注于以自主知识产权的新型碱基编辑系统为基础，开发突破性精准基因编辑疗法。牟晓盾博士获美国伦斯勒理工大学化学生物学博士学位，复旦大学学士学位。拥有近20年的国际工业界经验，曾带领团队建立生物药的工艺开发、生产和全球IND/BLA申报平台，覆盖mAb，ADC，pDNA，viral vectors，mRNA，VLP等多种药物分子。在肿瘤免疫和感染性疾病治疗领域有深入CMC研发和生产质控经验。在基因和细胞治疗和罕见病领域亦有快速临床推进的经验。曾在药明生物担任副总裁和分公司负责人、在默沙东（美国）和辉瑞（美国）担任项目和研发团队负责人。
CorrectSequence Therapeutics aims to use independent development innovative gene editing system to help people living with serious diseases. Dr. Susan Mou received a doctorate degree in Chemical Biology from Rensselaer Polytechnic Institute, Troy NY, U.S.A. and bachelor’s degree in Chemistry from Fudan University. She has nearly 20 years industrial experience in CMC development and commercial manufacturing, quality, supply chain and new business establishment starting from 0 to 600 pl. Experienced in mAb, ADC, mRNA, VLP, AdV, AAV in therapeutic and preventive treatment, vaccine, CGT, rare disease. Served as the Vice President in WuXi Biologics Development and Manufacturing and the Site Head of Hangzhou, China, the senior scientist and project lead in Pfizer’s BioTherapeutics division (US) and the principal scientist and analytical leader of new and enabling technologies and CMC leader for BioProcess Development in Merck (MSD US).

孙艳
上海细胞治疗集团公司共同创始人，集团COO，上海细胞治疗集团药物技术有限公司总裁
带领团队基于“非病毒载体基因写入、纳米抗体及mRNA”一体化技术平台建设，致力于自分泌抗体差异化创新细胞药物开发。目前团队申请细胞治疗相关专利超270件，完成一系列高品质低成本的CAR-T细胞产品管线布局，其中BZ019为国内首个获批的基于非病毒载体的CAR-T细胞治疗药物；BZDS1901为国内首个自分泌PD-1纳米抗体的CAR-T细胞，率先在恶性间皮瘤上获得突破性的疗效初步验证。

刘雅容, 美国南加州大学博士、博士后，沙砾生物创始人、首席执行官，中山大学孙逸仙纪念医院逸仙医学客座教授；苏州工业园区科技领军人才、姑苏领军人才、上海“千人计划”专家，上海市浦江人才；正高级研究员，CSCO会员，女医师协会会员，浦东新区青年联合会委员；拥有10余年从事腺病毒、慢病毒等各种病毒载体用于定向基因治疗的研究经验，以及慢病毒产业化的经验；在Nature Communications， Science Immunology，Gene Therapy，Molecular Therapy 等国际顶级杂志发表40多篇论文。并拥有1项美国技术专利，申请发明专利70余项，主持上海市生物医药科技支撑项目1项，参与国家重大专项新药创制CART专项，作为第二完成人获得2017年浦东新区科技进步奖创业团队三等奖；2021年获得上海市创业新秀、长三角女性创新创业大赛银奖。2019年创立沙砾生物，致力于创新细胞疗法TIL在实体瘤的研发和临床应用。沙砾生物已建立了三大核心技术平台，多个管线在中美布局，其中GT101已进入临床I期实验中，是国内首个获批临床的TIL产品。
Yarong Liu, Ph.D. and Postdoctoral at University of Southern California, Founder and CEO at Grit Therapeutics, Visiting Professor at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Science and Technology Leader of Suzhou Industrial Park, Gusu Leader, Expert of Shanghai Thousand Talents Program, Shanghai Pujiang Talent, Principal Investigator, member of CSCO, member of China Medical Women's Association, and member of Pudong New Area Youth Federation. Over 10 years of experience in AAV, LVV and other viral vectors for targeted gene therapy and experience in LVV industrial-grade manufacturing. She has published more than 40 papers in top international journals such as Nature Communications, Science Immunology, Gene Therapy, and Molecular Therapy. She holds one U.S. technology patent and more than 70 invention patent applications. She is in charge of a biompharmaceutical science and technology support project of Shanghai, and participates in the national major new drug development project CART. She won the third prize of Pudong New Area Science and Technology Progress Award for startup team in 2017 as the second person-in-charge, and Shanghai New Entrepreneur award and silver award of Yangtze River Delta Women's Innovation and Startup Competition in 2021. In 2019, she founded Grit Therapeutics, which is dedicated to R&D and clinical application of innovative cell therapy TIL targeting solid tumors. Grit Therapeutics has developed three core technology platforms and multiple pipelines in China and the US, among which GT101, the first TIL with IND approval in China, has entered clinical phase I.

Graduated from National University of Singapore (NUS), Dr. Cecilia Zhang has been engaged in the R&D and translational research of cancer immunotherapy. As Chief Science Officer of Biosyngen, a Singapore-based biomedical company, Dr. Zhang is now leading a team to develop several next generation CAR-T, TCR-T and universal cell therapy pipelines to target unconquered cancer types, including nasopharyngeal carcinoma, gastric cancer, colorectal cancer, EB (Epstein-Barr) virus-positive lymphoma, etc.,. Dr. Zhang is also the owner of multiple renowned academic paper publications and invention patents of the field.
Currently, multiple investigator-initiated clinical trials of CAR-T and TCR-T therapies targeting EB virus are underway in multiple clinical centers in China and abroad, for which good safety profile and preliminary efficacy have been observed. Home to scientific research talents from Singapore, China, Germany, Australia, and French, Biosyngen and Dr. Zhang are committed to provide next-level cancer cure utilizing cutting-edge cell therapies to benefit cancer patients worldwide.

Dr. Zhang Yu is the CEO of VCANPHARMA, and the CSO&SVP of VCANBIO Cell&Gene Engineering Corp.,Ltd (600645, SH)
Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University (former name Beijing University of Aeronautics and Astronautics), and Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf in Germany. Dr. Zhang was the former president and CEO of Aeon Therapeutics Inc. (now part of JW Therapeutics (02126, HK)), which focused on developing First-in-class CAR-T products for solid tumors in China. He was a visiting scholar in University of Applied Sciences Bonn-Rhein-Sieg, German Aerospace Center and University of Palermo. Dr. Zhang is also a distinguished professor in School of Basic Medical Sciences, Tianjin Medical University; and a Principal Investigator of the State Industrial Base for Stem Cell Engineering Products (SIBSCEP). He acts as the director of Tianjin Key Laboratory of Stem Cell and Regenerative Medicine, the director of Tianjin Key Laboratory of Blood Cell Therapy Technology. Dr. Zhang is a member of ISSCR, ISCT, German Society of Stem Cell, and Chinese Society of Cell Biology. He has published a number of papers in high-profile journals, including eClinicalMedicine, eBioMedicine, STTT and Scientific Reports, as either first or corresponding author. He has been granted several patents. He is also a reviewer of several cell therapy journals, e.g. Stem Cell Research&Therapy. Dr. Zhang was the winner of “Tianjin 131 talent plan in Tianjin” and “Wuhan 3551 talent plan”.

陆金华博士是TriArm Therapeutic Co.的联合创始人，首席科学家。此前他在美国食品和药物管理局，作为临床前专家审评员，负责审评细胞和基因治疗，医疗器械，以及组合产品。他专长的领域是免疫治疗，基因/干细胞治疗和治疗性疫苗。在审评工作之外，他还任职多个科学委员会和工作小组，参与撰写FDA指导文件等工作。他曾担任美国FDA癌症卓越中心科学委员会成员，并获得FDA监管科学卓越成就奖。在任职FDA之前，他作为资深科学家，部门主管和咨询顾问服务于政府和生物技术工业界，负责研发用于肿瘤治疗的病毒载体和病毒疫苗。
Dr Lu is the co-founder and CSO of TriArm Therapeutic Co. He was an expert nonclinical reviewer at OTAT, CBER, FDA and specializes in reviewing immunotherapies, stem cell and gene therapies, and therapeutic cancer vaccines. He has regulatory experience in all stages of clinical development, from the Interact stage to BLA. He also served on numerous scientific committees and working groups, and participated in other FDA outreach activities with the biotech industry. Dr. Lu served as a member of scientific committee of Oncology Center of Excellence, FDA and was the recipient of the CBER award for Excellence in Regulatory Science Research in 2015.
Prior to joining the FDA, Dr Lu worked in the biotechnology industry as a senior scientist, manager and consultant in the development of vaccines for viral diseases and developing viral vectors for cancer therapy.

Jimin Gao, M.D., Ph.D.
Leading Talent in Zhejiang Province, Qianjiang-endowed Professor, Director of Zhejiang Provincial Key Laboratory for Technology and Application of Model Organisms, Wenzhou Medical University
Dr. Gao is a Leading Talent in Zhejiang Province and Qianjiang-endowed Professor. His research interests are the pathogenesis, immunological diagnosis and treatment of inflammation-related diseases (such as tumors). He has undertaken 8 national scientific research projects, published 146 SCI papers with 88 of them as the (co-)corresponding author, applied for 28 patents of invention with 6 of them authorized, won the first prize of Zhejiang Science and Technology Award in 2013 with the project “Cell surface-modified tumor cell vaccine”, and obtained a national new drug certificate (98 WeiYaoZhengZi S-09) for Injectable Recombinant Human G-CSF in 1998 with the profit tax of more than ￥100 million. Currently, his team has focused on the development of armored CAR-T, HLA-independent TCR-T, CAR-NK cells and cell-surface-modified tumor vaccines for safe and effective therapy of cancer, infection and aging.

近20年从业经验
韩国延世大学博士
哈佛医学院博士后
无锡市“锡山英才”创业领军人才
中国基因与细胞治疗CGCT“青藜学士”
王海峰博士于2022年1月创立无锡科金生物并担任董事长兼首席执行官。创立公司之前，王海峰博士曾在诺华（中国）从事研究工作，负责病毒方向的研究，并在核心期刊发表论文；之后在药明康德（韩国）从事亚太地区市场开发工作。主要负责抗体药、细胞和基因疗法的CDMO市场开发，参与近300多个国际项目，为亚太地区客户提供一站式技术服务，包括研发、CMC、Tox、IND和临床服务等，并帮助数十家公司从研发到IND直至BLA的成功提交。
20+ years of experience
PhD from Yonsei University, Korea,
Postdoc at Harvard Medical school,
Innovation and Entrepreneurship Leading Talents award of Wuxi’s Xishan Talents Program
"Bachelor of Chenopodium Album" award from China Gene & Cell Therapy (CGCT)
Dr. Michael Wang is the founder, Chairman and Chief Executive Officer of CorrGene Biotechnology Co., Ltd since the company’s founding in January 2022. Prior to founding CorrGene, Dr. Michael Wang was a research investigator of virology in Novartis (China). During his tenure at Novartis, Dr. Wang published several papers in key SCI-cited journals. After Novartis, Dr. Wang worked for WuXi AppTec (Korea) and responsible for business development in the Asia-Pacific region. When he served for Wuxi AppTec, his main responsibility was developing CDMO business and marketing of antibody drugs, gene and cell therapy related services, participating in nearly 300 international projects, providing one-stop technical services for customers in the Asia-Pacific region, including R&D, CMC, Tox, IND and clinical services, etc. During his tenure at WuXi AppTec, Dr. Wang successfully provided regulatory supports, ranging from IND submission to BLA approval, to dozens of companies.

Dr. Jun Li is the Chief Executive Officer and Founder of Fundamenta Therapeutics. Prior to founding Fundamenta, Dr. Li was a senior director at Novartis （2001-2009），leading multiple projects from discovery to IND. At Fundamenta Therapeutics, Dr. Li has led the development of a novel non-gene-editing allogeneic CAR-T platform technology (ThisCART) with the first program into clinical stage at multiple centers.
He obtained his bachelor’s degree in virology and molecular biology from Wuhan University in June 1992. He obtained his master’s degree in medical immunology from Peking University in June 1995 and Doctor’s degree in biochemistry from University of Utah in 2001. Dr. Li has published over 30 original papers in SCI-cited journals and authored in 26 international patents.

CSCO肿瘤生物标志物（bio-marker）专家委员会委员
CSCO肿瘤免疫（IO）治疗专家委员会委员
CAC肿瘤药物研究专业委员会荣誉委员
中国医药教育协会转化医学专业委员会常务委员
江苏省药学会药物临床评价研究专业委员会委员
临床与基础研究经历：
陆军军医大学博士，从事肿瘤临床工作14年。复旦大学博士后，从事肺癌水通道蛋白RNA干扰基础研究。
制药企业经历：
1. 三维生物，高级研究员，从事溶瘤病毒研发，2005年全球第一个溶瘤病毒（安柯瑞）获得NMPA批准的主要贡献者。
2. 辉瑞中国，医学事务部总监，负责肿瘤新产品的上市前和上市工作。
3. BMS，医学事务部肿瘤邻域负责人，高级总监，负责PD-1抑制剂（纳武利尤单抗）中国上市前和上市工作。
4. 武田中国 医学事务部负责人，副总裁

Dr. Alex H. Chang, is currently the Adjuct Professor of Tongji University School of Medicine and the founder of Shanghai YaKe Biotechnology Ltd.. He obtained his Ph.D. from University of British Columbia, Canada, and completed his post-doctoral training in Cell Engineering and Gene Therapy at Weill Medical College of Cornell University, New York. He has worked at Memorial Sloan-Kettering Cancer Centre, New York, as a senior scientist. During that period, he has several publications in cell engineering and gene therapy in renowned journals such as Nature Biotechnology, Nature Medicine, and Molecular Therapy.

Dr. Changfeng Zhang is the director of the Department of Regulatory Affairs, Shanghai Pharmaceuticals Holding Co., Ltd. He was one of the core members of Dr. Carl June’s team at the University of Pennsylvania and contributed substantially to the IND affairs of CTL019 (AKA Kymriah). Dr. Zhang specialized in RA affairs of CART products and achieved the IND approval of the first gene-modified CART product in China. Additionally, he established collaborations with the Chinese FDA, NICPBP, and several regulatory agencies by introducing world-famous CART therapists such as Drs. Stephan Grupp and Joseph Melenhorst. Dr. Zhang has several publications in top-ranked journals such as Nature Medicine, Blood, etc. He is also the High-level Talent of Shenzhen, Zhuhai, Suzhou, and Nanchang.

Dr. XIE got his Master’s degree in Medicine from Peking University and Ph.D in Pathogenic Biology from China CDC. He started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. Dr. XIE is the founder, chairman and CEO of Corregene. He founded this cell therapy company in 2016, which focused on developing T-cell therapy for solid tumor patients.

Dr. Enxiu Wang used to work in Dr. Carl June team at University of Pennsylvania, the global pioneer of CAR-T immunothery. As a key member, he had been focused on solid tumor CAR design and evaluation. Dr. Wang and his colleges’ patents solft-activating CAR system has been approvaled by both US and European countries. He founded Nanjing CART medical Co. Ltd at 2017. Since then 3 patents have been approvaled and 35 submitted for solid tumor CAR-T. Recoginized by the field, Dr. Wang’s team obtained several fundings from the state and provinces. What’s more Nanjing CART got investment of noted investment institutions. Now leading with Dr. Wang, Nanjing CART Med is making great progress in both drug discovery and IND application.

• Base Therapeutics 创始人
• 在美国和中国的医疗领域具有近20年风险投资、创业、研发和临床医生的经验
• 仁济医院临床医生，Texas Children Hospital 临床遗传家，GE Healthcare主任科学家，应用干细胞公司首席科学家。主要科研成果包括世界上第一个发现了一种重要的遗传性心脏病ARVC的最主要的致病基因PKP2。
• 美国贝勒医学院（Baylor College of Medicine） 分子和人类遗传博士， 复旦大学临床医学七年制。

Life member of Chinese Society of Immunology, director of Immunology Committee of Hubei Cancer Society. Engaged in tumor immunotherapy research for nearly 20 years, involving preclinical and clinical studies of multiple Class I new drug projects. Presided over a number of major national science and technology projects such as "Major New Drug Development". He has applied for or obtained more than 20 national invention patents, obtained eight software copyrights, and published a monograph. Selected as the 2019 Leading Entrepreneur Talent Project in Suzhou Industrial Park. Entrepreneurship projects have won awards in multiple entrepreneurial competitions.

周国庆，在瑞典获得分子生物学博士学位，在加拿大、美国从事过多年的研发工作，拥有10年的新药研发经验，创立过3家生物技术公司，并担任过CEO、CSO和董事长；
公司研发团队有20年以上分子生物学、病毒学、免疫学、肿瘤治疗和转化医学、投融资等专业经验的专家, 拥有自主知识产权的核心技术，联合创始人团队拥有整合美国生物制药大公司新药研发和生产的专业技术，是一支高水准的新药研发团队。

Patrick Liu, MD, PhD is currently President at CureGenentics. Before joining CureGenetics, Dr. Liu had served as Chief Scientific Officer at Livzon Medicine Groups, Corporate Vice President and Chief Strategy Officer at Jiangsu Hengrui Medicine Groups, Vice President of Global Biologics at Teva Pharmaceuticals, R&D Director at Genentech, Inc. and Adjunct Professor at the University of Maryland.
Dr. Liu has more than 20 years of R&D strategies and management in innovative therapy development with increased responsibilities in the leadership role for the development and commercialization of a variety of new biologics and as well as cell and gene therapeutics products across the therapeutic areas of oncology, hematology, immunology, allergy, respiratory and infectious diseases. He has contributed to the success of developing many blockbuster innovative medicines including Avastin, Herceptin, Perjeta, Lucentis, Xolair and Copaxone, and many other biologics such as Lonquex, Granix, Ovaleap, Cinqair, Trogarzo and Ajovy. Dr Liu had practiced medicine, specializing in Endocrinology and also holds a Ph.D. in Molecular Biology and Biochemistry from Peking Union Medical College and Chinese Academy of Medical Sciences.

Dr. Cao is responsible for the business development and bioanalytical program management of gene therapy product, including method development, method validation, and clinical sample analysis for PK, PD, Nab, ADA and Biomarker assays
Dr. Cao holds a Ph.D. in Neuroscience from Fudan University, Shanghai. Prior to joining Accurant BioTech, Dr. Cao worked for Hengrui Pharmaceutical, focusing on gene therapy drug discovery and project management in disease areas of nervous system and ophthalmic disorders, from ideas to clinical candidates.

Fangfang Zhu, Founder and CEO of HemaCell Therapeutics Inc.
The tenure-track Associate Professor at Shanghai Jiao Tong University.
Dr. Zhu has over 15 years of experience in stem cell research and investment, she is the co-authors of many research articles published in high profile international journals, such as Cell Stem Cell, Nature Communication, PNAS, Nucleic Acids Research, et al, which have a total of nearly 2000 citations, and she is the inventors to several PCT patents, some of which have been licensed to biotech companies and research institute. Dr. Zhu was the Vice President of WI Harper Group, focusing on the early-stage investment at Healthcare field. Dr. Zhu was the Siebel Scholar at Stanford University and won the SVIEF “Sandhill” Investment Award. She was the former President and Chairman of PKU Alumni Association of Northern California (PKUAANC) and Secretary and Board Member of Zhejiang Chamber of Commerce, USA (ZCC-USA).
Dr. Zhu got her Ph.D. degree at cell biology from Peking University with the mentor Dr. Hongkui Deng and had her postdoctoral training in the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and her supervisor is Dr. Irving Weissman, the “Father of Stem Cells”.

星北·产业服务平台执行总监，星北·自贸壹号招商总监。拥有多年生物医药园区运营经验，擅长产业研究与平台搭建，服务并成功落地50多个重大创新生物医药项目。

Dr. Ting Zhang, founder and CEO of Regend Therapeutics, professor level senior engineer, doctor of biology of Tsinghua University, Shanghai "Pujiang Talent", innovation leader of Suzhou Industrial Park, Zhejiang "Qianjiang Talent", executive director of the base of the Tissue and Organ Regeneration and Manufacturing Engineering Research Center of the Ministry of Education, vice chairman of the Entrepreneur Federation of Nanchang National high-tech Zone Industry and Commerce Federation, Jiangxi Province, Vice President of East China Association of Entrepreneurs of Sichuan University Global Alumni Association, Entrepreneurship Tutor of Xi'an Jiaotong Liverpool University, and Member of the Alumni Association of Yihong Business School of Shenyang Pharmaceutical University. He used to be a postdoctoral researcher of the Genome Research Institute of A*STAR, Singapore, a postdoctoral researcher of UCSD and Sanford-Burnham Medical Research Institute in the United States, published 16 SCI papers on Nature, AJRCCM, EMBO Mol Med, Protein Cell, etc., three invention patents, served as the backbone of two national key research and development programs on stem cell and transformation research topics, won the second prize of Jiangsu Provincial Science and Technology Progress Award, and the 2022 Chinese Women Pioneer in Science and Technology.

李明明博士负责Cytiva思拓凡在亚洲地区的项目合作工作
李博士毕业于新加坡国立大学，主要研究方向为人胚胎干细胞分化成前体和成体细胞、单一组织及复合组织，用于药物筛选和移植治疗的临床前研究。
李博士曾就任于临床项目管理公司IQVIA负责临床项目管理，丰富了他在生命健康领域的实践经验和从科研到临床的转化。李博士也曾就任于亚洲覆盖范围最广的脐血库，并担任集团执行董事的职位，负责细胞治疗和诊断部门的运营。在此期间，李博士撰写并资助了亚洲第一个获批的自闭症的细胞治疗临床项目，并作为AABB和FACT的国际评审现场审查了欧洲和亚洲多家血库的产品制备合规性。

Dr. Zhu received his Ph.D. in neurobiology from Shanghai Institute of Physiology, Chinese Academy of Sciences; conducted postdoctoral training at University of California San Francisco and Smith-Kettlewell Eye Research Institute. He is a recipient of the Rachel C. Atkinson Fellowship and Jiangsu Province Entrepreneurship and Innovation Talent. With experience in biopharmaceutical R&D and management both in the United States and China, he was the VP and CMO of Wanbang PharmaTech (A member of Fosun Pharma), and the EVP and CMO of Voncolytic Therapeutics.
朱博士从中科院上海生理所获得神经生物学博士，在加州大学旧金山分校和Smith-Kettlewell眼科研究所接受博士后训练；是Rachel C. Atkinson Fellowship和江苏省双创人才获得者；拥有美国和中国两国生物制药研发及管理经验，曾任万邦医药科技有限公司（复星医药）副总经理兼首席医学官、万戎生物医药科技有限公司常务副总经理兼首席医学官。

Biao Dong, Ph.D., is the co-founder and CEO of Sichuan Real&Best Biotech Co. Ltd. He is a Professor in the State Key Laboratory of Biotherapy and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University. His research interests include: (1) rAAV gene therapy of genetic diseases and age-related diseases; (2) rAAV production technology. He served as a member of ASGCT Viral Gene Transfer Vectors Committee and ASGCT Physical Delivery, Therapeutics & Vector Development Committee. Two rAAV gene therapy programs on Hemophilia A and B he led have been in the clinical study phase.

免疫学博士，浙江大学教授、博导。长期致力于胞外囊泡与免疫的研究。以通讯作者在Immunity, Journal of Extracellular Vesicles, Nature Communications, Cell Research, Autophagy等知名期刊发表SCI论文25篇。主持国家自然科学基金6项，包括重点项目1项；主持国家重点研究计划子课题1项，“973”计划骨干1项；以第一发明人获国家发明专利授权7项，申请2项；参编专著2部。目前任中国研究型医学学会细胞外囊泡研究与应用专业委员会常委、Extracell Vesicles Circ Nucl Acids杂志编委。应邀为Advanced Science, Theranostics，Cellular & Molecular Immunology等期刊审稿。

Shi Hu is an Associate Professor of Biomedical Engineering in the Department of Biophysics, Second Military Medical University, China. Professor Hu’s research is focused on synthetic immunology and antibody engineering through the development of novel immune therapeutics. In the last decade, he has focused on the development of novel sensitizers for antibody-based therapies (e.g., anti-ERBB antibodies) that underlie the mechanism research of tumor heterogeneity and plasticity. He has authored over 40 scientific publications in peer-reviewed journals and additional reviews and chapters in books on the molecular, biochemical, and cellular aspects of synthetic immunology and antibody engineering.

龙钢博士，复旦大学基础医学院病原生物系教授，博导。中科院“百人计划”专家。曾任中国科学院上海巴斯德研究所研究员, 清华大学结构生物学高精尖创新中心合作研究员。2002年中科院武汉病毒所毕业获得硕士学位；之后加入病毒所与荷兰瓦赫宁根大学病毒系联合培养博士项目，2007年获得博士学位;同年获得玛丽居里博士后奖学金支持加入德国海德堡大学医学院 Ralf Bartenschlager 教授团队从事丙肝病毒和登革热病毒分子病毒学研究。主持,参与十二五艾滋病肝炎研究重大专项、国家重点研发丙肝项目（973），生物安全项目和自然科学基金委项目,上海市重大项目等。研究方向为医学病毒的感染和致病机制及嗜神经病毒感染活细胞示踪体系研发。近年来龙钢研究员主要关注病毒组装与宿主相互作用，聚焦病毒组装与脂蛋白颗粒和外泌体颗粒交叉界面，提出外泌体和脂蛋白参与调控病毒感染和免疫逃逸的新模式，相关研究结果在J Hepatology，Nature Communications, Journal of Extracellular Vesicles, J Virol， AntiViral Research等学生刊物上发表。

Dr. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. The CAR T cells invented in the June laboratory were awarded “Breakthrough Therapy” status by the FDA for acute leukemia in children and adults in 2014 and were approved by the FDA for acute leukemia in 2017 and afterwards, for diffuse large B cell lymphoma. These accomplishments have been recognized by the White House on several occasions. He has published more than 500 manuscripts and is the recipient of numerous honors, including election to the National Academy of Medicine, the National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society.

Dr. Kaufman is a native of Minnesota (USA). He did undergraduate work at Stanford University and then completed an MD and PhD (Immunology) at the Mayo Medical School and Mayo Graduate School in Rochester, MN. He then completed both residency training in Internal Medicine and fellowship training in Hematology at the University of Wisconsin-Madison. Dr. Kaufman was faculty at University of Minnesota from 2002- 2016. In 2016, Dr. Kaufman moved to UCSD to be a Professor in Department of Medicine, Division of Regenerative Medicine and Director of the Cell Therapy program.
Dr. Kaufman provides clinical care primarily for patients with blood cell cancers such as leukemia, lymphoma and myeloma, with special interest in blood and marrow transplantation (BMT) and cell-based immunotherapies. Research in the Kaufman lab uses human pluripotent stem cells to understand the development of blood cells and related mesodermal cell populations. Specific projects investigate development of distinct cell populations from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), including: hematopoietic stem/progenitor cells, lymphocytes, endothelial cells, cardio-vascular progenitor cells, and osteogenic (bone forming) cells. Recent studies have focused on the ability to use hESC and iPSC-derived natural killer (NK) cells to kill diverse types of human cancer cells both in vitro and in vivo. Additional work has used cellular engineering to enhance the anti-tumor activity of the hESC/iPSC-derived NK cells by expression of novel chimeric antigen receptors, stabilized expression of CD16, and other strategies. This work has now been translated into clinical trials for treatment of relapsed/refractory cancers- both hematologic malignancies and solid tumors. Dr. Kaufman also oversees the UCSD Advanced Cell Therapy Laboratory (ACTL) that provides GMP cell manufacturing to translate new anti-cancer cell-based therapies to clinic, such as NK cells, T cell-based therapies, MSCs, and other hESC/iPSC-derived cell populations.

Dr. Milone is an Associate Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. His research is focused on the development of engineered T cell immunotherapies. Dr. Milone is a co-inventor of tisagenlecleucel (CTL019, KymriahÒ), the first US FDA-approved gene therapy that employs T cells genetically modified with a chimeric antigen receptor (CAR) targeting CD19 for the treatment of B-cell malignancies. His research has led to over 150 pending and granted patents filed in the area of CAR technology and engineered T cell therapy. In addition to a major focus on cancer, Dr. Milone’s research also explores applications of engineered T cells to non-malignant disease, most notably antibody-mediated autoimmune disease. This research led to the development of chimeric autoantibody receptor (CAAR) technology in collaboration with Dr. Aimee Payne at the University of Pennsylvania. Dr. Milone is a scientific co-founder and co-chair of the Scientific Advisory Board Cabaletta Bio (NASDAQ: CABA) and Verismo Therapeutics that are developing technologies developed in his laboratory.
Dr. Milone received his M.D. and Ph.D. in experimental pathology in 1999 from New Jersey Medical School and UMDNJ-Graduate School of Biomedical Sciences. After an Internship in Internal Medicine at the Hospital of the University of Pennsylvania, he completed post-graduate medical training in clinical pathology, transfusion medicine and clinical chemistry/toxicology. In addition to his active research program, Dr. Milone is also a practicing clinical pathologist and Associate Director of the Toxicology Laboratory at the Hospital of the University of Pennsylvania.

Principal Investigator
CiRA Foundation, Kyoto, Japan
Rafal has obtained a M.D. degree in 1996 and trained as a pediatric surgeon at Medical University in Lodz’s pediatric hospital. Until 2005 he was an assistant professor at the Department of Pediatric Surgery and Oncology.
In 2005, he received a Japanese MEXT scholarship and started a doctoral course at Kobe University, where he became first interested in induced pluripotent stem cells (iPSC).
After obtaining the Ph.D. degree in 2010, he held several postdoctoral positions in Japan and received an iPS cell generation and maintenance training at Kumamoto University.
In January 2019, he joined the Research and Development Section in Facility for iPS Cell Therapy, Center for iPS Cell Research and Application, Kyoto University, headed by Prof. Shinya Yamanaka, where he is working on the manufacturing of iPS cells for clinical applications.
In 2020, the facility became a core of newly established CiRA Foundation (https://www.cira-foundation.or.jp/e/), which is a public interest incorporated foundation intended to serve as a bridge between academia and industry.
Currently, he is a principal investigator at the CiRA Foundation’s Research and Development Center.

Dr. Chen received his medical school training from the Shandong University and his Ph.D. training from the University of Manitoba (Canada).
After a successful postdoctoral training at Harvard University, he joined the faculty of the University of Pennsylvania in 1995. He was a tenured Professor of Pathology and Laboratory Medicine at University of Pennsylvania until 2020 when he joined the Shenzhen Institute of Advanced Technology as its founding Dean of Faculty of Pharmaceutical Sciences. Dr. Chen is a renowned immunologist who has made lasting impacts on immunological research. He has published more than 160 research articles with a total citation >18000 and an H-index of 66 (Google Scholar); he is ranked by the Stanford University as one of the Top 1% Scientists for Lifetime Scientific Impact; he is an elected Fellow of the American Institute for Medical and Biological Engineering, elected member of the Kunkel Society, recipient of the Colyton Prize for Autoimmune Research, and invited speaker for more than 100 international meetings. Dr. Chen’s major high-impact contributions to science include:
(I) He discovered a subset of T lymphocytes called regulatory T cells that secret transforming growth factor-beta and reported a paradigm-shifting concept that regulatory T cell development is specified by a lineage-specific “enhanceosome” (Science, 265: 1237, 1994 - cited for 2484 times; Immunity 31: 932, 2009 - cited for 406 times); these fundamental discoveries helped establish the current paradigm of regulatory T cell biology and made a major impact on our understanding of immune tolerance in general.
(II) He discovered crucial roles of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) in autoimmunity and liver failure (Nature Immunology 4:255, 2003; Journal of Clinical Investigation 113:58, 2004), and developed the first TRAIL-blocking antibody drug that is being tested in phase I clinical trials for treating hepatitis and liver failure, which afflict millions of people worldwide.
(III) He discovered and characterized three members of the TIPE (TNF-a-induced Protein 8-like) family (Cell 133:415, 2008; Nature Immunology 18: 1353, 2017): by genomic profiling of inflamed tissue, Dr. Chen’s laboratory identified, in 2008, three novel members of the TIPE family. They have since crystallized two of them and generated mice deficient in all of them. They discovered that TIPE family plays essential roles in colitis, encephalomyelitis, and carcinogenesis; They found that TIPE family is the transfer proteins of lipid second messengers PIP2 and PIP3. These ground-breaking discoveries helped deepen our understanding of the molecular pathways shared by inflammation and cancer, and provided new therapeutic opportunities for treating inflammatory and neoplastic diseases.

Dr. Sean Fu is a co-founder and CEO of RVAC Medicines.
Prior to RVAC, Dr. Fu was a Group VP of Luye Pharma responsible for R&D organizations in Boston, Princeton, Germany, Switzerland and Japan with activities ranging from discovery to clinical development and regulatory filing. Dr. Fu was also the CEO of GeneLeap, a Luye subsidiary company focusing on DNA and RNA therapeutics. GeneLeap had over 50 scientists working in both US and China, advancing multiple proprietary preclinical assets.
Prior to joining Luye, Dr. Fu worked at Merck & Co., for 15 years with a wide range of responsibilities covering R&D, business development, finance and operational management. He managed the finance of a $300M late-stage clinical portfolio and led the integration of global R&D network after the landmark $42B merger between Merck and Schering.
Dr. Fu is an honorable recipient of multiple awards, including Merck & Co’s highest award for R&D innovation, the Best Business Value Award; the prestigious William Oxley Thompson Alumni Award by The Ohio State University and the Research Gold Award by Materials Research Society (MRS).
Dr. Fu earned his PhD from The Ohio State University and his MBA from the Wharton School of Business, University of Pennsylvania.

Dr. Shanshan Wang has obtained her PhD degree in Molecular Biology at Heidelberg University in Germany. She started her industrial career in antibody drug discovery against cancer and autoimmune diseases at HiFiBiO Therapeutics and joined Innoforce Pharmaceuticals since 2022 January. Currently she serves as senior scientist in the department of Process Research and Development at Innoforce Pharmaceuticals, working on the process development of mRNA products.

Huimin Tao is a principal scientist in the analytical development department at Novartis gene therapy. She leads of AD Molecular biology team in the development, qualification, and QC transfer of high-throughput sequencing and ddPCR assays to characterize AAV drug products. She has more than 15 year’s industry experience in molecular biology assay development. She was part of team at Sequenom launched the first NGS-based NIPT test in 2011. She is a member of the British Pharmacopeia Advanced Therapy Medicinal Products Working Party. Huimin used to be an attending physician in the third hospital of Wuhan, China, specializing in Neurology before she went to U.S. She received her master's degree in Neurology from Wuhan University, China, and her master's degree in public health from the University of Virginia, United States.

刘冬琴，华东理工大学生物工程专业硕士，拥有9年基因及细胞治疗行业工作经验，熟悉多种病毒载体上游生产及下游纯化工艺开发，于2021年2月加入颇尔公司，担任颇尔上海工艺开发中心经理一职。负责基因及细胞治疗等生物制药领域产品的工艺开发项目管理及工艺开发中心实验室运营管理等工作。

王捷思，博士，毕业于华东师范大学生命科学学院。现为安捷伦细胞分析事业部PLXF产品专员，具有多年产品应用和技术支持经验。
Jiesi Wang received her PhD degree from East China Normal University. Currently she works as the PLXF product specialist in Cell Analysis Division, Agilent Technologies China. She has multiple years experience in product applications and technical supports in different research areas in life science business.

Markus finished his PhD in 2008 in Molecular Cell Biology at the Max-Planck-Institute for Biochemistry in Munich. He subsequently joined McKinsey&Company as a consultant taking over international strategy and operations projects for clients within the Pharma, Biotech and High-Tech industry.
By the end of 2010 Markus joined Roche at the Biotech Centre in Penzberg. Since then he was holding positions as a Groupleader and Department Head in Bioprocess Development and Analytical Development & New Technologies before he took over the Lead for Roche’s efforts towards Technical Development for in vivo Gene Therapy

Dr. Bose Kalampanayil is the Chief Technology Officer of Neurophth. He has more than 20 years of experience in the biopharmaceutical industry, including cell therapy, gene therapy and vaccine production processes, impurity research, quality research, stability research, etc. In the field of cell gene therapy, he is mainly responsible for the GMP production of plasmids and the GMP production of Adeno-Associated Viruses. As a senior "subject expert", he has been active in the production process, process development and overall CMC of drug product development. He has held management positions in various biotechnology companies and CMOs, including Vigene Biotech, Therabron Therapeutics, AERAS, Iomai (Intercell) and Charles River Laboratories. Dr. Kalampanayil holds a Ph.D. in Biochemistry, M.S. in Molecular and Cellular Biology, B.S. in Biochemistry and Molecular Biology from the University of Maryland, and a fellowship from the American Association for Clinical Research.

陈功教授是国家海外重点人才计划教授，现为暨南大学粤港澳中枢神经再生研究院大脑修复中心主任。复旦大学毕业，中科院上海生理所神经生物学博士。美国耶鲁大学和斯坦福大学博士后。曾任宾夕法尼亚州立大学终身教授和冠名主任教授（Endowed Chair Professor）。陈功教授领导的团队在国际上首次报导了用神经转录因子NeuroD1将大脑内源性胶质细胞原位高效地转化为功能性神经元这一里程碑工作，被干细胞顶尖杂志Cell Stem Cell评为2014年度最佳论文，为大脑修复开辟了全新的神经再生型基因疗法。2015年再次在Cell Stem Cell上发表小分子化合物诱导培养的人源胶质细胞高效转化为功能性神经元的工作，为开发利用脑内胶质细胞再生神经元的药物疗法奠定了基础。2020年又在国际上首次发表灵长类大脑原位神经再生的里程碑工作。陈功教授有160多项发明专利申请，已经获得国际范围内的40项专利授权。陈功教授是NeuExcell Therapeutics 的科学创始人。NeuExcell 致力于运用神经再生型基因疗法治疗神经退行性疾病和神经损伤相关疾病。2021年，NeuExcell与罗氏制药子公司Spark达成了1.9亿美金的合作协议，共同开发治疗亨廷顿舞蹈症的基因治疗药物。

Dr. Jose-Carlos Segovia has focused his research on the study of hematopoietic stem cells (HSC), on their interaction with viral pathogens, on their ex vivo purification and manipulation and on the gene transfer to HSC, with the aim of developing protocols of gene therapy for the treatment of genetic diseases with hematopoietic pathology. He defended his doctoral thesis in April 1993 and is currently Head of the Cellular Technology Division and the Flow Cytometry and Cell Separation Laboratory (LACISEP), at the Center for Energy, Environmental and Technological Research (CIEMAT). Throughout his scientific career, he has published more than 100 scientific articles in high-impact journals in the areas of Gene and Cell Therapy, he has participated in more than 45 projects, being Principal Investigator of more than 10 and he has obtained 7 patents, one of them already licensed to the biotechnology company Rocket Pharmaceuticals (New York, USA). During the last years, he has focused his research on the development of gene therapy protocols for the treatment of Pyruvate Kinase Deficiency (PKD). He has achieved orphan drug designation by the European Agency and the American Drug Agency (EMA and FDA, respectively) for an addition gene therapy drug, which is already being tested in a first global human clinical trial. He has coordinated international meetings with PKD patients, relatives and physicians, in Spain and Europe to inform about the progress that is being made and to make this new therapy reach the largest number of patients. Recently, he has applied new gene editing technologies for the treatment of PKD, the next frontier in the application of gene therapy, and he is starting its application to other anemias, such as Congenic Dyserythropoietic Anemia. Because of these later studies, he has published 5 scientific papers and presented two patents. In this area, he has directed three workshops on gene editing in recent years, one of them of an eminently practical nature. Dr. José Carlos Segovia is also a collaborator in numerous master's degrees in biotechnology and biomedicine that are taught at various public and private universities. Lastly, he has been secretary of the Spanish Society of Gene and Cell Therapy and he is Vice President of the Iberian Society of Cytometry and currently CSO and co-founder of Wuxi CorrGene Co.Ltd.

Jørn Henriksen has more than 15 years of experience in Life Science. Since 2011 he has worked at ArcticZymes Technologies both as a scientist and leading internal teams when developing methods for enzymatic purification of various biological materials. He also has extensive experience in guiding external partners in implementing enzymatic purification methods in their processes and platforms. Over the last year he has focused on how enzymes with novel features can be used to simplify purification of protein-based products in bioprocessing, e.g., viral vectors, vaccines, and other biomolecules.
Jørn holds a Ph.D. in Biotechnology / Molecular Biology from University of Tromsø, Norway.

Shanghai Refreshgene Therapeutics is focusing on gene delivery to meet unmet medical need. To achieve this goal, we have assembled a highly experienced scientific and clinical team and built platforms for both AAV-based and nucleic acid-based gene therapy. Since July 2020, we have some milestones in both AAV-based and nucleic acid-based gene therapy. In AAV-based gene therapy, we are focused on developing transformative treatments to restore and improve vison and hearing loss. We are currently developing gene therapy product candidates for the treatment of AMD and heritable hearing loss, and the two leading pipelines have already confirmed the leading molecules for IND filing study.
Dr. Nova(Xinxing) Liu owns Ph.D of Physilogy from Peking University. He participated in the incubation of a gene therapy company spin-off from Peking University and was responsible as president for strategy formulation and implementation, team building, project management and clinical cooperation. At present, he works as general manager in Refreshgene.

Prof. Dr. Dr. Rolf G. Werner is Honorary Senator of University of Tübingen and Professor for Industrial Biotechnology. After his promotion at University Tübingen he spent more than three years in academia at Max Planck Institute for Molecular Genetics, Berlin, Germany and Massachusetts Institute for Technology, Cambridge, USA and has more than 35 years experiences in industry at Boehringer Ingelheim in top leading positions. He was responsible for the development and registration of the first, genetically engineered, protein therapeutic from mammalian cell culture: tissue plasminogen activator for myocardial infarction and stroke. More than 20 therapeutic proteins and monoclonal antibodies have been developed, manufactured and regulatory approved under his responsibility. He designed an operated the first 6x15.000 L mammalian cell culture plant in Europe, constructed in 18 months. Under his supervision, also processes for viral therapeutics and vaccines have been developed. He is consulting biopharmaceutical, viral therapeutic and vaccine companies in Europe and Asia in all aspects of research and production technologies as well as conceptual design of GMP biotech plants. His achievements are recognized by the Prize of the City of Vienna, Austria, for outstanding scientific work as well as from the Hangzhou Government, China, as Hangzhou Qian Jiang Distinguished Expert in Biotechnology. He is National Foreign Expert in China.

大学毕业于南京大学, 法国INSERM-巴黎第7大学分子生物学博士。
1996年加入 IBEX Pharmaceutical 公司，开发酶替代治疗产品。
2000-2006, Human Genome Sciences / Glaxosmithkline 带领40多人团队从事重组蛋白，抗体等产品的工艺开发、技术转移和 GMP生产。
2006-2011, Intercell/Valneva 公司领导 疫苗产品的工艺开发和GMP生产。
2012-2014，BioMerieux （生物梅里埃）美国的子公司Advanced BioSciences Laboratories (ABL inc)， 成功把公司从CRO 转型成CDMO 。专注做病毒产品的CMC开发，开发了几十个高难度的病毒产品的生产工艺和分析方法。包括： 慢病毒， Ebola-VLP，Adenovirus 和 基因治疗用的 AAV 载体 。
2015-2020，REGENXBIO inc 任AAV工艺开发总监，开发六个AAV产品 的生产工艺， 完成技术转让和GMP生产临床用的 AAV载体。 成功放大HEK293 悬浮细胞3质粒转染 生产工艺到2000L。是AAV生产工艺两个专利的第一作者。
2020.3月至今： 朗信生物CTO， 公司第一个AAV 基因治疗产品的IND 被CDE 受理；建立朗信生物的生产工艺平台/中试车间和质量系统， 完成了 3批次 200L 悬浮细胞的AAV生产， 将于2022年秋递交第二个AAC基因治疗产品的 IND。
张瑰宜博士有 25年北美生物制药公司的工艺和分析方法开发和 GMP生产经验。 成功拿到美国FDA 批准的 20 多个 IND， 2 个 BLA。

魏继业博士毕业于中国科学院上海生理所（1991-1995年），师从杨雄里院士，获视觉脑科学博士学位，随后赴美国耶鲁大学医学院眼科中心从事博士后研究（1995-1998）， 并升任耶鲁大学眼科中心副研究员（1998-2001）,独立主持自己的实验室。自2001年，分别在美国Alcon（2001-2010）, Novartis （2010-2013, NIBR）, Intrexon (2013-2014)和Allergan(2014-2015)等多家著名跨国生物制药公司担任资深科学家，首席科学家和主任科学家。2018-2019年，他作为主持人（PI）赢得NIH基金一项（NIH STTR， President of Skyran Biologics， Philadelphia, PA, USA）。另外，他还赢得2012年诺华制药（Novartis）研究院火花创新奖。他自2015年9月担任新加坡国立眼科中心（SERI）及新加坡科技署分子细胞研究院（IMCB，A*STAR）新生血管项目(SIPRAD)联合所长（2015-2018），全权管理2000万美元BMRC国家基金及全球合作项目。旅美生活及工作20多年，在中国，美国和新加坡著名的大学及国际跨国公司担任领导职位。

姜儒鸿博士，ASC Therapeutics Inc (ASCTx)创始人，董事长，总裁及首席执行官。ASCTx公司以其独特的干细胞和精准基因修饰技术确立了其在干细胞、精准基因编辑和干细胞及基因治疗领域的国际领先地位。 自2008年成立以来，公司持续保持着年增长率100%以上的优秀业绩，几家国际著名生物创投机构投入7500万美元。 2014年4月和2016年9月两度被《自然生物技术》（Nature Biotechnology）评为“引领精准基因编辑应用技术的全球前十名公司”。
姜儒鸿博士1986年毕业于复旦大学生物系，1991年获北京农业大学硕士学位（现为中国农业大学），1997年在美国俄克拉荷马州立大学获博士学位。 毕业后进入德州贝勒医学院继续深造，在著名的Douglas Burrin博士组中作博士后。期间共发表学术论文40余篇，涵盖人类遗传学、药物基因组学及动物疾病模型等多个领域。姜儒鸿博士曾在多家美国生物技术和生物医药公司担任技术和管理要职。姜博士领导的课题组曾开发出全美市场最早的个性化药物诊断测试技术FamilionTM，该技术2007年市场利润超过1200万美元。 在创建ASCTx公司之前，他曾任美国MicuRx医药有限公司中国区总经理，全权负责其在中国的业务。姜儒鸿博士对于个性化药物、再生医学和全球健康产业等课题有深入的研究。
姜儒鸿博士以其执着精进，敢为人先的创新精神，勤奋务实的工作作风，敏锐前瞻的市场洞察力，优秀的资源整合能力和真诚、谦虚、积极、乐观的处事风格，深受员工的爱戴和合作伙伴的尊敬，在业内具有良好的口碑和广泛的影响力。
Ruhong Jiang, Ph.D., is CEO of ASC Therapeutics Inc. - A global leading company in stem cell and precise genome editing. He has held a variety of technical and managerial roles with increasing responsibilities in several biotechnology/biopharmaceutical companies. Before starting Applied StemCell, Ruhong was general manager of MicuRx(Shanghai)Pharmaceutical, Inc. a California‐based biopharmaceutical company where he set up its entire China operation. From 2005‐2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi‐millions of annual budgets. Prior to relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then director of project management at Genaissance Pharmaceuticals from 2000‐2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development. Dr. Jiang graduated from Fudan University with a B.S. degree in biology and received M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma state University in 1997. From there Ruhong went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin’s lab. Dr. Jiang has authored and co‐authored more than 40 publications in the fields of human genetics, pharmacogenetics and disease animal models. Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker‐based molecular assays or diagnosis, CRO service, and drug research and development.

- Founder, Chairman and CEO, Neukio Biotherapeutics
- VP & CTO, Fosun Pharma
- Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years
- COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies.
- Head of Operations, GSK R&D Center in China
- Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China
- Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA
- Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA
Richard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.

· Professor of Molecular Physiology and Director of Regenerative Medicine Centre, Aston Medical School
· Founder of Allife Medicine，CSO
Pro.Gu is a Ph.D. supervisor, director of Molecular Physiology and Director of Regenerative Medicine Centre at Aston Medical School, a scientist and founder of Allife Medicine, and a visiting professor at Beijing Hospital. He used to be a professor at the Institute of Molecular Medicine of Peking University, an associate professor at the University of Birmingham, an honorary consultant at the Obstetrics and Gynecology Hospital of the University of Birmingham, a researcher at St. Edmund’s College and Wolfson College of Cambridge University, and a consultant for GSK drug research; an officer of the Royal Society of Physiology and a member of the British Society for Microcirculation. With many years of experience in the development and production of new immune cells and stem cell drugs, he has led the development of "off-the-shelf" allogeneic chimeric antigen receptor natural killer cell (CAR-NK) injections for ovarian cancer and human induced pluripotent stem cells for acute stroke. (iPSC)-derived endothelial progenitor cell injection is the first breakthrough cell product in this field that has been accepted for clinical trial application by CDE, and is an important milestone in the development of domestic immune cells and stem cell therapy applications.

Shi-Jiang (John) Lu, PhD, MPH, is currently the President and CEO of HebeCell Corporation, focusing on the development and clinical translation of regenerative medicine and cell therapy technologies, especially iPS-CAR-NK cells for the treatment of cancer, autoimmune and viral infectious diseases. Before establishing HebeCell, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which was acquired by Astellas Pharma in 2016. John is an expert in stem cell biology and regenerative medicine with 20 years of experiences. He has been conducting translational research and discovery of novel therapeutic strategies utilizing human pluripotent stem cells (PSC) and their derivatives. The goal of his research is to generate human PSC-derived products for the treatment of human diseases. He also has extensive experience in process development and large-scale production of human PSC derivatives under defined conditions for clinical trials. John is the inventor of more than 20 patents in stem cell field: in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, John’s patent application and citation ranked No. 7 and No. 5, respectively. In addition to stem cell research, Dr. Lu also has more than 10 years of experiences in cancer research. John received his BS degree in Biochemistry from Wuhan University, MSc degree in Oncology/Pathophysiology from Peking Union Medical College, MPH degree in Molecular Toxicology/Environmental Sciences from Columbia University and PhD degree in Molecular Cancer Biology from University of Toronto.

Graduated from the Munich university of applied sciences and has been worked in the German National Center for Environmental Sciences as an assistant scientist. His work was mainly focused on the field of microbiology.
Since 2014 Mr. Wang has joined the Miltenyi Biotec and held different positions within the company. With 8 years of work experience, he is very familiar with the CGT manufacturing workflows and total solutions based on MACS technology.
He has participated in the establishment of the Miltenyi global technical support system and training system for the CliniMACS Prodigy and Plus portfolio.

Dr. Dong Wei joined EdiGene as CEO in 2018, a biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer.
Prior to EdiGene, Dr. Wei had over 20 years of experience in innovative drug development and management, including leading over 10 global clinical-stage programs in multiple therapeutic areas at BioMarin, Elan, Johnson & Johnson and Shire, advising healthcare and life science clients on strategic and operational issues at Deloitte Consulting, as well as conducting drug discovery and technology development at Chiron and Applied Biosystems.
He holds BS in Genetics from Peking University, Ph.D. in Microbiology from Michigan State University and MBA from the Wharton School of University of Pennsylvania.

Patrick Liu, MD, PhD is currently President at CureGenentics. Before joining CureGenetics, Dr. Liu had served as Chief Scientific Officer at Livzon Medicine Groups, Corporate Vice President and Chief Strategy Officer at Jiangsu Hengrui Medicine Groups, Vice President of Global Biologics at Teva Pharmaceuticals, R&D Director at Genentech, Inc. and Adjunct Professor at the University of Maryland.  
  Dr. Liu has more than 20 years of R&D strategies and management in innovative therapy development with increased responsibilities in the leadership role for the development and commercialization of a variety of new biologics and as well as cell and gene therapeutics products across the therapeutic areas of oncology, hematology, immunology, allergy, respiratory and infectious diseases. He has contributed to the success of developing many blockbuster innovative medicines including Avastin, Herceptin, Perjeta, Lucentis, Xolair and Copaxone, and many other biologics such as Lonquex, Granix, Ovaleap, Cinqair, Trogarzo and Ajovy. Dr Liu had practiced medicine, specializing in Endocrinology and also holds a Ph.D. in Molecular Biology and Biochemistry from Peking Union Medical College and Chinese Academy of Medical Sciences.

Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center. He was a tenured professor in the Department of Pathology and Immunology, Baylor College of Medicine. Dr. Zheng worked for GlaxoSmithKline R&D Center as the head of Immunological Discovery Sciences. He was a global vice president of the Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, responsible for the innovative immunological drug pipeline in the region. Dr. Zheng is now the Chief Executive Officer at BRL Medicine.
Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.

· Dr. Xu has over 20 years of academic and biopharma experience in Immunology/oncology. As the head of R&D at Innovent cells, Dr. Xu oversees the discovery, CMC, Quality management, clinical development, and business development &alliance management.
· He has spent 3 years at Innovent Biologics working as VP, Head of Biology &Translational Medicine where he was responsible for the discovery of novel biologics and translational research of clinical assets.
· Prior to joining Innovent Biologics, he was a group leader and principal scientist at Roche Oncology Discovery (Switzerland), where he has delivered 4 NMEs to the clinical development, co-invented 15+ patents of FIC/BIC molecules including P329G-CAR during his 7 year’s tenure.
· He has authored 20+ publications in the high-impact journals e.g. Science Translational Medicine, Nature Communications, Blood, Journal of Experimental Medicine, Journal of Thoracic Oncology, etc.
· He obtained his PhD in Medicine in 2007 at Leiden University Medical Center, the Netherlands, followed by a post-doctoral training at Baylor Institute for Immunology Research in the US.

·5年以上细胞治疗产品质量分析方法开发、验证、样本分析和IND申报经验。熟悉细胞治疗产品的结构设计、作用机制、CMC质量分析和临床生物分析等。
•负责2个流式分析、2个活性分析平台的搭建，负责多个产品从早期研发—CMC生产—临床生物分析的全流程管理，具有数万个细胞治疗产品样本分析经验。
•熟悉细胞治疗产品的流式分析和活性分析，能够充分结合各检测方法的功能特点，深入分析产品在开发、生产以及临床应用过程中的关键特征，客观准确的选择临床生物检验的分析策略。
•5+ years experience in quality analytical method development, validation, sample analysis and IND filing of cell therapy product. Familiar with the structural design, mechanism of action, CMC quality analysis and clinical bioanalytical analysis of cell therapy products.
•Established and operated 2 flow cytometry and 2 biological activity analysis platforms. Leading the whole process management of multiple products from early R&D to CMC production and clinical bioanalysis.
•Familiar with flow cytometry analysis and biological activity analysis of cell therapy products. Be able to fully combine the functional characteristics of each method, deeply analyze the key features of product in the process of development, production and clinical practice, and objectively and accurately select the analytical strategy for clinical bioanalysis.

8 years physician in the internal medicine department in tertiary care hospital. Worked as head of CO for MNC of various industries for 16 years. BI, AZ, BMS, managing and leading over 300 clinical projects. Prior to joining PPC, Senior VP of a leading China-originated biotech company, rich experience by managing clinical, medical & regulatory affairs. Insight into R&D needs & paths of China-originated biotech.

Mr. Liu formerly served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, Tony held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global e-commerce platform. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider. Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process. Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S. Mr. Liu obtained his Washington State CPA certificate in 1992. He had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013 and was appointed as Chief Financial Officer in January 2014. He was appointed as Chief Executive Officer of the Company in February 2016.

Dr. Wen (Maxwell) Wang currently is the Chief Executive Officer in IASO Biotherapeutics Co., Ltd. He obtained his M.D. degree in Wuerzburg University in Germany and Ph.D. degree from University of Aberdeen in UK and then did his postdoctoral training in at UConn Health Center in USA.
Dr. Wang has over 7 years of experience in Chinese Leading cell therapy companies including JW Therapeutics, Cellular Biomedicine Group (Nasdaq: CBMG) in clinical, preclinical, and translational development including CART cell and stem cell therapy. He held one of leading position in the 1st Chinese CD19-targeted CART cell and Mesenchymal Stem Cell INDs.
Before industry career, Dr. Wang worked as a Resident and Attending in Orthopedic Department in Shanghai TCM Hospital for 5 years.

Dr. Lin Yang is currently a Distinguished Professor at the Cyrus Tang Hematology Center of Soochow University, China, and an adjunct professor of Department of Lymphoma and Myeloma at the MD Anderson Cancer Center, USA. Dr. Yang is the founder/chairman/chief scientific officer of PersonGen BioTherapeutics (Suzhou) Co., Ltd., and Chairman/CEO of PersonGen-Anke Cellular Therapeutics Co., Ltd. Dr. Yang received many awards, including Innovation and Entrepreneurship Talent of Jiangsu Province, Six Peak Talent of Jiangsu Province, Gusu Innovation and Entrepreneur Leading Talent, Pioneer of Suzhou Industrial Park Technology, Nanjing “321” Technology Leaders, Second Prize of China Innovation and Entrepreneurship Competition, and many other honorary titles and awards. He has published more than 70 research articles in recognized peer reviewed journals, such as Cancer Cell, Cancer Research, Oncogene, JBC, and Cancer Science, etc., which were all funded by international, national and provincial foundations.
As a principle investigator, Dr. Yang plays a major role in the immunotherapy of CAR-T cells and CAR-NK cells of China, and has obtained impressive achievements in the industrialization and clinical trials of CAR-T cell therapy. Among them, several clinical trials are the first-in human projects performed globally, including CAR-T cell therapy for T-cell acute lymphoblastic leukemia, and 4th generation CAR-T cell therapy for solid tumors. Led by Dr. Yang, PersonGen-Anke’s CD19-CAR-T product has been submitted to Chinese FDA and is being under the evaluation process which is expected an approval from CFDA within next few months.

Grace Zhou, professor, doctoral supervisor, national high-level distinguished expert, the only winner of the 2019 International "Anti-Virus Female Scientist Award". Co-founder, CEO and Chairman of ImmVira Group.
Grace Zhou is a Ph.D. from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and a former associate professor of the Department of Microbiology at the University of Chicago. She has devoted more than 20 years of research in the field of antiviral infection and herpes oncolytic virus tumor immunotherapy. With scientific research projects at all levels and provinces and cities, nearly 50 SCI papers have been published as the first author or corresponding author, with a citation index of 1055; more than 10 international invention patents in the United States, Europe, and Asia have been obtained, and nearly 20 international patents have been applied for. Served as an editorial board member of the international journal Frontiers Virology, and reviewed manuscripts for Proc Natl AcadSci US A, Mbio and Journal of Virology. Dr. Zhou is the international inventor of herpes-targeted oncolytic viruses. She has changed the way herpes viruses enter host cells for the first time. This research is called the cornerstone of herpes-targeted tumors by international colleagues.
ImmVira was founded by Grace Zhou and other 5 co-founders on May 18, 2015 as a biotechnology company focused on genetically modified oncolytic viruses as potential cancer therapeutics. The company has developed science, technology and know-how to support ongoing research, development and commercialization of best in class oncolytic viruses on the OvPENS (OV+ Patent, Enabling, Novel & Safe) platform.

赵春林 博士，安龙基金创始合伙人，安龙生物创始人，为清华大学生物系首届毕业生，获得美国匹兹堡医学院分子生物学博士和芝加哥大学工商管理硕士，曾任美国辉瑞制药资深经理，国科嘉和及康桥资本董事总经理，拥有三十多年生命科学及医疗健康领域的创业和投资经验，投资过信达生物，贝瑞合康，天镜生物，歌礼药业，莱凯医药，创响生物及国科恒泰等杰出企业。赵春林博士曾任清华大学生命科学院，医学院及药学院首届校友会主席，为百华协会资深会员。 安龙基金是一只专注于国内早期生命科学与医疗健康领域的基金，投资领域横跨生命科学，医药研发，医疗器械，医疗服务及相关领域。 安龙生物是国内核酸药物领先企业，专注基因治疗，RNA，基因编辑等核酸药物的新药研发。专业之外，赵春林博士喜欢足球，滑雪，曾做过DJ，拥有三个漂亮可爱的女儿。
Chunlin Zhao, Ph.D
Founder of the AnlongMed/AnlongBio. Dr. Zhao is among the first class graduated from Biological Science and Technology department at Tsinghua University in 1990. Then, he received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China, he founded Beijing LongMed biological technology co., LTD and then became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, GKHT and Imagine. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association of School of Life Sciences，School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading fund in Chinese life sciences and health care, focusing on biotech & pharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.

Dr. Yi Jin obtained her Ph.D. degree from Iowa State University and received postdoc training at University of California at Berkeley later. She has 15 years experience on therapeutic biologics discovery and development in Pharmaceutical and Biotech companies in US and China. Worked as project leaders for lead discovery at Bayer (USA), responsible for antibody discovery and novel technology platform. During her tenure, she led multiple projects through different stages of the development, including target discovery and validation on autoimmune disease and cancer immunotherapy. Currently, she serves as Chief Scientific Officers in Shanghai Genbase Biotechnology Co., Ltd.

Life member of Chinese Society of Immunology, director of Immunology Committee of Hubei Cancer Society. Engaged in tumor immunotherapy research for nearly 20 years, involving preclinical and clinical studies of multiple Class I new drug projects. Presided over a number of major national science and technology projects such as "Major New Drug Development". He has applied for or obtained more than 20 national invention patents, obtained eight software copyrights, and published a monograph. Selected as the 2019 Leading Entrepreneur Talent Project in Suzhou Industrial Park. Entrepreneurship projects have won awards in multiple entrepreneurial competitions.

Fangfang Zhu, Founder and CEO of HemaCell Therapeutics Inc.
The tenure-track Associate Professor at Shanghai Jiao Tong University.
Dr. Zhu has over 15 years of experience in stem cell research and investment, she is the co-authors of many research articles published in high profile international journals, such as Cell Stem Cell, Nature Communication, PNAS, Nucleic Acids Research, et al, which have a total of nearly 2000 citations, and she is the inventors to several PCT patents, some of which have been licensed to biotech companies and research institute. Dr. Zhu was the Vice President of WI Harper Group, focusing on the early-stage investment at Healthcare field. Dr. Zhu was the Siebel Scholar at Stanford University and won the SVIEF “Sandhill” Investment Award. She was the former President and Chairman of PKU Alumni Association of Northern California (PKUAANC) and Secretary and Board Member of Zhejiang Chamber of Commerce, USA (ZCC-USA).
Dr. Zhu got her Ph.D. degree at cell biology from Peking University with the mentor Dr. Hongkui Deng and had her postdoctoral training in the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and her supervisor is Dr. Irving Weissman, the “Father of Stem Cells”.

Dr. Zhang Yu is the SVP&CSO of Vcanbio Cell&Gene Engineering Co.,Ltd (A listed company on Shanghai A stock). Prior to join Aeon, Dr. Zhang was president and CEO of Aeon Therapeutics, a joint-venture biotech company between Eureka Therapeutics Inc. and Vcanbio; assistant president in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and a Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf. In the period of Germany, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several cell therapy journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan” and “Tianjin Green Card Plan”.

周立博士,现任合源生物首席科学官（CSO），深耕抗体和免疫细胞治疗领域超过20年，曾就职于诺华制药，丽珠医药集团，Sangamo therapeutic/TxCell和绿叶制药等全球知名制药企业的研发部门，拥有丰富的新技术研发和产品开发经验，曾领导过多项CAR-T产品、双特异抗体产品、创新技术平台的研发工作，包括人源化的CD19 CAR-T产品、双特异性CAR-T、多款血液瘤和实体瘤CAR-T产品、可调控CAR-T技术、隐形CAR-T技术、全球第一款克服器官移植中的免疫排斥的CAR-Treg TX200-TR101、以及T cell engager bispecific 抗体等。周立博士曾在SCIENCE、PNAS等期刊发表文章、拥有超过20项专利和专利申请。

Dr. Xu is the founder and CSO for Biocelltech Therapeutics, Ltd. His research work on CAR-T therapy started in 1996. As the first Project Manager for CAR-T therapy in Dr. Carl June’s lab at the University of Pennsylvania, Dr. Xu made significant contributions for the CTL019 development that was the first FDA-approved autologous CAR-T therapy. He also led HLA-mismatch allogenic CAR-T therapy application （“Beijing Approach”）that is used worldwide currently. His research on gene editing platform MgCRISPR was granted for a patent，which is an easy-used tool for gene therapy. His research on protein-editing will overcome the issue of “off-targeting” in gene therapy.
Dr Xu is a medical doctor and scientist, as well as guest professor at Peking University, Capital Medical University and other research institutes. He is the first Chairman of Penn Medicine China Club.

David (Zhenwei) Miao, Ph.D, is the President and Chief Executive Officer of the Imbioray (Hangzhou) Biomedicine Co.,Ltd. Dr. Miao holds a Ph.D. in chemistry from Peking University. He received his postdoctoral training at Vanderbilt University Medical Center.
2000-2003，Dr. Miao served as the Principal Scientist at Enanta Pharmaceuticals, where he led a drug discovery program that resulted in the HCV drug (Viekira Pak) in collaboration with Abbvie. Viekira Pak was approved by FDA in 2014, and was the second drug in the world to cure HCV.
2004-2011, Dr. Miao held the position of the Senior R&D Team and Director/Head of Chemistry at Ambrx Inc. He initiated and led many biotherapeutic programs. One of them was Arx-788, the anti-Her2-ADC drug undergoing phase II clinical trials.
2011-2014, as a serial entrepreneur, Dr. Miao founded a number of biotech companies: Concortis Biosystems Corp., Levena Biopharma（Nanjing,）,Levena Biopharma（Suzhou）、ImmunoMab、Zova Biotherapeutics Inc.
In 2014 Dr. Miao founded Imbioray (Hangzhou) Biomedicine Co.,Ltd，focusing on NK/CAR-NK immunotherapy and CD47 bispecific antibody drug development. In 2016 Dr. Miao was awarded as a Leading Talents of Hangzhou city and the Expert of Leading Talents of Zhejiang Province.

Dr. Changfeng Zhang is the director of the Department of Regulatory Affairs, Shanghai Pharmaceuticals Holding Co., Ltd. He was one of the core members of Dr. Carl June’s team at the University of Pennsylvania and contributed substantially to the IND affairs of CTL019 (AKA Kymriah). Dr. Zhang specialized in RA affairs of CART products and achieved the IND approval of the first gene-modified CART product in China. Additionally, he established collaborations with the Chinese FDA, NICPBP, and several regulatory agencies by introducing world-famous CART therapists such as Drs. Stephan Grupp and Joseph Melenhorst. Dr. Zhang has several publications in top-ranked journals such as Nature Medicine, Blood, etc. He is also the High-level Talent of Shenzhen, Zhuhai, Suzhou, and Nanchang.

Dr. Xueqiang Zhao is the CEO and co-founder of China Immunotech (Beijing) Biotechnology Co. Ltd. He received his PhD degree in tumor immunology from Chinese Academy of Sciences, and got his postdoctoral training in MD Anderson Cancer Center, studying the activation of T cells. In 2014, he joined Tsinghua University as an associate professor, working on genetically engineered T cells for cancer immunotherapy. Dr. Zhao has more than 15 years’ experience in tumor immunology and has 20 patents on CAR-T and TCR-T therapies, and over 30 peer-reviewed publications. Currently, he is a co-founder of China Immunotech, which pioneered the innovative TCR-based STAR technology. The STAR-T cell therapy combines the advantages of TCR-T and CAR-T cell therapies, exhibiting HLA-independent killing of tumor cells and generating low CRS effects in clinical trials. The STAR-T therapy has done clinical trials in 30 patients with hematological malignancies, which were reported by the 2020 ASH and will be presented on EHA meeting next month. And The effects of STAR-T cells on treating solid tumors were published by Science Translational Medicine in March, 2021.

Dr. XIE got his Master’s degree in Medicine from Peking University and Ph.D in Pathogenic Biology from China CDC. He started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. Dr. XIE is the founder, chairman and CEO of Corregene. He founded this cell therapy company in 2016, which focused on developing T-cell therapy for solid tumor patients.

Prof. Lai Wei received his Bachelor of Medicine from Beijing University of Chinese Medicine China and Ph.D. in Bioinformatics and Pathology from University of Tennessee Health Science Center USA. He then worked as a Research Fellow, Staff Scientist, and Principal Investigator in National Institutes of Health, USA. He then worked as a Professor of Ophthalmology and the Deputy Director of Research Institute in Zhongshan Ophthalmic Center, Sun Yat-sen University between 2013 and 2021. Prof. Wei co-founded Smilebiotek and MingMed Biotechnology, and joined MingMed as the CSO and serves as a member of the Board of Directors in 2022. Prof. Wei has published 113 peer reviewed articles in journals including Cell, Nature, Nat Med., Cancer Cell, Nat Immunol., Immunity, Prog Retin Eye Res., PNAS et al. (total IF>1300 and total citations>11000). He also serves as scientific editors and reviewers on multiple journals and reviewers for domestic and international grant agencies. His current work focuses on investigating pathogenesis of ocular inflammatory diseases and developing novel diagnostic tests and therapeutic agents for eye diseases.

Wei Zuo, Professor is the founder and chairman of Regend Therapeutics Inc., a leading company in cell therapy and regenerative medicine with expertise in lung and kidney field. He is also the professor and PI of Organ Regeneration Laboratory of Tongji University, Shanghai, China. Prof. Zuo graduated from Sichuan University in 2006 and obtained Ph.D. degree in Biology from Tsinghua University. After that, he had his postdoc training in University of California, San Diego, US and Genome Institute of Singapore, A*STAR, Singapore. Then he relocated back to China and became the leading scientist of National Key R&D Plan for stem cell research, and the National Distinguished Expert. Prof. Zuo and his team accomplished the first human lung stem cell transplantation clinical trial in the world. He developed the first-in-class stem cell product REGEND001, which has been approved by NMPA for Phase II clinical trials. He published many research papers in Nature, AJRCCM, EMBO etc., and serves as the editor of multiple journals (Gene Therapy, Stem Cell Internationals etc.) Because of Prof. Zuo’s great contribution of regenerative medicine, he was officially elected as the “Top 10 Innovation Pioneers of China of the Year”.

陆金华博士是TriArm Therapeutic Co.的联合创始人，首席科学家。此前他在美国食品和药物管理局，作为临床前专家审评员，负责审评细胞和基因治疗，医疗器械，以及组合产品。他专长的领域是免疫治疗，基因/干细胞治疗和治疗性疫苗。在审评工作之外，他还任职多个科学委员会和工作小组，参与撰写FDA指导文件等工作。他曾担任美国FDA癌症卓越中心科学委员会成员，并获得FDA监管科学卓越成就奖。在任职FDA之前，他作为资深科学家，部门主管和咨询顾问服务于政府和生物技术工业界，负责研发用于肿瘤治疗的病毒载体和病毒疫苗。
Dr Lu is the co-founder and CSO of TriArm Therapeutic Co. He was an expert nonclinical reviewer at OTAT, CBER, FDA and specializes in reviewing immunotherapies, stem cell and gene therapies, and therapeutic cancer vaccines. He has regulatory experience in all stages of clinical development, from the Interact stage to BLA. He also served on numerous scientific committees and working groups, and participated in other FDA outreach activities with the biotech industry. Dr. Lu served as a member of scientific committee of Oncology Center of Excellence, FDA and was the recipient of the CBER award for Excellence in Regulatory Science Research in 2015.
Prior to joining the FDA, Dr Lu worked in the biotechnology industry as a senior scientist, manager and consultant in the development of vaccines for viral diseases and developing viral vectors for cancer therapy.

Huashun Li MD & PhD is the founder of ATCG Corp.based in Suzhou,Dr. Huashun Li graduated from the Second Military Medical University in Shanghai, China in 1986. He got his master degree from the PLA General Hospital in Beijing in 1989. He was a visiting scholar in Johns Hopkins University School of Medicine, Baltimore, Maryland, USA from 1991 to 1994. He did the PhD dissertation in the laboratory of Dr. Yi Rao in the Department of Anatomy & Neurobiology from 1994 to 1999, and received his PhD from Washington University School of Medicine in St. Louis, Missouri, USA in 1999. He was a postdoctoral fellow in the laboratories of Drs. Yuh Nung Jan and Lily Jan in the Department of Physiology, Howard Hughes Medical Institute at the University of California San Francisco from 1999 to 2005. He has been an assistant professor in Developmental Neurobiology Program in the Institute of Molecular Medicine and Genetics at the Medical College of Georgia, Augusta, Georgia, USA since 2005. He was recruited to become a founding director of West China Developmental & Stem Cell Institute at Sichuan University in 2007 and has become the founding director of SARITE Center for Stem Cell Engineering Translational Medicine in Shanghai East Hospital Tongji University School of Medicine. He found the ATCG Corp. Ltd, based in Biobay, Suzhou, China in 2013, focusing on developing “off-shelf” cell drug for cancer immunotherapy.

Emily holds a Masters degree in Epidemiology from London School of Tropical Medicine and Bachelor of Pharmacy (Hons) from National University of Singapore. Emily has 25 years in the pharmaceutical industry and deep leadership experience in clinical development, operations, and commercial management. She has worked for a number of multinational pharmaceutical companies (Astrazeneca, Pfizer) and clinical CROs (Syneos, Parexel).
With a particular focus on global project management and strategic business development, she was responsible for establishing Asia-Pacific Clinical Teams in various companies. At Parexel, she was global account head responsible for developing global key customers, and successfully supported Chinese pharmaceutical companies including BeiGene in entering overseas markets and running multiregional clinical trials.
In 2020, she relocated to China, serving as Chief commercial officer at DMed Global and later entered the Cell & Gene Therapy arena as Chief operating officer of Origincell Therapeutics
Emily拥有伦敦热带病医学院流行病学硕士学位和新加坡国立大学药学荣誉学士学位，加入临床研究领域前任职于新加坡国立大学医院。
Emily在制药行业25年，在临床开发、运营和商业管理方面拥有深厚的领导经验。她曾在多家跨国制药公司（阿斯利康，辉瑞）和临床CRO（Syneos，Parexel）工作。
她特别善于全球项目管理和战略业务发展，在多家公司负责建立亚太临床团队。在Parexel，她曾担任全球客户主管，负责开发全球大客户，并成功支持中国制药公司，包括百济神州进入海外市场并开展多区域临床试验。
2020年，她移居中国，担任缔脉的首席商务官，后来进入细胞与基因治疗领域，担任原启生物的首席运营官。

Dr. Yijia Li has a bachelor degree of biology from Tsinghua University and double degree of Economics and Management from Peking University. After his Ph.D. at Florey Institute of Neuroscience and Mental Health at University of Melbourne, he joined Shunxi-Monash University Joint Lab, participated and facilitated several translational projects.
In 2015, he was appointed as the founding director of Yunnan Province Stem Cell Bank. In 2018, he joined Tsinghua University Yangtze Delta Research Institute focusing on Stem cell translational research. He leads several projects in both China and Australia with fund up to nearly 5 million USD and has translated several books into Chinese including 6th Edition of NetCord-FACT Cord Blood Accreditation Manual and Common Standards for Cellular Therapies. In 2022, Dr. Li has set up a 4600 sqm GMP CDMO platform, which is the first one in China focusing on stem cell drugs production.

华毅乐健总裁&联合创始人。吴凤岚博士在医药领域拥有丰富的产业和金融背景，在医药研发、资本运作、公司运营等方面有13年的实践经验。其曾在葛兰素史克、再鼎医药担任资深科学家近10年时间，承担6个临床前项目的IND申报。目前，这些项目已全部进入上市销售或临床试验阶段。后又在浩悦资本、华兴资本担任副总裁等职位，主导境内外多起生物科技公司私募融资。吴凤岚拥有同济医学院生物药学士学位，和上海交大医学院免疫学硕士及药学博士学位。

第二军医大学医学学士, 加拿大阿尔伯塔大学免疫学博士。曾任上海长海医院医生，美国麻省大学医学院讲师及研究助理教授，上海恒瑞医药细胞免疫治疗部负责人，国家科技部肿瘤免疫治疗重大攻关项目PI。现为亘喜生物SVP和研发负责人。

Zefeng Wang is a principal investigator and the CAS Shanghai Institute for Nutrition and Health, and scientific founder of CirCode BioMed and Enzerna Bioscience Inc. Zefeng received his bachelor degrees as double major in Biological Science and Computer Technology from Tsinghua University, and a PhD degree at Johns Hopkins University. After working as a Damon Runyon post-doc fellow at MIT, he became an assistant professor at UNC at Chapel Hill in 2007 and was promoted to associate professor with tenure in 2013. In 2015, he moved his lab to Shanghai and became the director of CAS-MPG Partner Institute for Computational Biology (PICB), a partner institute jointly run by Chinese Academy of Science (CAS) and Max-Planck-Gesellschaft (MPG), which was merged to SINH in 2021. He is also the director of CAS key lab in computational biology.
As a scientist and an entrepreneur, Zefeng’s research focuses on the system biology of RNAs. He has made significant contribution to the filed of RNA biology by developing a series of genomic approaches to study RNA splicing and dysregulation in a systematic fashion. His lab is the first group to discover that circular RNAs can be translated inside cells, and further studies the regulatory mechanism of circRNA translation. He has also pioneered the filed of engineering RNA binding proteins to specifically manipulate RNA metabolism, which can be used as a research tool or potential therapeutic reagents. Based on the technology developed in his lab, he has founded two Biotech companies focusing on the development of new therapeutics using circRNAs and the engineered RNA binding proteins. He has published >70 research papers that were cited >9000 time, and served on the editorial board of dozens of journals (including Genome Biology, JBC, BBA, Molecular Cancer, etc.). His work was recognized by several research awards, including RNA Society/Scaringe Young Scientist Award, Alfred Sloan Research Fellow, Kimmel Scholar Award, Beckman Young Investigator, Max-Planck Fellow, Mercator fellow and MOST innovation team leader.

星北·产业服务平台执行总监，星北·自贸壹号招商总监。拥有多年生物医药园区运营经验，擅长产业研究与平台搭建，服务并成功落地50多个重大创新生物医药项目。

CTU-UIBE MBA
清华工研院细胞与基因治疗创新中心负责人
北京荷塘生华医疗科技有限公司常务副总经理
中国医药生物技术协会合成生物技术分会秘书长
农工党党员
2019年北京市科技新星
主持清华工研院细胞与基因治疗创新中心运营建设。现主持省级以上科技项目2项，作为骨干参与省级以上科技项目5项。现有国际专利4项，在申专利5项。曾参与主持全球首款合成生物基因治疗药物SynOV1.1的研发，该产品目前已经通过中国（CDE）和美（FDA）临床实验许可，正同时在中美开展临床I/IIA期临床研究。

左炽健 博士，苏州科锐迈德生物医药科技有限公司首席科学家。博士毕业于德国弗莱堡大学。苏州科锐迈德生物医药科技有限公司创始合伙人，首席科学家，主要从事环状mRNA平台建设，包括新的成环框架的研发，环状mRNA功能元件的筛选及优化，以及环状mRNA工艺开发研究。同时将环状mRNA应用于肿瘤免疫，肿瘤治疗性药物的研发，以及致力于新型冠状病毒等传染病疫苗的开发工作。已参与申报环状mRNA相关专利17项，公开相关学术论文4篇。同时主导并成功开发全套mRNA核心蛋白原料。

Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,300 patients in clinical trials since 1996. He is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis. Dr. Levine is co-inventor on 28 issued US patents and co-author of >180 manuscripts and book chapters with a Google Scholar citation h-index of 89. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. Dr. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, the National Marrow Donor Program/Be The Match ONE Forum 2020 Dennis Confer Innovate Award, serves as President of the International Society for Cell and Gene Therapy, and serves on the Board of Directors of the Alliance for Regenerative Medicine. He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Bloomberg, Forbes, BBC, and other international media outlets.

Dr. Yangbing Zhao is the President and CSO of UTC Therapeutics Inc. He received an MD and PhD in Immunology from the Third Military Medical University in Chongqing. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as an Adjunct Associate Professor and the Director of T Cell Engineering Lab. The research work at the University of Pennsylvania let to multiple clinical trials using CART or TCR T to treat cancer patients. Dr. Zhao has more than 20 years’ experiences in T cell engineering and his seminal work directly led to multiple clinical trials of treating cancer patients with T cells modified with TCR, CARs and CRISPR genome editing. Dr. Zhao has over 50 TCR-T and CART related publications and filed over 90 patents. Dr. Zhao is co-founder of Tmunity Therapeutics.

 Dr. Yuling Li is a seasoned executive with proven experience in biopharmaceutical development from clinical to commercialization. She was a R&D Director and Fellow at MedImmune/AstraZeneca and Senior Director of Purification Sciences at HGS (now GSK). She played key roles in the development of 3 approved products and contributed to over 30 clinical development programs.
In 2014, she received the Rising Star Award from the Healthcare Businesswomen’s Association. She served as the President of the Chinese Biopharmaceutical Association and co-founded the Alliance of ALL-CABPA in 2008.
Dr. Li has authored over 40 publications and is the primary inventor for seven issued patents. She received her Ph.D. from Robert Wood Johnson Medical School at Rutgers University.
玉玲博士是一位有着丰富经验的企业管理者，在生物制药工艺开发及生产领域有着资深的实战经验。李博士曾任AstraZeneca（阿斯利康）旗下美国生物制药公司MedImmune的科技和工艺研发主任，以及美国人类基因科学公司（现为葛兰素药业）的资深主任。李博士参与了30多个药品的注册申请，并且成功主持报批了其中三个产品。
2014年，李博士获得了医疗行业女企业家协会新星奖，曾担任美国华人生物医药科技协会（CBA）2007‐2008的会长，CBA董事会和顾问董事会的成员，也是美华生物医药联盟(All‐CABPA) 的发起人和创任会长之一（该联盟于 2008 年 5 月成立）。
李博士发表了40多篇科学论文，有5项批准专利。李博士在罗格斯大学RWJ医学院获得博士学位。

丁力承，现上海药品审评核查中心药品检查员，主要从事生物制品生产检查，包括药品生产许可检查、药品注册生产现场检查、药品GMP。曾在生物制品生产企业从事质量管理、验证及工程工艺设计等工作。

宋晓东博士现任优替济生生物医药有限公司首席执行官，专注开发肿瘤免疫治疗细胞药物。在强生公司任职期间，宋博士代表强生深度参与了南京传奇BCMA CART的合作项目，成功获得了全国第一个CART注册临床批件和国内CART药物在美国的第一个注册临床批件。在上海恒润达生生物科技有限公司任副总经理期间，宋博士带领团队在1998获得了全国仅有的7个CAR-T注册临床批件中的3个，并在上海中山医院率先启动了全国第一个CART注册临床试验。宋博士还利用特殊审评通道，成功获得了国内CART药物在以色列的第一个临床批件。
宋博士曾任美国强生公司全球法规注册事务部总监并在强生工作6年。他是强生亚太地区药品生产领导团队的成员之一。宋博士负责监督和支持强生公司在中国以及亚太地区有关药物研发，药品生产和注册申报中的法规事务。宋博士也曾担任过RDPAC药学理事会主席。他一直积极参加与中国药品监管和法规注册相关的活动，并与国家药品监督管理局以及各行业协会合作共同促进中国医药行业法规的健全和发展。应国家药监局的邀请，宋博士起草了第一稿细胞治疗产品的GMP附录。
在加入强生公司之前，宋博士曾在美国辉瑞公司工作16年。他曾在辉瑞公司全球药物研发中心，全球药品生产总部和全球仿制药专利侵权调查部门任职。宋博士曾担任辉瑞全球仿制药专利侵权调查部门的负责人。他还创立了辉瑞制药公司辅料化学协会并担任首届主席，领导开展与辅料相关的技术研究和制剂开发。宋博士也曾是辉瑞全球药物研发中心新药剂型研发团队的主要成员。
在加入辉瑞公司之前，宋博士在美国康涅狄格州的奥林公司接受生物化学博士后训练。他于1995年在美国路易斯安娜大学获得药物化学博士学位，于1990年在中国科学技术大学获得分析化学硕士学位，于1987年在浙江工业大学获得分析化学学士学位。

Stephan Grupp, MD PhD, is the Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Medical Director of The Cell and Gene Therapy Lab at the Children’s Hospital of Philadelphia (CHOP), as well as the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine.
Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology.
He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest and most successful engineered T cell therapy clinical trial conducted to date (1, 2), as well as the global registration trial for CTL019 (3). As a result of this work, he presented the Clinical Perspective at the July 2018 FDA ODAC meeting, at which reviewers voted 10-0 for recommendation of approval for Kymriah in pediatric ALL. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Dr. Grupp is a reviewer for several journals and the author of over 200 peer-reviewed journal articles, as well as numerous abstracts and book chapters.

Dr. Hartmut Tintrup is the Global Head of Business Development & Partnering activities for Lonza’s Cell & Gene Technologies Business Unit. He started at Lonza in 2017 with the responsibility of Business Development & Partnering Activities for the EMEA region. Dr. Tintrup has more than 15 years of experience in the biotech industry spanning leading positions in R&D, industrial sales as well as partnering activities including licensing. He holds a PhD in Biochemistry received at the Max-Planck-Institute for Brain Research in Frankfurt/Germany.

Dr Mickey Koh received his medical degree in Singapore and all his subsequent specialist Haematology training including his FRCPath, MRCP and PhD in London.
He holds several joint positions. Dr Koh is a Consultant Haematologist and Senior Lecturer at St George’s Hospital and Medical School, London, UK. He is also the Programme Director of the Stem Cell Transplant Programme as well as being the Clinical Lead for Bone Marrow Failures and Rare Haematological Diseases at St George’s Hospital.
At the same time, he is also the Programme Director of the Cell Therapy Facility in Singapore involved in cell therapy trials cross haemato-oncology and regenerative medicine. He was also previously the Deputy Director of the National Blood Service in Singapore
Dr Koh sits on the board of various transplant and cell therapy organizations including being the Chairperson of the Cell Therapy Working Party at International Society Blood Transfusion and Chairperson of the Graft Processing/Cellular Therapies subcommittee of Worldwide Network for Blood and Marrow Transplantation. He is a past Board member of the International Society of Cellular Therapy Therapy and is Vice _president of the ISCT presidential Task force on Unproven therapies. Dr Koh has also been an advisor to the World Health Organisation on matters of transfusion and cellular therapies. He is widely published and is also on the editorial board of various peer reveiwed journals

Dr. Steve Oh obtained his PhD from Birmingham University, UK (1990) and is the Director of Stem Cell Bioprocessing and Institute Scientist, Stem Cell Group. He holds several industry leadership roles e.g. Past Vice President of International Society of Cell and Gene Therapy (ISCT); Member of International Society of Stem Cell Research (ISSCR); Member of International Stem Cell Banking Initiative (ISCBI); Vice President of Stem Cell Society Singapore (SCSS). He is also an Adjunct Associate Professor at NTU, PhD Supervisor at A*STAR Graduate Academy and has received research funding grants ranging from SGD 10 to 25 million. He has 42 Patents, granted and pending, 107 scientific publications, written the book “Sensational Stem Cell: How to cure medical complications.” and created 2 companies: Veristem and Zenzic Labs.
Our research is focused on human adult and pluripotent stem cell bioprocessing. Our team has developed a range of patent families for the manufacture of mesenchymal stem cells, reprogrammed human induced pluripotent stem cells and created neural cells, cardiomyocytes, blood cells, cartilage, bone and retinal pigment epithelial cells at bioreactor scale using a range of microcarrier technologies including biodegradable ones. Most recently, we have achieved a novel method of directed differentiation using CRISPR technology that will accelerate therapeutic applications of stem cells. A complimentary technology that has been developed is the use of microfluidics for separations of cell and particulates.

Richard received degrees of B.S of Cell Biology from the University of Science & Technology of China, Ph.D of Molecular Biology from the University of Maryland, Baltimore, and MBA from Xavier University, Cincinnati in the US. He obtained his post-doctoral training at the National Institutes of Health, Baltimore, USA. Richard now is the CEO of Fosun Kite Biotechnology. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients. Richard is very experienced in biopharmaceutical industry. Having spent close to 20 years in R&D and management positions in both the US and China, he has taken senior roles and increasing leadership responsibilities in Procter & Gamble Pharmaceutical, Bristol-Myers Squibb in the US, AstraZeneca Innovation Center and GSK R&D Center in China. Prior to Fosun Kite, Richard was the Chief Operation Officer of Cellular Biomedicine Group (NASDAQ: CBMG), where he was in charge of the company’s immunotherapy pipeline including manufacturing, clinical development and registration, and the stem cell business unit.

Biliang Hu obatined PhD degree in University of Southern California. Then he continued Postdoc training of CART cell immunotherapy under Dr. Carl June’s mentoring in University of Pennsylvania, and has developed the fourth generation of CART secreting IL-18. After postdoc training, he founded celledit in US and Siweikang Therapeutics in China to develop the SAFET platform to resolve CRS during CART therapy.

Dr. Yangbing Zhao is the President and CSO of UTC Therapeutics Inc. He received an MD and PhD in Immunology from the Third Military Medical University in Chongqing. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as an Adjunct Associate Professor and the Director of T Cell Engineering Lab. The research work at the University of Pennsylvania let to multiple clinical trials using CART or TCR T to treat cancer patients. Dr. Zhao has more than 20 years’ experiences in T cell engineering and his seminal work directly led to multiple clinical trials of treating cancer patients with T cells modified with TCR, CARs and CRISPR genome editing. Dr. Zhao has over 50 TCR-T and CART related publications and filed over 90 patents. Dr. Zhao is co-founder of Tmunity Therapeutics.

 Dr. Lu graduated from Peking University  Medical School, and had her residency training at the University of Nebraska Medical Center in USA. 
She completed her hematology and  oncology fellowship at Stanford University  Medical Center. 
• American Board Certified Hematologist & Oncologist, with American and Chinese Medical License.
• Member of ASH，ASCO & CAHON
• Chairman of Hematology Specialty Committee of  Chinese Non-government Medical Institutions Association (CNMIA)
• Member of Chinese Marrow Donor Program(CMDP) Expert Committee
• Member of Chinese Society of Clinical Oncology (CSCO) Anti-Leukemia Alliance Expert Committee
• Member of the Hematology Translational Medicine Committee of China Anti-Cancer Association（CACA）
• Vice Chairman of Sanhe Private Hospital Industry Association
• She has had many awards which including National Cancer Institute individual fellowship award, physician scientist award  (K011)

Grace Zhou, professor, doctoral supervisor, national high-level distinguished expert, the only winner of the 2019 International "Anti-Virus Female Scientist Award". Co-founder, CEO and Chairman of ImmVira Group.
Grace Zhou is a Ph.D. from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and a former associate professor of the Department of Microbiology at the University of Chicago. She has devoted more than 20 years of research in the field of antiviral infection and herpes oncolytic virus tumor immunotherapy. With scientific research projects at all levels and provinces and cities, nearly 50 SCI papers have been published as the first author or corresponding author, with a citation index of 1055; more than 10 international invention patents in the United States, Europe, and Asia have been obtained, and nearly 20 international patents have been applied for. Served as an editorial board member of the international journal Frontiers Virology, and reviewed manuscripts for Proc Natl AcadSci US A, Mbio and Journal of Virology. Dr. Zhou is the international inventor of herpes-targeted oncolytic viruses. She has changed the way herpes viruses enter host cells for the first time. This research is called the cornerstone of herpes-targeted tumors by international colleagues.
ImmVira was founded by Grace Zhou and other 5 co-founders on May 18, 2015 as a biotechnology company focused on genetically modified oncolytic viruses as potential cancer therapeutics. The company has developed science, technology and know-how to support ongoing research, development and commercialization of best in class oncolytic viruses on the OvPENS (OV+ Patent, Enabling, Novel & Safe) platform.

Lijun Wang is a co-founder and CTO of Exegenesis Bio. She has over 20 years biotech industry experience and the most recent 15 years were focused gene therapy viral vector CMC, including process development, process engineering and cGMP manufacturing of viral vectors (AAV, LV, Ad and oHSV). Prior to her venture, working for a well-known CDMO in the field, Brammer Bio (formerly Florida Biologix), she has led a number of viral vectors projects from early process development to cGMP CTM batches using multiple production platforms from early to late phase clinical applications. She is a successful leader dedicated to bring bench scale processes to clinical stage ready and future commercial-viable.

汪敏博士毕业于中国科学技术大学，获得细胞生物学专业博士学位，现任博生吉医药科技（苏州）有限公司技术总监。
汪敏博士致力于CART细胞药物的开发与产业化事业。她赴德国接受美天旎全自动CART工艺培训期间，以其专研、严谨的工作态度，获得了合作方的好评。汪敏博士带领博生吉的CART细胞部门，不仅建立了全自动CART细胞制备工艺平台，而且进行了大量的优化和改进工作，为打造适合中国国情的CART细胞全自动生产线作出了突出的贡献。在汪敏博士的具体领导下，博生吉获得了“靶向CD19嵌合抗原受体T细胞输注剂”的新药临床试验批件，这也是中国首个以全自动工艺获得临床批件的CART项目，为博生吉未来的产业化发展奠定了坚实的基础。
汪敏博士代表公司参加”创响中国“安徽省创新创业大赛决赛，荣获生物医药组第一名。此外，汪敏博士还带领公司技术部门，对多个First-in-class CART新药进行了大量的工艺开发和优化，为博生吉新一代CART细胞药物的IND申报创造了条件。
Dr. Wang received her Phd of Cell Biology from University of Science and Technology of China(USTC), and is currently the Technical Director of PersonGen BioTherapeutics(Suzhou) Co., Ltd.
Dr. Wang is committed to the development and industrialization of CART cell drugs. She led the CART cell department of PersonGen and has not only established the automatic CART cell manufacture platform, but also carried out a lot of optimization and improvement work.Under the leadership of Dr. Wang, PersonGen has obtained the clinical trial approval for "CD19 chimeric antigen receptor T cell infusion agent", which is also the first CART project in China to obtain clinical approval by the whole-automatic process, laying a solid foundation for PersonGen's future industrial development.
On behalf of the company, Dr. Wang participated in the final of the "Innovation and Entrepreneurship Competition of Anhui Province" and won the first place in the biomedical group.In addition, Dr. Wang led the technology department of the company to develop and optimize a number of first-in-class CART new drugs, creating the conditions for PersonGen to apply IND for a new generation of CART cell drugs.

Dr. Wang has more than twenty years of experiences in Biochemistry and Molecular Biology and in the development of biologic products. Currently is Executive Director of Plasmid and Gene Therapy Process Development and manufacture at Innoforce Pharmaceuticals in Hangzhou. Prior to joining Innoforce, he is Director of Plasmid Production at Vigene Biosciences in Maryland USA. He obtained his Ph.D in Biochemistry from Shanghai Institute of Organic Chemistry, Chinese Academia of Sciences.

Dr. Frank Fan, Chief Scientific Officer of Legend Biotech Co., is the co-founder of the company. Frank received his medical degree at Xi’an Jiaotong University in 1993 and worked as surgical resident in kidney Transplantation Centre of the university before he pursued and obtained his Ph.D. in applied immunology at Hiroshima University. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of the mechanism of human B cell tolerance. A breakthrough he made in the area was published in Nature Medicine and the knowledge led to a major revision in the clinical guideline of pediatric organ transplantation. He was awarded a “New Key opinion leader” by The International Society of Transplantation in 2006. He published more than 40 peer-reviewed scientific reports in human B cell biology, transplant immunology, and gene therapy. Funded by GenScript, Dr. Fan founded Legend Biotech in 2014 and built an elite R&D team exploring innovative precision cell therapy. In just 3 years, the company grew from a fresh start to a global leader in cell therapy of multiple myeloma. The LCAR-B38M product Dr. Fan invented is the first cell therapy product obtained IND approval from both the CFDA and the FDA.

陆金华博士是TriArm Therapeutic Co.的联合创始人，首席科学家。此前他在美国食品和药物管理局，作为临床前专家审评员，负责审评细胞和基因治疗，医疗器械，以及组合产品。他专长的领域是免疫治疗，基因/干细胞治疗和治疗性疫苗。在审评工作之外，他还任职多个科学委员会和工作小组，参与撰写FDA指导文件等工作。他曾担任美国FDA癌症卓越中心科学委员会成员，并获得FDA监管科学卓越成就奖。在任职FDA之前，他作为资深科学家，部门主管和咨询顾问服务于政府和生物技术工业界，负责研发用于肿瘤治疗的病毒载体和病毒疫苗。
Dr Lu is the co-founder and CSO of TriArm Therapeutic Co. He was an expert nonclinical reviewer at OTAT, CBER, FDA and specializes in reviewing immunotherapies, stem cell and gene therapies, and therapeutic cancer vaccines. He has regulatory experience in all stages of clinical development, from the Interact stage to BLA. He also served on numerous scientific committees and working groups, and participated in other FDA outreach activities with the biotech industry. Dr. Lu served as a member of scientific committee of Oncology Center of Excellence, FDA and was the recipient of the CBER award for Excellence in Regulatory Science Research in 2015.
Prior to joining the FDA, Dr Lu worked in the biotechnology industry as a senior scientist, manager and consultant in the development of vaccines for viral diseases and developing viral vectors for cancer therapy.

武汉华大吉诺因生物科技有限公司，总经理
广东省精准医学应用学会免疫治疗分会，副主任委员；
深圳市医学学会第一届肿瘤免疫治疗专业委员会，常务委员；
中国医药生物技术协会基因检测技术分会第一届委员会，委员。
研究员，从事基因组学、肿瘤免疫治疗研究；发表包括《Nature》、《CELL》在内的SCI文章28篇，文章累计引用次数超过2300次。主持开发了靶向肿瘤新抗原T细胞药物，获得国内首个肿瘤新抗原药物的临床试验批件。

Life member of Chinese Society of Immunology, director of Immunology Committee of Hubei Cancer Society. Engaged in tumor immunotherapy research for nearly 20 years, involving preclinical and clinical studies of multiple Class I new drug projects. Presided over a number of major national science and technology projects such as "Major New Drug Development". He has applied for or obtained more than 20 national invention patents, obtained eight software copyrights, and published a monograph. Selected as the 2019 Leading Entrepreneur Talent Project in Suzhou Industrial Park. Entrepreneurship projects have won awards in multiple entrepreneurial competitions.

刘光华 于清华大学获得博士学位，目前担任北京艺妙神州医药科技有限公司开发总监一职，参与负责了IM19 CAR-T细胞药物的细胞工艺及非临床药理药效毒理研究，完成IM19 IND申报所需非临床研究资料。成功支持IM19 CAR-T细胞注射液获得临床试验批件。

Dr. Pengfei Yuan has more than ten years of experience in gene editing technology development and application transformation. He is currently the Chief Technology Officer at EdiGene.
Dr. Yuan is part of the earliest group of Chinese scholars exposed to genome editing technologies. He has made many valuable contributions to improve and develop genome editing technologies. His research results have been published in Nature, Cell, Nature Biotechnology and other top science publications. Dr. Yuan was also the former executive director of many key projects funded by the National Natural Science Foundation of China. His personal honors include being selected as Beijing Science and Technology New Star, Zhongguancun Young Eagle Talent, and winning the first prize of Beijing Youth Excellent Science and Technology Paper.
Dr. Yuan holds a double bachelor's degree and doctorate degree from Peking University. During his PhD and postdoctoral studies, he studied under Professor Wei Wensheng, a well-known expert in the gene editing field. He also has the title of Associate Researcher in the Beijing Natural Science Research Series.

Dr. Mingyao Liu received his PhD degree in the University of Maryland College Park (1992), did his postdoctoral training and fellowship in John Hopkins University School of Medicine and California Institute of Technology (Caltech) (from 1993-1998), respectively. He started his independent lab as an assistant professor in 1999 at the Institute of Biosciences and Technology, Texas A&M University and was promoted to tenured full professor in 2006. He was the Dean of the School of Life Sciences, East China Normal University from 2012-2020. Now he is the nationally-endowed professor and the Director of Institute of Biomedical Sciences and Shanghai Key Laboratory of Regulatory Biology in East China Normal University, Shanghai. He is also the founder and Chairman of Shanghai Bioray Laboratories Inc. and two other biotech companies. Dr. Liu's research interests are focused on developing innovative gene editing strategies in cell and gene therapies for cancer and genetic diseases, as well as GPCR-signaling based drug discovery. He has been the PIs for major national scientific research programs from MOST, national key research projects from NSFC, and national new drug discovery projects. He has published more than 350 peer-reviewed journal articles, including Science, Nature, Nature Medicine, Nature Biotechnology, PNAS etc. He has applied for more than 100 patents and won the first prize of National Science and Technology Progress Award in 2012 and the Shanghai Magnolia Memorial Award in 2014. He is the president of Chinese Society for Cancer Cell Biology since 2017.

曹卫博士（Ph.D.，B.M.）于2017年5月创立亘喜生物科技集团（纳斯达克股票代码：GRCL），担任董事长兼首席执行官。曹博士在生物技术研发领域深耕超过30年，包括成功（联合）创立了两家在纳斯达克上市的细胞与基因疗法公司。在创立亘喜生物前，曹博士是前纳斯达克上市公司西比曼生物科技集团（前纳斯达克股票代码：CBMG）的联合创始人。该公司致力于开发用于治疗癌症和退行性疾病的专利细胞疗法。2010年8月至 2016年1月，他曾在西比曼担任多个职位，包括首席运营官、首席执行官和董事等。在此之前，曹博士还曾在Chiron公司（诺华和拜耳）以及全球遗传分析行业领导者Affymetrix（赛默飞世尔）公司先后担任科研领域的高管职位。在学术领域，曹博士同样积累颇丰，他曾在哈佛医学院和斯坦福大学医学中心从事免疫药理学领域相关研究，并持有复旦大学上海医学院医学学士学位和美国弗吉尼亚医学院药理学博士学位。值得一提的是，曹博士同时还是80多个国内外细胞治疗技术专利（申请）的主要发明人。
Dr. William (Wei) Cao, Ph.D. B.M., has been the Founder, Chairman and Chief Executive Office of Gracell Biotechnologies Group (Nasdaq: GRCL) since its foundation of May, 2017. Dr. Cao has over 30 years of research and development experience in the biotechnology industry, including founded and co-founded two Nasdaq-listed companies in the field of cell & gene therapies. Prior to founding Gracell, Dr. Cao co-founded Cellular Biomedicine Group, Inc. (formerly Nasdaq: CBMG), a formerly Nasdaq-listed company engaged in the development of proprietary cell therapies for the treatment of cancer and degenerative diseases, and served as COO, CEO and director from August 2010 to January 2016. Before that, Dr. Cao served at senior scientific management positions at Chiron (Novartis and Bayer) and Affymetrix (ThermoFisher). Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College in Shanghai, China and a Ph.D. in Pharmacology from The Medical College of Virginia, U.S. Dr. Cao also has over 80 issued patents and applications for advanced cell therapies.

Mr. Liu formerly served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, Tony held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global e-commerce platform. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider. Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process. Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S. Mr. Liu obtained his Washington State CPA certificate in 1992. He had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013 and was appointed as Chief Financial Officer in January 2014. He was appointed as Chief Executive Officer of the Company in February 2016.

王建勋教授是广东君厚生物医药有限公司的联合创始人兼首席科学家，加州大学圣迭戈分校博士后，现任北京中医药大学特聘教授，博士生导师，深圳北京中医药大学研究院细胞和基因治疗研究所所长。王建勋博士师从美国科学院院士Michael G. Rosenfeld，Christopher K. Glass，在Nature等世界顶级杂志发表多篇论文，为表观遗传学专家，主要探索利用表观遗传性状改变来增强T细胞识别和杀伤肿瘤的功能，实现CAR-T治疗实体肿瘤的突破。曾是美国Sorrento Therapeutics公司资深科学家，建立了CAR-T cGMP生产体系, 具有丰富的细胞治疗标准工业化生产经验。是构建逆病毒，慢病毒等基因载体的国际顶级专家，具有丰富的病毒载体标准工业化生产经验。

Chunlin Zhao, Ph.D
Founder of AnlongMed and AnlongBio. Dr. Zhao is among the first class graduated from Department of Biological Science and Biotechnology at Tsinghua University in 1990. He received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China in 2003, he founded LongMed Inc., and became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment track record, invested in Innovent, BerryGenomics, ASLETIS, GKHT and Inmagine. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association for School of Life Sciences，School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading fund in Chinese life sciences and health care, focusing on biotech & pharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio, a leading player in genetic medicine in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.

Dr. Jimmy Zhang has 20+ years of experience and expertise in both large pharmas and start-up companies, in strategy, management, business development, and operations, as well as in venture investments. Jimmy is founder, chairman and CEO of AccuGen Group, focusing on gene and cell therapy. He was a Venture Partner at Lilly Asia Ventures (LAV), and Vice President of Transactions at Johnson & Johnson, where he led the transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, as well as fund relationship and partnership. Jimmy was the Managing Director, MSD Early Investments – Greater China at Merck & Co., and a member of Merck Research Lab (China) Senior Leadership Team. He was also a Board Director of BeiGene (Beijing) Co, Ltd. and an Advisor Board member of Cenova Ventures. Jimmy was previously SVP at Synergenics (an accelerator founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry), a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis).
Jimmy was a founding member and former Chairman of BayHelix Group. He is an adjunct professor and master degree mentor at Yeehong Business School at Shenyang Pharmaceutical University. He holds an MBA from MIT Sloan School of Management, where he was elected as the treasurer of MIT Graduate Student Council; a PhD in biomedical sciences from University of Texas Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates; and a BS in biochemistry from Nanjing University. Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents.

Dr. Alvin Luk is the CEO at Neurophth Therapeutics, Inc., bringing over 29 years of leadership experience in global drug development, strategic portfolio management and clinical development. Prior to joining Neurophth, he has served as Senior Vice President and Chief Medical Officer at Shanghai Henlius Biotech, Inc., and he has held executive roles at various companies such as Spark Therapeutics, Inc. (acquired by Roche), Biogen-Hemophilia (acquired by Sanofi), Bayer Healthcare, Avigen, Inc. (acquired by Sanofi Genzyme) and Tularik, Inc. (acquired by Amgen) of progressive responsibilities since the late 1990s. Until 2003, his early research was primarily investigating gene regulation and expression with the emphasis on rare diseases, oncological diseases, biologics and regenerative medicines. He also served as a member at the industrial board of the US FDA Rare Disease Clinical Design Committee, focusing on optimizing clinical trial design to shorten drug development timeline between 2006 and 2009. Under his leadership in strategic drug development, he has won regulatory marketing approvals of 18 products in neurology, ophthalmology, gene/cell therapy, hematology and cancer therapy as of today.
Dr. Luk has published more than 85 book chapters, scientific and medical articles in highly regarded peer-reviewed journals, including New England Journal of Medicine, Nature, Cell, and Science, and is an inventor on over 10 patent applications. Dr. Luk holds an MBA from Harvard Business School. He is ACRP-certified in clinical research and also received his PhD in Neuroscience from the University of California San Francisco Medical School.

Dr. Bin Xiang, a biologist by training, has solid research experience in disease biology, intestine biology, genome editing, AAV and bacterial vector gene therapy. Dr. Xiang founded CommBio Therapeutics Co., Ltd. in 2019 and devote to develop novel medicine by focusing on intestine biology and bacterial delivery system. Currently, Dr. Xiang is the CEO of CommBio, and the College Advisor at ShanghaiTech University.
Dr. Xiang obtained Ph.D in neurobiology from Fudan University Shanghai Medical in 2001, followed by postdoctoral training in cancer biology at Cold Spring Harbor Laboratory and cancer translational research at Vanderbilt University Medical Center.
In 2008, Dr. Xiang switched career to drug discovery and joined AstraZeneca Innovation Center China working on oncology translational medicine. In 2011, Dr. Xiang joined China Novartis Institutes for Biomedical Research (CNIBR). At Novartis, Dr. Xiang was the project team leader having directed both small molecular drug and AAV gene therapy in oncology and metabolic disease. In addition, Dr. Xiang led an innovation group exploring novel disease mechanism from intestine biology and developing new class of drug approaches including genome editing and gene therapy.

阿姆斯特丹大学医学博士，风险投资公司Forbion Capital的合伙人，原UniQure 的联合创始人和首席科学官，莱顿大学的转化胃肠病学教授。 Sander 是一位卓越的科学家，发表了400多篇科学论文，组织过多次大型的国际学术会议，指导了40多名博士研究生。1998年，他与人合作创立了阿姆斯特丹分子治疗中心(AMT，即UniQure的前身)，开发基于AAV的基因治疗产品。 Sander曾成功创建多个生物制药公司，在开发世界第一个靶向人TNF人鼠嵌合单克隆抗体药物（Remicade)和推动第一个基因治疗药物（Glybera)获得上市许可发挥了关键的作用，现加入博腾生物，任职CSO。

中国科学院遗传学研究所硕士，美国北卡罗来纳州立大学生物化学博士，杜克大学Dr. Joseph Nevins实验室的博士后；美国基因与细胞治疗学会基因编辑委员会理事，拥有16项基因治疗的相关专利。孔令洁博士曾在美国默沙东制药公司和美国应用干细胞公司担任研发副首席科学家/副总监和副总裁等重要领导职位，有超过20年的生物制药、基因治疗和细胞治疗经验；参与了默沙东多个药物的研究开发，其中Januvia ® 年销售额超过60亿美元；领导了多项基因治疗和细胞治疗药物的研发，包括推进两个基因治疗和细胞治疗的项目在美国分别进入临床I期和临床II期阶段。
Dr. Ling-Jie Kong got his BS degree in biology from Shandong University and MS degree from Institute of Genetics, Chinese Academy of Sciences. He got his PhD in Biochemistry from North Carolina State University, and postdoc training at Dr. Joseph Nevins Lab at HHMI, Duke University. Dr. Kong has over 20-year experience in drug discovery in oncology, hematology and metabolic diseases. He served as associate principal scientist at Merck and Vice President at Applied StemCell. Dr. Kong is an expert in gene and cell therapy especially gene editing base gene therapy. He has led numerus drug discovery programs including two IND stage programs in gene and cell therapy, applied 16 patents in gene therapy related areas. Most recently he was elected to the Gene Editing Committee of American Society of Gene and Cell Therapy. Dr. Kong Joined Porton Bio as CTO, taking charge the technology development in gene and cell therapy.

Eddie Sun obtained his Ph.D in Biology from University of Nottingham in UK, and started his career in a cell and gene therapy start-up company in China. Later, Eddie served across MNC as technical support and business development, and now supports cell biology business including cell and gene therapy for Thermo Fisher in regions of Great China and Japan.
Eddie focuses introducing Thermo Fisher innovation to regions and bringing regional needs to Thermo Fisher R&D team.

于艳，毕业于华东理工大学，药学硕士，于2017年9月加入颇尔公司，担任整体解决方案专家一职。拥有9年的行业经验，她现在主要负责基因及细胞治疗整体解决方案业务的推广，熟悉单抗和基因及细胞治疗等生物制药领域的工艺流程，致力于为客户提供优质的全流程工艺解决方案。
Yan Yu served as GTCT Integrated Solution Specialist of Pall China Biotech with a master’s degree in pharmacy from East China University of Science and Technology. She joined Pall in 2017, with 9 years biotechnology experience, Yan’s currently responsible for business promotion of Pall’s total solutions. With solid knowledge of mAb and GTCT process, she’s dedicated to serve customers’ needs with Pall’s excellent products and services.

谢胜华，06年毕业于西安交通大学。拥有十二年的病毒载体生产和研发经验，参与过多个细胞治疗病毒载体的工艺开发项目并顺利完成2个中美项目的注册申报，现就职于金斯瑞蓬勃生物，负责质粒病毒载体工艺开发和商业化生产工作。
Shenghua Xie has nearly 12 years’ experience on viral vectors from lab scale to industrial grade after graduated from Xi’an Jiaotong University in 2006. As a key member, he successfully delivered two CMC projects of Gene and Cell therapy in China (NMPA) and US (FDA). Now, Mr. Xie works as a lead of plasmid and virus process development and manufacturing in GenScript ProBio.

马墨，深圳市深研生物科技联合创始人，公司专注于细胞与基因治疗中的核心生产工艺以及自动化生产设备的开发。公司提供基于稳定细胞系的慢病毒生产系统，无需质粒瞬时转染，使用无血清悬浮工艺，极大的提升慢病毒的产能及一致性。同时公司也提供基于封闭系统的细胞自动化生产设备，实现细胞制备的封闭化与自动化。
MA MO, co-founder of Eureka Biotechnology. Eurekabio focuses on the development of core production processes and automated production equipment in cell and gene therapy. Eurekabio provides a lentivirus production system based on stable cell lines that does not require transient plasmid transfection and uses a serum-free suspension process, which greatly improves the productivity and consistency of lentivirus. At the same time, Eurekabio also provides automated cell production equipment based on closed systems to achieve the closed and automated cell production.

Yu Lei, M.D. / Ph.D., is currently a “Zijiang” Distinguish Professor, Director of the Institute of the Biomedical Engineering and Technology (iBET), East China Normal University, China. He is also a member of Shanghai Pharmaceutical Committee, and member of China Clinical-Research Society of Cell Therapy Specialized Committee; At same time, Dr. Yu was also appointed an Adjunct Professor, Department of Chemical Pharmaceutical and Pharmaceutical and Department of Biological Engineering, University of Utah, US. Dr. Yu is an interdisciplinary experiences in medicine, clinical practice, basic medical research, translational medicine, pharmaceutical research, as well as a successful entrepreneur.

李懿，英国莱斯特大学博士，国家特聘专家，广东省领军人才，广东香雪精准医疗技术有限公司总裁兼CSO，中国科学院广州生物医药与健康研究院感染与免疫中心研究员，呼吸病研究国家重点实验室兼职研究员。在英国长期从事抗体和T 细胞受体的药物研发，主要论文发表在Nature Biotechnology, Nature Medicine，JBC, Molecular Cancer Therapy 等，开创性地将噬菌体展示技术应用于T细胞受体的定向进化研究，并开发出了全球第一个人源高亲和可溶性TCR，使TCR识别pHLA的亲和性提高了100万倍以上，这是TCR领域的关键性突破。曾在英国 Immunocore 公司领导团队成功研发出了多个高亲和性TCR，最终用于FDA批准的免疫治疗临床研究产品。2012 年回国主导建立了中国第一个高亲和TCR介导的T细胞治疗平台，带领香雪团队研发的第一款特异性TCR-T产品TAEST16001注射液已获得国家药监局批准的全国第一个TCR-T新药临床试验许可。
Yi Li, Ph.D. University of Leicester, UK, the National Distinguished Expert, Leading Talent of Guangdong Province, President and CSO of Guangdong Xiangxue Life Sciences, LTD, Principal Investigator of Center for Infection & Immunity at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, PI at the State Key Laboratory of Respiratory Diseases. He has been engaged in the development of antibody and T cell receptor drugs in the UK for a long time. Representative papers have been published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy, etc. He pioneered the application of phage display technology to the directed evolution of T cell receptors. He developed the world first human high-affinity soluble TCR, which the affinity for recognizing pHLA was increased by more than one million times as a key breakthrough in the field of TCR. Under his leadership his team has successfully developed a number of high-affinity TCRs at Immunocore in the UK, which has eventually been used in FDA-approved immunotherapy clinical research products. In 2012, he returned to China and led the establishment of China's first high-affinity TCR-mediated T cell therapy platform. The TCR-T product TAEST16001 injection developed by the Xiangxue team has obtained the first TCR-T IND approved by CDE of the National Medical Products Administration.

张雷，中科院生化细胞所博士毕业，在瑞士弗雷德里希生物医学研究所从事博士后研究，加入复星凯特后主持了Yescarta的技术转移落地，和早期临床阶段的CMC管理，目前正在进行全新一代CAR-T细胞药物的研发工作。

朱亚青，博士毕业于德国格赖夫斯瓦尔德大学，并在德国联邦动物健康研究所从事研究工作。现任阿思科力（苏州）生物科技有限公司工艺总监，负责公司CAR-NK细胞药物平台各管线产品的工艺转移，中试放大及产业化，并致力于适应现货型细胞治疗产品的新一代工艺开发工作。

Dr. Xinpo Jiang, Senior Director of Analytical Department/QA/QC at Legend Biotech, works on development of novel CAR T products in the pipeline. He was CMC Head leading LCAR-B38M CAR T product to clinical trial in China and US (collaborating with Janssen). He was Director of Pharmacology Department at GenScript for assay developments on biologicals and developed many cell-based and biochemical assays, oncology and antibody related functional assays. He received his Doctor of Philosophy from University of Minnesota, Twin Cities. He did a postdoctoral fellowship at Toronto Western Hospital, University of Toronto. Prior to his position at GenScript, Dr. Jiang was a research scientist at NeuroMed Pharmaceuticals. He published around 20 peer-reviewed journal articles and filed around ten patents.

Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a PhD in Molecular Cell Biology from the University of California, Berkeley.

Dr. Zhang Yu is the SVP&CSO of Vcanbio Cell&Gene Engineering Co.,Ltd (A listed company on Shanghai A stock). Prior to join Aeon, Dr. Zhang was president and CEO of Aeon Therapeutics, a joint-venture biotech company between Eureka Therapeutics Inc. and Vcanbio; assistant president in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and a Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf. In the period of Germany, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several cell therapy journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan” and “Tianjin Green Card Plan”.

Dr. Peter Xiaowen He has worked on R&D in the fields of immunotherapeutics, vaccine and cell-based products for more than twenty years with 25 patents and over 30 SCI published articles. Dr. He developed the therapeutic Serratia Marcescens formula approved by cFDA as Class I biological product and won the second prize of Science and Technology Progress Award for his development of therapeutic vaccine against hepatocellular carcinoma. Dr. He has been research professor and PIs in Stem Cell Center of New Jersey and Merck USA. Dr. He got a lot of funding from NIH and National Natural Science Foundation of China and led the teams to establish the key manufactory and quality control systems for cell-based therapeutics. Currently Dr. He worked as Co-founder and CSO in Origincell.

Tong-Cun, Zhang, Ph.D, M.D; a distinguished professor in Hubei Province, is currently the Dean of College of Life Sciences and Health at Wuhan University of Science and Technology(WUST).
Dr. Zhang has got his Ph.D degree in 2000 from Institute of Biophysics, Chinese Academy of Sciences. Dr. Zhang was once honored with the of NRC Postdoctoral Fellowship Award in 2000-2003 in USA and then joined in UNC at Chapel Hill as assistant professor. Since 2012 he has taken a full-time professor and dean in WUST.
Dr. Zhang has aimed to the scientific research of the gene regulation, related to human diseases and development of biological drugs. In recent years, he has focus on CAR-T cell therapy for blood and solid cancers. His team has carried out novel CAR-T clinical trial in several hospitals and got excellent clinical effects and safety, which were published in Blood and Leukemia. CAR-T targeting to CD30 is trialed in clinical phase I.
Dr. Zhang has obtained several grants from The National Natural Science Foundation of China and ministry of Science and Technology, including National Key Research Program, 863 Programs, 973 Program. He has published over 100 theses in relevant research fields at high level scientific Journals. Novel patents for CAR-T cell-therapy over world has been obtained in his leading team.
Since he come back China, Dr. Zhang has been honored with local and national talent and outstanding titles. He was also awarded US-EPA's Scientific and Technological Achievement Award in 2003.

Dr. XIE got his Master’s degree in Medicine from Peking University and Ph.D in Pathogenic Biology from China CDC. He started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. Dr. XIE is the founder, chairman and CEO of Corregene. He founded this cell therapy company in 2016, which focused on developing T-cell therapy for solid tumor patients.

Dr. Mingjun Wang，Executive President of Shenzhen Institute for Innovation and Translational Medicine, received his MD from Anhui Medical University in China and his PhD degree in Cellular Immunology from the University of Copenhagen in Denmark in 2009, and finished his postdoctoral training in cancer immunology at Baylor College of Medicine in Houston of the United States. His research is focused on identification of cancer antigens and the development of T cell-based cancer immunotherapy using TIL, TCR-T cells or CAR-T cells for various types of malignancies. Dr. Mingjun Wang has published more than 30 peer-reviewed papers and three book chapters in the field of cancer immunology.

David (Zhenwei) Miao, Ph.D, is the President and Chief Executive Officer of the Imbioray (Hangzhou) Biomedicine Co.,Ltd. Dr. Miao holds a Ph.D. in chemistry from Peking University. He received his postdoctoral training at Vanderbilt University Medical Center.
2000-2003，Dr. Miao served as the Principal Scientist at Enanta Pharmaceuticals, where he led a drug discovery program that resulted in the HCV drug (Viekira Pak) in collaboration with Abbvie. Viekira Pak was approved by FDA in 2014, and was the second drug in the world to cure HCV.
2004-2011, Dr. Miao held the position of the Senior R&D Team and Director/Head of Chemistry at Ambrx Inc. He initiated and led many biotherapeutic programs. One of them was Arx-788, the anti-Her2-ADC drug undergoing phase II clinical trials.
2011-2014, as a serial entrepreneur, Dr. Miao founded a number of biotech companies: Concortis Biosystems Corp., Levena Biopharma（Nanjing,）,Levena Biopharma（Suzhou）、ImmunoMab、Zova Biotherapeutics Inc.
In 2014 Dr. Miao founded Imbioray (Hangzhou) Biomedicine Co.,Ltd，focusing on NK/CAR-NK immunotherapy and CD47 bispecific antibody drug development. In 2016 Dr. Miao was awarded as a Leading Talents of Hangzhou city and the Expert of Leading Talents of Zhejiang Province.

金华君，博士，研究员。上海君赛生物科技有限公司创始人，CEO/CTO，民建上海市生物医药专委会执行主任。金华君博士拥有丰富的高校、医院、企业的产学研跨界从业经历，深耕肿瘤免疫机制研究和细胞疗法开发十多年，积累大量第一手研发与临床研究经验，熟练掌握细胞新药早期设计、工艺与检测技术开发、临床前研究、临床研究、新药注册申报等全流程。曾开发全球首个自表达抗体的CAR-T细胞治疗实体瘤的临床级技术，以及国内首个基于非病毒载体的CAR-T细胞新药品种，自主建立高效简便的TIL细胞富集培养技术以及转基因TIL细胞治疗方案。主持“重大新药创制”国家科技重大专项项目2项，国家自然科学基金2项，其它省部级课题6项；申请发明专利82项（已授权13项）；发表SCI论文30篇（以第一作者或通讯作者发表20篇）；曾作为技术端负责人，开展21项细胞免疫治疗项目的临床研究。

Dr. Bin Xiang, a biologist by training, has solid research experience in disease biology, intestine biology, genome editing, AAV and bacterial vector gene therapy. Dr. Xiang founded CommBio Therapeutics Co., Ltd. in 2019 and devote to develop novel medicine by focusing on intestine biology and bacterial delivery system. Currently, Dr. Xiang is the CEO of CommBio, and the College Advisor at ShanghaiTech University.
Dr. Xiang obtained Ph.D in neurobiology from Fudan University Shanghai Medical in 2001, followed by postdoctoral training in cancer biology at Cold Spring Harbor Laboratory and cancer translational research at Vanderbilt University Medical Center.
In 2008, Dr. Xiang switched career to drug discovery and joined AstraZeneca Innovation Center China working on oncology translational medicine. In 2011, Dr. Xiang joined China Novartis Institutes for Biomedical Research (CNIBR). At Novartis, Dr. Xiang was the project team leader having directed both small molecular drug and AAV gene therapy in oncology and metabolic disease. In addition, Dr. Xiang led an innovation group exploring novel disease mechanism from intestine biology and developing new class of drug approaches including genome editing and gene therapy.

Yun Jiang, a member of the Chinese Peasants and Workers Democratic Party, holds a CTU-UIBE MBA and is the winner of the Beijing Science and Technology New Star Program in 2019.
He is now the chairman and COO of Beijing Syngentech Co., Ltd; DGM of Beijing Lotuslake Biomedical Co., Ltd; Secretary General of synthetic biotechnology branch of China Pharmaceutical Biotechnology Association; Deputy Secretary General of liver cancer special committee of Asia Pacific Alliance for diagnosis and treatment of liver diseases.
Beijing SyngenTech Co., Ltd. is a national high-tech enterprise which is committed to using synthetic biology to develop new gene and cell therapy methods for tumor and gene diseases. Synov1.1, the world's first anti-tumor synthetic biotech gene therapy drug, was approved by FDA in 2020.

Dr. Yi Jin obtained her Ph.D. degree from Iowa State University and received postdoc training at University of California at Berkeley later. She has 15 years experience on therapeutic biologics discovery and development in Pharmaceutical and Biotech companies in US and China. Worked as project leaders for lead discovery at Bayer (USA), responsible for antibody discovery and novel technology platform. During her tenure, she led multiple projects through different stages of the development, including target discovery and validation on autoimmune disease and cancer immunotherapy. Currently, she serves as Chief Scientific Officers in Shanghai Genbase Biotechnology Co., Ltd.

Dr. Daozhan Yu graduated from Molecular Medicine at University of Maryland, School of Medicine. He has been working on several disease models, including diabetes, obesity, cardiovascular disease and neural diseases, for drug screening and gene therapies. He developed a new method to induce brown fat differentiation, which can increase the metabolism and cure obesity and diabetes; He also developed a new peptide drug for cardiovascular diseases that are a first-in-class drug in preclinical stage; Dr. Yu first established the iPSC model for Niemann-Pick disease and screened a small molecule, which are at phase III clinical trial.
Recently, Dr. Yu has been focusing on AAV mediated gene therapy. He worked as scientist at AAV gene therapy expert’s lab and led the virus production department as director in a renowned industrial company. In 2019, he founded AAVnerGene developing new technologies to solve bottleneck problems for AAV gene therapy. AAVnerGene has established the AAV capsid screening platform and is emerging as a game changer for next generation of AAV gene therapy.

Dr. Wen (Maxwell) Wang currently is the Chief Medical Officer in IASO Biotherapeutics Co., Ltd. He obtained his M.D. degree in Wuerzburg University in Germany and Ph.D. degree from University of Aberdeen in UK and then did his postdoctoral training in at UConn Health Center in USA.
Dr. Wang has over 7 years of experience in Chinese Leading cell therapy companies including JW Therapeutics, Cellular Biomedicine Group (Nasdaq: CBMG) in clinical, preclinical, and translational development including CART cell and stem cell therapy. He held one of leading position in the 1st Chinese CD19-targeted CART cell and Mesenchymal Stem Cell INDs.
Before industry career, Dr. Wang worked as a Resident and Attending in Orthopedic Department in Shanghai TCM Hospital for 5 years.

孙艳，上海细胞治疗集团副总裁，细胞药物BU总经理，主要从事CAR-T细胞药物开发及相关管理工作。带领团队完成国内首个非病毒载体CAR-T细胞药物的研究及注册申报，获得临床试验许可。

Dr. Wei Wang is the Vice President of Clinical Development at CARsgen. She leads CAR-T and monoclonal antibodies China clinical development programs and manages medical affairs, clinical operation, biometrics and pharmacovigilance.
She has over a decade experiences in China and global clinical development programs in Merck, Novartis and Pfizer, managing team in clinical development, medical affairs and pharmacovigilance. Dr. Wei Wang worked as the practicing pediatric physician for 6 years in Xiangya Hospital of Central South University. She earned her Master degree in clinical medicine from Central South University, and the M.D. & Ph.D. degree from Fudan University.

Jiangtao Ren is co-founder and Chief Scientific Officer of Nanjing Bioheng Biotechology. With 14 years gene-editing and cell therapy experiences, Dr. Ren had accumulated rich knowledge in the field of gene and cell therapies. Dr. Ren earned his Ph.D from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences in 2013, focusing on universal cell therapy using iPSCs and gene-editing. Dr. Ren pursued his doctoral training at UPenn and developed the first CRISPR-based “off-the-shelf” universal CAR-T cells for cancer treatment, together with professors Dr. Carl June and Dr. Yangbing Zhao. Dr. Ren previously worked at Novartis and TCR2 Therapeutics for the gene-editing and automated manufacture of cell therapies. Dr. Ren was the recipient of Innovation and Entrepreneurship Talent of Jiangsu Province and other awards, he also served as off-campus mentor for postgraduates of Hunan University and member of the Lymphoma Committee of Jiangsu province.

Dr. Xueqiang Zhao is the CEO and co-founder of China Immunotech (Beijing) Biotechnology Co. Ltd. He received his PhD degree in tumor immunology from Chinese Academy of Sciences, and got his postdoctoral training in MD Anderson Cancer Center, studying the activation of T cells. In 2014, he joined Tsinghua University as an associate professor, working on genetically engineered T cells for cancer immunotherapy. Dr. Zhao has more than 15 years’ experience in tumor immunology and has 20 patents on CAR-T and TCR-T therapies, and over 30 peer-reviewed publications. Currently, he is a co-founder of China Immunotech, which pioneered the innovative TCR-based STAR technology. The STAR-T cell therapy combines the advantages of TCR-T and CAR-T cell therapies, exhibiting HLA-independent killing of tumor cells and generating low CRS effects in clinical trials. The STAR-T therapy has done clinical trials in 30 patients with hematological malignancies, which were reported by the 2020 ASH and will be presented on EHA meeting next month. And The effects of STAR-T cells on treating solid tumors were published by Science Translational Medicine in March, 2021.

Dr. Enxiu Wang used to work in Dr. Carl June team at University of Pennsylvania, the global pioneer of CAR-T immunothery. As a key member, he had been focused on solid tumor CAR design and evaluation. Dr. Wang and his colleges’ patents solft-activating CAR system has been approvaled by both US and European countries. He founded Nanjing CART medical Co. Ltd at 2017. Since then 3 patents have been approvaled and 35 submitted for solid tumor CAR-T. Recoginized by the field, Dr. Wang’s team obtained several fundings from the state and provinces. What’s more Nanjing CART got investment of noted investment institutions. Now leading with Dr. Wang, Nanjing CART Med is making great progress in both drug discovery and IND application.

Pamela Yin, is the Application Development Manager of China region in CPC. Pamela has 10+ years’ experience of Application and Technical role in Pharmaceutical and Biotech industries, including the past 7 years focusing on single use technology in Bioprocessing. Her expertise is helping CPC to develop connection technology that support pharmaceutical customers to find the best connection solution with single-use technology.

清华大学肿瘤药理学硕士，复旦大学药理学博士生。具有十几年药品法规注册和研发项目管理经验，多年创业型生物医药企业工作经验。2017年初加入上海复星凯特生物科技有限公司担任总裁助理兼药政注册及公共事务总监，推动细胞治疗政策法规建立和中国第一个CAR-T的NDA申报。曾任上海医药质量协会细胞治疗专委会秘书长。此前，在复宏汉霖申报10了中国IND和2个双报项目，推动中国的生物类似药的法规其并推动中国第一个BiosimilarNDA批准上市。
Master Degree of Tumor Pharmacology, graduated from Tsinghua University. She has more than 10 years drug registration, regulatory affair and project management experience.
Crystal Sun joined Fosun Kite biotechnology company in early 2017, served as CEO assistant and director of regulatory affairs and government affair. She promoted the establishment of Development and Review Guideline of CAR-T cell Therapy in China and makes great effort to standardize commercialization of CAR-T cell-therapy product, following the pathway of drug registration. She also taked in charge of FKC876 NDA application as a first CAR-T in China.
Prior to join Fosun Kite, she was in charge of the department of drug registration in Shanghai Henlius Biotech, Inc, registered 10 IND projects in China and 2 projects both in China and Europe. These projects have all been approved for clinical trial. Crystal Sun has been dedicated to promoting establishment of Biosimilar Guideline in China. Anti-CD20 mAb, Rituximab of Henlius, has been approved NDA as a first Biosimilar in China.

抗CD20/19 CAR-T细胞在B细胞非霍奇金淋巴瘤中的应用  
朱丹 西比曼生物科技有限公司临床开发部 副总裁  
现负责西比曼肿瘤免疫产品的临床开发工作，毕业于南开大学医学院，拥有10余年的肿瘤领域医学临床经验，曾先后任职于诺华肿瘤医学部和新基医药医学部，加入企业前，曾在中国医学科学院血液病医院工作4年

孟会敏，MD & PhD，于潍坊医学院护理学专业毕业，获得医学学士学位；于南方医科大学病理学专业毕业，获得医学硕士学位；于苏州大学唐仲英医学研究院血液学研究中心毕业，获得医学博士学位。2012年曾赴美国休斯敦Apocell公司接受CTC技术培训。现任博生吉博生吉医药科技（苏州）有限公司高级医学官。 孟会敏博士在攻读博士学位期间，接受了系统的CAR-T细胞免疫治疗技术与临床转化应用的系统培训；负责博生吉CAR-T临床试验方案的开发与撰写，领导与协调和各个临床研究机构的合作、推动和管理了多项CAR-T的临床试验项目，涵盖血液瘤和实体肿瘤，其中包括博生吉自主开发的First-in-class CART细胞药物的临床试验，为博生吉这些项目的顺利进行提供了强有力的保障。

现任上海自贸壹号生命科技产业园 资本运营部总经理，曾就职于大型央企，主要负责股权投资，并购重组，子公司IPO及资产处置。曾主持军工上市公司重大资产重组项目，以及多个项目并购重组工作，并担任多家公司董事，具有比较丰富的投资和公司运营经验。

陈苗苗，现任高级项目经理，负责上海（南翔）精准医学产业园招商、项目引进、政策对接和融资服务等工作。2019年毕业后加入复旦大学宁波研究院，接触到的项目近800余家，落户服务项目20家，针对项目需求给出不同的解决方案，最终达到双赢的目标。从项目选址到最终项目入驻全部一手服务。

毕业于哈尔滨工业大学获得生物化学与分子生物学硕士学位，于2018年加入赛多利斯，负责下游过滤产品技术支持工作，后加入赛多利斯中国层析团队，专注层析产品在中国的推广和支持。在此之前，他曾就职于上海药明生物技术有限公司做下游纯化工作。

中国科学院上海生化与细胞所生物化学与分子生物学博士，师从中科院刘新垣院士。中科院生化与细胞所副研究员，宾夕法尼亚大学访问学者。目前主要从事癌症的靶向基因-病毒抗癌策略的科研产业化，担任上海元宋生物技术有限公司联合创始人,董事兼总经理。主持过国家自然科学院基金1项，四川省科技厅技术创新工程专项基金1项，上海市科技型中小企业技术创新资金3项，上海市2019年度科技创新行动计划生物医药领域科技支撑项目1项，作为骨干还参与过多项国家科技部及中科院系统科研资助项目。同时作为发明人参与靶向基因-病毒抗癌专利申请13项，参与编写一部癌症研究学术专著1部，为国际细胞因子与干扰素学会会员，荣获过中国第三届“《中国细胞生物学学报》—Cell Signaling Technology细胞生物学科研新秀奖”、中科院上海生化与细胞所多次年度优秀员工，上海奉贤区第二届滨海青年英才，上海奉贤区滨海贤人拔尖人才系列等荣誉。曾与合作单位制药公司开展过对正在美国、新加坡开展临床试验的某生物I类新药抗癌临床转化研究工作。在国内外知名学术期刊如Clinical Cancer Research, Human Gene Therapy, GeneTherapy, Cancer Gene Therapy, Protein Cell等发表专业学术论文38篇，并担任多家国内外专业期刊的特邀审稿人。
作为药物研发初创公司创始人兼CEO，熟悉职能部门内控管理和团队建设，人力资源管理，科研项目精细化管理，竞业科研情报数据信息化系统研发与构建，从科研基础研发到新药临床转化，商务拓展具有实战经验。带领团队参加第七届全国创新创业大赛总决赛，荣获“国家优秀企业”称号，同时使企业先后获得“高新技术企业”和“知识产权贯标认证”、“星耀榜-2020中国生物医药最具创新力企业50强”、“2020上海最具投资潜力50强创业企业”等多项资质与荣誉。是一名溶瘤病毒抗癌药物科研产业化积极践行者!

NMPA特聘讲师中国医药教育协会制药技术专业委员会常务委员医药工程高级工程师30余年行业经验，曾经在国内多家药企担任生产、质量的高管，从事过设备、工艺、科研、工程管理等各管理岗位。主导完成宜明细胞的GMP体系、质量平台的搭建，主导完成多个细胞、基因药物的质控、放行工作，在GMP体系建设、法规解读领域拥有非常丰富的经验。

张瑜博士是辉大基因副总裁，负责对外合作和产品授权。在加入辉大基因之前张博士担任天士力生物副总裁兼执行董事。通过张博士的投资和对外合作，成功的把一家传统的中药企业带进了全球医药企业的朋友圈。加入天士力之前，张博士曾服务于辉瑞，拜耳，IMS，艾尔弗雷德曼基金会和瑞银等全球机构，负责包括并购，产品引进及外包，新产品上市，中国市场战略，产品销售，新产品研发及证券投研。在处方药，细胞治疗，OTC及保健品，可植入医疗器械方面积累了丰富的经验。
张博士毕业于北京医科大学，在北大医院完成了骨科住院医师培训。在美国罗切斯特大学同时获得了病理学博士学位及健康科学管理与金融工商管理硕士学位。
Dr. Zhang is Vice President of HuiGene Therapeutics and responsible for licensing and external collaboration. He has over 15 years working experience in healthcare industry in both China and US. Before joined HuiGene, Dr. Zhang worked as Executive Director & Vice President at Tasly Biopharmaceuticals. Through his efforts, Dr. Zhang successfully brought a traditional Chinese medicine company into the friend circle of global biopharmaceutical enterprises. Prior Tasly, Dr. Zhang served several positions in Pfizer, Bayer, IMS, Alfred Mann Foundation, and UBS with different responsibilities including M&A, license-in/out, new product launch, China strategy, sales and marketing, product development, and equity research. He has built solid experience in prescription drugs, cell therapy, OTC/nutrition supplement, and implantable medical device.
Dr. Zhang graduated from Beijing Medical University and finished his orthopedic resident training in Peking University First Hospital. He received both PhD of Pathology and MBA of Health Science Management & Finance from University of Rochester.

现任江苏谱新生物医药有限公司首席战略官，负责公司整体业务布局，投资并购及海外拓展。美国杜克大学医学院免疫学博士，复旦大学MBA，复旦大学遗传学学士。曾担任美国T-Cure Bioscience中国区负责人，诺华亚太区临床运营经理，美国杜克大学医学中心助理研究员，此外还任职于GSK上海研发中心， VI Ventures风投基金，上海交通大学医学院附属新华医院。曾主持国家自然科学基金，上海市科委，上海市教委等新药研发项目。拥有15年以上药物研发，临床试验管理，投融资与商务拓展经验。
Dr. Zhu has over 15 years’ experience in drug development, clinical operation, financial investment and business development in healthcare area, especially in the field of cell and gene therapies. He got his Ph.D in Immunology from Duke University Medical Center and MBA and B.S. in Genetics from Fudan University. Initially he committed himself as a scientist in GSK R&D Center to new drug development for neuro-inflammation diseases. This helped him to further develop his career as a Principal Investigator in Xinhua Hospital in Shanghai working on primary nephropathies. He later joined Novartis as the Clinical Trial Leader for Asia Pacific region and led several global multi-center studies including one Gleevec Ph III Trial. Dr. Zhu started to explore his new career track in financial investment after he was awarded his MBA degree from Fudan University. He focused on new technology innovation and rising stars in the cell and gene therapy area. He was appointed as AP business development head and president of China subsidiary in T-Cure Bioscience. Currently he is the Chief Strategy Officer of Hillgene, a newly founded CDMO in cell and gene therapy area..

Dr. Wang received her Bachelor of Medicine from Shan Xi Medical University and Master of Medicine from China Medical University. She further earned her PhD in Cancer Biology from the National University of Singapore. She has over 20 years’ experience in the field of oncology in biopharmaceutical industry, clinical practice, and translational medical research. She led the Asia Pacific medical team for the successful launch of VENTANA PD-L1 assays at Roche Diagnostics APAC. She has driven autologous CD30 CAR-T cell therapy into clinical trials by leading the US FDA IND clearance to treat lymphoma at Tessa Therapeutics. Currently, she is Chief Operating Officer at Lion TCR, a Singapore biotech company developing first-in-class & best-in-class TCR T cell therapy against viral infections and their related cancers.

Dr. Li-Feng Zhang is the R&D Director of TCRCure Biopharma. He received his Ph.D. degree in Molecular Genetics from Baylor University in 2002, and completed his postdoc research at Harvard Medical School in 2008. He joined Nanyang Technological University in Singapore as an assistant professor in 2009. His research is focused on epigenetic regulation of gene expression and genetic engineering of the mammalian genome. Dr. Zhang joined TCRCure in 2020. He is supervising the development of multiple immune cell therapy products targeting solid tumors, including TCR-T, CAR-T and CAR-NK.

22年新药研发和投资的丰富经验；成功地创立和管理过3家新药开发和制药公司，并担任CEO 、董事长和CSO；主持投资或并购过中国和美国20多家新药开发和制药企业, 其中7家上市公司；
Over 22-years experiences in Biotech & Pharmaceuticals in US.，Mainland, Hong Kong of China；Co-Founder & CEO for 3 Biotech Companies and sold two of them; Invested over 20 biotech companies, 14 in US. 7 of all have completed IPO.

谢宏林，恺佧生物科技(上海)有限公司客户应用总监，专注于生物医药领域酶/因子/蛋白等原料的需求。此前就职于abcam和金斯瑞从事了10年的抗体发现工作，主导了上千个科研，诊断，药物抗体的研发。

Dr. Changfeng Zhang is the associate director of the Department of Cell Therapy, Livzon Biotech, with expertise in CMC, clinical applications and regulatory affairs of CART cells. He was one of the core members of Dr. Carl June’s team responsible for translational study and process development. After returning to China, Dr. Zhang started working as the RA director of UniCar Therapy, Ltd., China, and achieved the first IND approval of a gene-modified CART product in China.
Dr. Zhang has 8 publications in top-ranked journals such as Nature Medicine, Blood and etc., and was awarded the High-level Talent prizes of the cities of Shenzhen, Zhuhai, Suzhou and Nanchang. Additionally, he established academic collaborations with the Chinese FDA, NICPBP and several regulatory agencies by introducing world-famous CART therapist such as Dr. Stephan Grupp and Dr. Joseph Melenhorst, which greatly facilitated the policy development of CART therapy in China.

Dr. Chelsie He achieved her Ph.D degree in Immunology at Shanghai Jiao Tong University and MBA at Manchester Business School. She has more than 20 years’ pharmaceutical industry experiences, ranging from R&D, BD and manufacturing. She also has outstanding performance in investment and incubation. Dr. He had served as the board member of several domestic and oversea companies. In 2020, she founded Suzhou GenAssist Therapeutics with Professor Xing Chang from Westlake University. Now she is the CEO and chairman of GATx.

Mr. Liu formerly served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, Tony held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global e-commerce platform. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider.
Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process. Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S.
Mr. Liu obtained his Washington State CPA certificate in 1992. He had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013 and was appointed as Chief Financial Officer in January 2014. He was appointed as Chief Executive Officer of the Company in February 2016.

Dr. Xin Lin currently is a Professor and the Chairman of the Department of Basic Medical Sciences in Tsinghua University Medical School. Dr. Xin Lin obtained his Ph.D. degree from University of Texas Health Science Center in Houston in 1995. Following a postdoctoral training in UCSF/Gladstone Institutes in San Francisco, Dr. Lin started as an Assistant Professor in the State University of New York at Buffalo in 2000. In 2004 he was recruited to the University of Texas MD Anderson Cancer Center as an Associate Professor. Subsequently, he was promoted to Professor and then Endowed Professor in the University of Texas MD Anderson Cancer Center before his returning to China. He has been studying the molecular mechanism of signal transduction controlling lymphocyte activation, and their impacts on inflammation and anti-microbial and anti-cancer responses. Currently, his lab is developing therapeutic approaches using TCR-T/CAR-T cell methods to target cancer and viral infection.

Dr. Luk is the CEO at Neurophth Therapeutics, Inc. Prior to joining Neurophth, he has served as Senior Vice President and Chief Medical Officer at Shanghai Henlius Biotech, Inc., and he has also held executive roles at various MNCs such as Spark Therapeutics, Inc., Biogen Idec-Hemophilia (acquired by Sanofi), Bayer Schering Pharma LLC., Avigen, Inc.(acquired by Genzyme Corporation) and Tularik, Inc. (acquired by Amgen, Inc.) since 1998. Until 2003, his early researches were primarily investigating gene regulation and expression with the emphasis on rare diseases, oncological diseases, biologics and regenerative medicines. He served on the Clinical Design Committee for rare disease at the U.S. Food and Drug Administration focusing on adaptive clinical trial design to shorten drug development timeline between 2006 and 2009. Under his leadership in strategic drug development, he has won regulatory marketing approvals of 16 products in neurology, ophthalmology, gene/cell therapy, hematology and cancer therapy as of today.
Dr. Luk has published more than 85 book chapters, scientific and medical articles in highly regarded peer-reviewed journals, including New England Journal of Medicine, Nature, Cell, and Science, and is an inventor on over 10 patent applications. Dr. Luk holds an MBA from the Harvard Business School. He is ACRP-certified in clinical research and also received his Ph.D. in Neuroscience from the University of California San Francisco Medical School as well as bachelor’s degree in Molecular and Cell Biology from the University of California Berkeley in the United States.

Dr. Su Xiao currently serves as the Chief Technical Operation Officer of Neurophth and she has served as a co-founder and board member of Neurophth since 2019. She has ten years of experience in translational sciences, early and late stage gene therapy development and manufacturing of biologics. Her goal is to make gene therapy affordable and accessible and she has primarily worked for organizations both large and small, including gene therapy development at Pfizer and National Institutes of Health and GMP manufacturing at Vigene Biosciences. She received her B.S. in Chemical Engineering from Tsinghua University and Ph.D. in Chemical and Biomolecular Engineering from the Johns Hopkins University.

Founder of Anlong Biology, Dr. Zhao Chunlin, 1985, the first undergraduate of Department of Biology, Tsinghua University. After graduating in 1990, he went to school in the United States. He received his Ph. D. in molecular biology from the University of Pittsburgh School of Medicine in 1996 and has been doing biological research in the United States for the past eight years. After getting an MBA from Chicago, he moved to business management, where he has more than 30 years of experience in research, multinational enterprises, entrepreneurship and investment. He has rich experience in the field of gene therapy and cooperation with European and American enterprises. Through years of Industry Experience, Dr. Zhao Chunlin believes that gene therapy uses viruses, DNA, its stability and portability is better than protein, gene therapy is a radical cure, and believes that as the technology matures, gene therapy could revolutionize medicine. With the maturity of Gene Biotechnology, Dr. Zhao Chunlin is determined to make his own contribution in the field of biomedicine, especially in gene therapy. At present, the strength of the R & D team is strong, with a large number of excellent doctors and returnees.

程玉龙 Cytiva 细胞治疗亚太区产品经理
- 中国科学院上海生命科学研究院博士
- 在细胞治疗领域工作多年，负责Cytiva产品的技术支持与推广等工作
- 拥有细胞治疗工业开发和产业化的经验

Dr. Ting He is the founder and CEO of Immunochina Pharmaceuticals. Dr. He received his B.S. in biology from Xiamen University and Ph.D. in cancer biology from Tsinghua University. With years of experience in basic research of cancer immunology, he is dedicated to develop innovative CAR-T therapy for treatment of cancer. He was awarded Beijing Nova program and Beijing Eagle Talents.

Dr. Min graduated from the University of California at Berkeley majoring in Molecular Biology in 1991 and held a Ph.D. in Molecular Biology from the University of California at Los Angeles in 1997. Dr. Min’s expertise includes biologics development from discovery to manufacturing as well as strategic planning and business development.
Dr. Min worked at Amgen in the U.S. as a principal scientist for over 10 years. He was in charge of biologics discovery and optimization, developing multiple protein therapeutics that are currently in clinical trials or on the market. After that, Dr. Min joined Samsung Advanced Institute of Technology. In that job, he worked as the Head of Antibody Engineering responsible for the development of a novel antibody-based therapeutic platform and as a leader for the oncology therapeutic development program. From 2010 to 2011, he carried out the responsibilities as Oncology Program Director in Biosimilar Group and Vice President of Strategic Business Development Group, focusing on antibody biosimilars development. From 2012 to 2017, he worked as Vice President of Process Team at Samsung Bioepis Co., Ltd. With responsibilities covering a full range of upstream and downstream process development, as well as tech transfer and GMP production. Just before joining GenScript, in 2018, Dr. Min worked at the Drug Substance Team of Samsung Bioepis Co, Ltd. as a senior Vice President, leading the process development of all biosimilars and new biologics in Samsung’s pipeline.

Dr. Xinpo Jiang, Senior Director of Analytical Department/QA/QC at Legend Biotech, works on development of novel CAR T products in the pipeline. He was CMC Head leading LCAR-B38M CAR T product to clinical trial in China and US (collaborating with Janssen). He was Director of Pharmacology Department at GenScript for assay developments on biologicals and developed many cell-based and biochemical assays, oncology and antibody related functional assays. He received his Doctor of Philosophy from University of Minnesota, Twin Cities. He did a postdoctoral fellowship at Toronto Western Hospital, University of Toronto. Prior to his position at GenScript, Dr. Jiang was a research scientist at NeuroMed Pharmaceuticals. He published around 20 peer-reviewed journal articles and filed around ten patents.

Yi Li, Ph.D. University of Leicester, UK, the National Distinguished Expert, Leading Talent of Guangdong Province, President and CSO of Guangdong Xiangxue Life Sciences, LTD, Principal Investigator of Center for Infection & Immunity at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, PI at the State Key Laboratory of Respiratory Diseases. He has been engaged in the development of antibody and T cell receptor drugs in the UK for a long time. Representative papers have been published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy, etc. He pioneered the application of phage display technology to the directed evolution of T cell receptors. He developed the world first human high-affinity soluble TCR, which the affinity for recognizing pHLA was increased by more than one million times as a key breakthrough in the field of TCR. Under his leadership his team has successfully developed a number of high-affinity TCRs at Immunocore in the UK, which has eventually been used in FDA-approved immunotherapy clinical research products. In 2012, he returned to China and led the establishment of China's first high-affinity TCR-mediated T cell therapy platform. The TCR-T product TAEST16001 injection developed by the Xiangxue team has obtained the first TCR-T IND approved by CDE of the National Medical Products Administration.

CAR-T therapy specialist, technical core personel in Carl June group at UPENN. Dr. Wang has long engaged in CAR design-evaluation, he is the participant in the first CAR-T drug R&D. He takes the lead in solid tumor CAR design and achieved recognition. He accomplished two solid tumor CAR-T patents together with Dr. Carl June and Dr. Michael Milone.
After returning to China, he finished the early exploration of donor CAR-T infusion for ALL patient and got succuess. Now Dr. Wang's team has been authorized two patents for invention. 25 patents application has been accepted by SIPO(State Intellectual Property Office). Multiple IIT clinical trials with Dr. Wang's CAR-T products have been carried out both in hematologic malignancies and solid tumors treatment.

As Vice President of Business Development APAC at Miltenyi Biotec, Hermann is responsible for Miltenyi’s strategic collaborations with Biotech and Pharma in Cell and Gene Therapy (CGT) in Asia. Joining Miltenyi Biotec in 2009, he was instrumental in building Miltenyi’s cell and gene therapy business as Business Area Manager, including the release of key ancillary materials and the T Cell Transduction Prodigy platform. In 2016 he led Miltenyi’s Australian business as Managing Director. Before joining Miltenyi, Hermann was responsible for the project management for early drug and monoclonal antibody development at MediGene Immunotherapies, Munich. He holds a doctoral degree from the University of Bonn and the Helmholtz Research Center Juelich for studies on bioprocess development of DCs and ACT in solid tumor indications. He continued similar studies at King’s College London (Guy’s Hospital) with Cancer Research UK.

As the Head of the Industrial Process Development Team at Miltenyi Biotec, Silvio is responsible to provide automated Cell and Gene Therapy procedures on the CliniMACS Prodigy for industrial customers. Silvio has more than 10 years of R&D experience in various fields of cell biology, including Immunology, Regenerative Medicine and Pharmacology. After joining Miltenyi, Silvio has been coordinating custom-tailored development of automated processes for T-cell mediated Immunotherapy, Stem Cell Engineering and other innovative Cell and Gene Therapy approaches using the Miltenyi Biotec CliniMACS Prodigy platform. Silvio holds a Diploma degree in Biochemistry from the University of Bielefeld and a Doctoral degree in Biochemistry from the University of Kiel.

孙艳，上海细胞治疗集团副总裁，细胞药物BU总经理，主要从事CAR-T细胞药物开发及相关管理工作。带领团队完成国内首个非病毒载体CAR-T细胞药物的研究及注册申报，获得临床试验许可。

Pete Gagnon is a widely respected global authority in the field of downstream processing. He is the author or more than 100 scientific publications and inventor on more than 100 awarded patents in the United States, Europe, and Asia. His expertise covers purification of monoclonal antibodies, virus particles, extra-cellular vesicles, plasmid DNA, and mRNA. He is currently Chief Scientific Officer at BIA Separations, a European manufacturer of specialized chromatography media for purification of gene therapy products.

Dr. Wen (Maxwell) Wang currently is the Chief Medical Officer in IASO Biotherapeutics Co., Ltd. He obtained his M.D. degree in Wuerzburg University in Germany and Ph.D. degree from University of Aberdeen in UK and then did his postdoctoral training in at UConn Health Center in USA.
Dr. Wang has over 7 years of experience in Chinese Leading cell therapy companies including JW Therapeutics, Cellular Biomedicine Group (Nasdaq: CBMG) in clinical, preclinical, and translational development including CART cell and stem cell therapy. He held one of leading position in the 1st Chinese CD19-targeted CART cell and Mesenchymal Stem Cell INDs.
Before industry career, Dr. Wang worked as a Resident and Attending in Orthopedic Department in Shanghai TCM Hospital for 5 years.

Dr. Mingjun Wang，Executive President of Shenzhen Institute for Innovation and Translational Medicine, received his MD from Anhui Medical University in China and his PhD degree in Cellular Immunology from the University of Copenhagen in Denmark in 2009, and finished his postdoctoral training in cancer immunology at Baylor College of Medicine in Houston of the United States. His research is focused on identification of cancer antigens and the development of T cell-based cancer immunotherapy using TIL, TCR-T cells or CAR-T cells for various types of malignancies. Dr. Mingjun Wang has published more than 30 peer-reviewed papers and three book chapters in the field of cancer immunology.

Summary
• XIAOLIANG works with senior leadership teams of Cytiva in Asia Cell & Gene Therapy markets to develop profitable go-to-market growth strategies. With over 15 years successful commercial experiences in Pharmaceutical industry, XIAOLIANHG helps clients assess dynamics of their needs and grow their business further more.
• XIAOLIANG has worked in life science industry (IVD, Academia, Bio-Pharma, Cell & Gene Therapy) for around 20 years and brings a wealth of experience to every client engagement. His deep knowledge, networking and experience of Industry-Academia-Research platform has accelerated many small-/medium-size firms to scale up and go-to-market in past 10 years.
XIAOLIANG earned his Mini MBA and Diploma Leadership Development Program from China Europe International Business School, with honors, and his Bachelor of Science degree from ZheJiang University.

Dr. Zhang Yu is the president and CEO of Aeon Therapeutics Inc., a joint-venture biotech company established by Eureka Therapeutics Inc. and Vcanbio Cell&Gene Engineering Co.,Ltd. Prior to found Aeon, Dr. Zhang acted as assistant president and senior strategic planning expert in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf in Germany. Before the industrial career, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan”and “Tianjin Green Card Plan”.

Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center 1996-1999. He has been a professor in the Department of Pathology and Immunology, Baylor College of Medicine since 1999. Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. He was the vice president of Global Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, from 2015 to 2018, responsible for the innovative immunological drug pipeline in the region. He was the Chief Scientific Officer of Genfleet Therapeutics 2018-2020. Dr. Zheng recently joined Iaso Biotherapeutics as the Chief Scientific Officer.
Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.

Tong-Cun, Zhang, Ph.D, M.D; a distinguished professor in Hubei Province, is currently the Dean of College of Life Sciences and Health at Wuhan University of Science and Technology(WUST).
Dr. Zhang has got his Ph.D degree in 2000 from Institute of Biophysics, Chinese Academy of Sciences. Dr. Zhang was once honored with the of NRC Postdoctoral Fellowship Award in 2000-2003 in USA and then joined in UNC at Chapel Hill as assistant professor. Since 2012 he has taken a full-time professor and dean in WUST.
Dr. Zhang has aimed to the scientific research of the gene regulation, related to human diseases and development of biological drugs. In recent years, he has focus on CAR-T cell therapy for blood and solid cancers. His team has carried out novel CAR-T clinical trial in several hospitals and got excellent clinical effects and safety, which were published in Blood and Leukemia. CAR-T targeting to CD30 is trialed in clinical phase I.
Dr. Zhang has obtained several grants from The National Natural Science Foundation of China and ministry of Science and Technology, including National Key Research Program, 863 Programs, 973 Program. He has published over 100 theses in relevant research fields at high level scientific Journals. Novel patents for CAR-T cell-therapy over world has been obtained in his leading team.
Since he come back China, Dr. Zhang has been honored with local and national talent and outstanding titles. He was also awarded US-EPA's Scientific and Technological Achievement Award in 2003.

陈皓先生
英诺维尔智能科技（苏州）有限公司
创始人，CEO/总工程师
*GE 智能控制系统高级研发经理
*AMAI半导体设备系统工程师
*10年+ 复杂系统研发与管理经验
*英国巴斯大学控制工程硕士研究生
*北京航空航天大学飞行器设计
*北京航空航天大学通讯工程
重要项目经验
*3000米+ 超深水钻井系统控制系统
*深水转井多组态液相防喷预测系统
*C19 IMA架构通讯导航系统
*ARJ21机载核心控制网络
*10代TFT-LCD液晶面板CVD系统
*300mm晶圆45nm PVD系统
均有10年以上大型项目经验，丰富的一线实战经验，强大的执行力

Dr. Liming Yang is the Co-founder and Chairman at Wyze Biotech Co., Ltd, a Hangzhou China based clinic stage company, engaged in the development and commercialization of novel allogeneic DNT (Double Negative T) cells and off-the-shelf cell immunotherapies to improve the lives of cancer patients and their overall survival by leveraging the clinically validated DNT cell technology. The first-in-class phase I clinic trial to relapsed AML patients after allo-HSCT has been finished in June 2020 with very promising clinic data. The IND application of RC1012 injection to r/r AML has recently been accepted by CDE of NMPA. Dr. Yang was associate director of product development in Stemgent and quality control manager in BD Biosciences Pharmingen, both based in San Diego, California, USA. He also worked previously as postdoctoral fellow at University of Toronto, Canada on DNT project and is one of the key inventors of DNT technology. Dr. Yang served as PI and associate professor when he worked in Medical School at Shanghai Jiaotong University in China. He received his M.D. from the Medical School at the Zhejiang University and finished his joint Ph.D. program in both Shanghai Jiaotong University in China and University of Toronto in Canada. Dr. Yang has published nearly 30 papers in peer-reviewed journals including first author in Nature Medicine and is an inventor on 5 patent applications in the field of DNT Technology.s

Dr. Wei Wang is the Vice President of Clinical Development at CARsgen. She leads CAR-T and monoclonal antibodies China clinical development programs and manages medical affairs, clinical operation, biometrics and pharmacovigilance.
She has over a decade experiences in China and global clinical development programs in Merck, Novartis and Pfizer, managing team in clinical development, medical affairs and pharmacovigilance. Dr. Wei Wang worked as the practicing pediatric physician for 6 years in Xiangya Hospital of Central South University. She earned her Master degree in clinical medicine from Central South University, and the M.D. & Ph.D. degree from Fudan University.

Dr. Wang received her PhD in Immunology from Washington University in St. Louis, focusing on T cell signaling transduction and T cell engineering. During her Postdoc research in Scripps-Calibr and her work as senior scientist at Poseida Therapeutics, Dr. Wang participated and led the development of multiple autologous and allogeneic CAR-T programs using different platform technologies. She joint Gracell Biotechnologies in 2018 and had led the development of “off-the-shelf” CAR-T program since then.

Dr. Lyu Lulu obtained her Ph.D. in clinical medicine (internal medicine, hematology) in 2006. Prior to 2007, she mainly undertook the clinical and scientific research on hematopoietic and mesenchymal stem cells. In 2001, Dr. Lyu participated in the first umbilical cord blood transplantation in China for the treatment of childhood leukemia. She pioneered and established the domestic technology of isolating mesenchymal stem cells from the umbilical cord in 2004. In the following year, she continued her research on hematopoietic cell transplantation and mesenchymal stem cells at Westchester Medical Center of New York Medical College. Dr. Lyu published various papers in domestic and international journals. After joining a multinational pharmaceutical company in 2007, Dr. Lyu was engaged in the research and development of innovative drugs and the strategic planning for new products in the fields of hematology and oncology for more than a decade. With key appointments being held in multinational companies including Novartis, Genzyme, Roche, AstraZeneca, and Merck, she has garnered a wealth of experience in R&D and product life-cycle management in the areas of targeted drugs, immunotherapy, and cell therapy. In addition, she has played a vital role in the R&D, registration, and market expansion of ground-breaking products for treating cancers such as Gleevec®, Herceptin®, Tagrisso®, and Keytruda®. In June 2018, Dr. Lyu left the international pharmaceutical corporate world to become a trailblazer focusing on the development of innovative drugs domestically. As the current CEO of Juventas Cell Therapy Ltd., she is committed to promoting the clinical research of cell therapy and to pushing forward the industrialization thereof, thus creating world-leading products based on cell therapy.

Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a PhD in Molecular Cell Biology from the University of California, Berkeley.

Henry Ji, Ph.D., co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012 and as its Interim Chief Executive Officer from April 2011 to September 2012.
Dr. Ji served as VP of Sales and Business Development at CombiMatrix, and was responsible for strategic technology alliances. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as VP of Business Development at Stratagene (later acquired by Agilent Technologies), a biotechnology company. In 1997, Dr. Ji co-founded Stratagene Genomics, a wholly-owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer and Director from its founding until 1999. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. He held many executive positions in biotechnology and life sciences companies during his career.

Jianqiang Li is currently the Founder and Chief Science Officer of Hebei Senlang Biotech, a company focuses on the development and clinical translation of next generation cell therapy technology. Dr. Li obtained his PhD degree from University of Wuerzburg in Germany. He did his postdoctoral training at City of Hope and Fred Hutchinson CRC. His expertise covered the following fields: Gene modified adoptive T cell therapy; In vitro expansion and gene editing of Hematopoietic stem cells; Transplant Immunology.

Dr. Lin Yang is currently a Distinguished Professor at the Cyrus Tang Hematology Center of Soochow University, China, and an adjunct professor of Department of Lymphoma and Myeloma at the MD Anderson Cancer Center, USA. Dr. Yang is the founder/chairman/chief scientific officer of PersonGen BioTherapeutics (Suzhou) Co., Ltd., and Chairman/CEO of PersonGen-Anke Cellular Therapeutics Co., Ltd. Dr. Yang received many awards, including Innovation and Entrepreneurship Talent of Jiangsu Province, Six Peak Talent of Jiangsu Province, Gusu Innovation and Entrepreneur Leading Talent, Pioneer of Suzhou Industrial Park Technology, Nanjing “321” Technology Leaders, Second Prize of China Innovation and Entrepreneurship Competition, and many other honorary titles and awards. He has published more than 70 research articles in recognized peer reviewed journals, such as Cancer Cell, Cancer Research, Oncogene, JBC, and Cancer Science, etc., which were all funded by international, national and provincial foundations.
As a principle investigator, Dr. Yang plays a major role in the immunotherapy of CAR-T cells and CAR-NK cells of China, and has obtained impressive achievements in the industrialization and clinical trials of CAR-T cell therapy. Among them, several clinical trials are the first-in human projects performed globally, including CAR-T cell therapy for T-cell acute lymphoblastic leukemia, and 4th generation CAR-T cell therapy for solid tumors. Led by Dr. Yang, PersonGen-Anke’s CD19-CAR-T product has been submitted to Chinese FDA and is being under the evaluation process which is expected an approval from CFDA within next few months.

As the Chief Scientific Officer in Shenzhen PREGENE Biopharma Company, Ltd, Dr. Zhang Jishuai graduated from Zhengzhou University, receiving a B.S. degree in clinical medicine. Then, he got his M.S. degree in molecular immunology in the Fourth Military Medical University, and Ph.D. in genetics in Beijing Institute of Biotechnology. After that, he obtained the postdoctoral training in the Hormel Institute in the University of Minnesota.
As an expert on tumor biology, Dr. Zhang once did detailed study on tumor gene function (including tumor initiation, differentiation and metastasis), about which he published over 20 papers. In 2016, he founded the PREGENE Company and acted as the Chief Scientific Officer, from which he began the research and development of CART drug. Having built a platform of “Nanobody discovery, CART research and drug development”, PREGENE is now mainly focused on CART therapy for hematologic tumors.

Dr. Zhu has over 10 years’ experience in drug development, clinical operation, financial investment and business development in healthcare area, especially in the field of cell therapies. He got his Ph.D in Immunology from Duke University Medical Center and B.S. in Genetics from Fudan University. Initially he committed himself as a scientist by serving the GSK China R&D Center to identify new drug targets for neuro-inflammation diseases. This helped him to further develop his career as a Principal Investigator in Xinhua Hospital in Shanghai working on the MIF soluble receptor. He joined Novartis as the new translational medicine department was founded and became the Clinical Trial Leader for Asia Pacific region. At that time, he led several global multi-center studies including one Gleevec Ph III Trial. Dr. Zhu started to explore his new career track in financial investment after he was awarded his MBA degree from Fudan University. He focused on new technology innovation and rising stars in the cell therapy area. Prior to joining T-Cure Bioscience, Dr. Zhu was the BD head of Hrain Biotech and in charge of the licensing and financing of this well-known CART company in China.

Hui Wang, MD, is the Deputy Director of the Clinical Diagnostic Department(vice chairman grade), and Director of Flow Cytometry Lab at the Ludaopei Medical Group, as well as Director, CEO, and CMO of Synarc Research Laboratory (Beijing) Ltd.
Dr. Wang graduated from the Peking University Health Science Center.
She completed internal medical residency at the Beijing Shijitan Hospital, followed by a fellowship in Hematology Institute at the People’s hospital. She then joined the faculty at Ludaopei Medical Group in 2008. She primary area of clinical research is the clinical diagnosis of flow cytometry. Having been worked in flow cytometry field for 18 years, She has signed more than 300,000 diagnostic reports of immunophenotyping and MRD detection, of which more than 40% coming from other hospitals around China.
She has taken part in writing 10 professional books, given nearly 600 professional oral presentations in 29 provinces of China(including Taiwan). She has hundreds of students from over 100 well-known hospitals, distributed in 26 provinces of China (including Taiwan).
The chairman of flow cytometry branch of professional committee on laboratory medicine, Chinese association of integrated traditional and western medicine
The vice chairman of blood & body fluid branch of Beijing Medical Laboratory Society
The standing committee member of hematology branch of Chinese non-public Medical Association
The standing committee member of Chinese flow cytometry Union
The member and special expert of lymphoma branch of Chinese Anti-cancer Association, flow cytometry branch of Chinese society of hematology and immunology, cell analysis special committee of Chinese society of bioengineering, and other societies.

胡大裕，华中科技大学同济医学院药理学博士，拥有20多年的药品研发和医药行业管理经验，曾担任湖北省中医药大学附属医院药学部副主任、康诚科瑞医药研发（武汉）有限公司总经理。现任阿思科力（苏州）生物科技有限公司首席运营官。负责公司CAR-NK肿瘤免疫细胞药物产业化发展。 阿思科力专注于研发肿瘤免疫治疗货架细胞药物，其第一代广谱CAR-NK细胞药物治疗晚期癌症达到76.5%疾病控制率，在国际上处于领先地位。

Dr. Jijun Yuan is co-founder and chief executive officer of Shanghai Genbase Biotechnology Co. Ltd, which was established in 2015 to focus on developing new therapeutic drugs, including cell therapies, gene therapies and therapeutic antibodies. Prior to that, Dr. Jijun Yuan spent six years at Shanghai Hengrui Pharmaceutical Co. as the associate director in charge of the biological division. He has been involved in more than 30 drug discovery programs, including oncology, diabetes and cardiovascular therapeutic drugs. Dr. Jijun Yuan holds a PhD degree in molecular biology from Ohio State University and worked as postdoctoral researcher at University of California Los Angeles.

Stephan Grupp, MD PhD, is the Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Medical Director of The Cell and Gene Therapy Lab at the Children’s Hospital of Philadelphia (CHOP), as well as the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine.
Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology.
He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest and most successful engineered T cell therapy clinical trial conducted to date (1, 2), as well as the global registration trial for CTL019 (3). As a result of this work, he presented the Clinical Perspective at the July 2018 FDA ODAC meeting, at which reviewers voted 10-0 for recommendation of approval for Kymriah in pediatric ALL. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Dr. Grupp is a reviewer for several journals and the author of over 200 peer-reviewed journal articles, as well as numerous abstracts and book chapters.

Dr. Yangbing Zhao is an Associate Professor and the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with T cells against Mart1, NY-ESO-1, Her2/Neu, CD19 (Yescarta) and VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania in 2009 as the Director of TCEL. his research work at the University of Pennsylvania led to clinical trials to treat cancer patients with TCRT or CART against NY-ESO-1, CD19 (kymriah), Mesothelin, cMet, GD2 and CD123, as well as first in human CRISPR/CAS9 application in the world. Dr. Zhao has more than 20 years’ experiences in T cell engineering with over 50 publications and filed over 90 patents in the CART field. Dr. Zhao is the scientific co-founder of Tmunity Therapeutics.

Dr. Wang was trained by Dr. Adolfo García-Sastre and received her Ph.D. in Biomedical Sciences from the Mount Sinai School of Medicine in NYC. She joined Dr. Peter Cresswell’s laboratory in the Department of Immunology at Yale University as a Howard Hughes Medical Institute fellow, and later as a Cancer Research Institute postdoctoral associate. Dr. Wang joined Memorial Sloan Kettering Cancer Center in 2007, and is currently an Associate Lab Member in Department of Molecular Pharmacology, and the Assistant Director of the Michael G Harris Cell Therapy and Cell Engineering Facility. Dr. Wang is in charge of the R&D, process development and manufacturing. She has overseen the successful manufacturing of all the CAR T cell products used in 13 phase I/II clinical trials as well as over 20 batches of cGMP grade viral vectors. She served in the translational science and product development committee in the American Society of Gene and Cell Therapy (ASGCT). She is currently a member for the National Heart, Lung and Blood Institute (NHLBI) independent external panel and a committee member for the Alliance of Regenerate Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).

Dr. Ni is Senior Director, Process & Product Development at Allogene Therapeutics, leading the company’s manufacturing process development activities for its pipeline of off-the-shelf CART candidates. During her tenure at Allogeneic Therapeutics and previously at Pfizer from 2015 to now, she has led her team to establish platform allogeneic CART manufacturing processes for enabling pipeline programs quickly advancing to early clinical testing using robust enough 1^st generation process and transiting to late stage clinical & commercial manufacturing using more controlled 2^nd generation automated & closed process. From 2000 to 2010 she held a senior technical role at VIRxSYS, where she conducted pioneering adaptive T cell therapy development work using lentiviral vector modified autologous CD4 T cells for HIV infection together with Dr. Carl June’s lab at the University of Pennsylvania. Through that work, they were 1^st to bring lentiviral vector modified autologous adoptive T cell therapy into the clinic, and 1^st to demonstrate feasibility of large scale GMP manufacturing of lentiviral vector and ex vivo expansion of gene-modified T cells in WAVE bioreactor. That work also accumulated a large set of patient safety data for lentiviral vector modified adaptive T cell therapy and laid down the groundwork for lentivector modified autologous CART therapy to be first tested in the clinic by Dr. Carl June’s lab. Dr. Ni earned a M.D. in internal medicine from the Kunming Medical College, P.R. China and received her Ph.D. in virology from the Kyoto University, Japan. She then conducted post-doctoral training in gene delivery at the NIH, USA before embarking on her gene & cell therapy product development career in both small biotech and big pharma.

吴宇轩，上海邦耀生物科技有限公司研发副总裁，华东师范大学生命科学学院研究员，博士生导师，入选上海市浦江人才计划，东方学者岗位计划。2015-2018年，在哈佛医学院和波士顿儿童医院进行博士后研究期间，开发和优化了造血干细胞中基于CRISPR/Cas9的基因编辑系统，通过高效激活胎儿血红蛋白的表达来治疗地中海贫血及镰刀状贫血疾病，相关疗法被美国FDA批准进入临床实验阶段，初步临床结果显示出了极佳的治疗效果。同时在国内与各大医院合作推动地中海贫血的基因治疗。以第一作者或共同通讯作者在Nature Medicine（2 篇）、Cell Stem Cell（2 篇）和Cell Research（1 篇）等国际著名期刊上发表研究论文多篇。

刘滨磊教授，武汉滨会生物科技股份有限公司董事长，博士生导师，湖北工业大学特聘教授，湖北省百人计划入选者，曾任中国抗癌协会生物治疗专业委员会常委和中国免疫学会肿瘤免疫与生物治疗分会常委。
刘滨磊博士长期致力于肿瘤免疫及溶瘤病毒研究，其在英国BioVex生物技术公司原研的溶瘤病毒注射液（T-VEC）已被美国FDA及欧盟EMEA批准上市销售。归国后，刘滨磊教授带领国内研究团队研发出具有溶瘤活性更高及增强抗肿瘤免疫特点的新型溶瘤病毒OH2，其专利已授权。OH2溶瘤病毒已获NMPA临床试验批文并完成两项临床I期研究（黑色素瘤和其它实体瘤）。已获得的立项资助有十三五重大新药创制、973、863、十二五支撑项目、自然科学基金等。迄今为止，已在国内外杂志发表近40余篇科研论文。

Dr. Blanchard’s career spans four decades in diverse leadership roles across North America and Asia. In February 2020 he was appointed as CEO of Everest Medicines after having served as Operating Partner at CBC Group, a healthcare private equity firm and one of the leading investors in Everest Medicines, since November 2019. Prior to CBC Group, he was Chief Science Officer at Innovent Biologics, where he oversaw the NDA preparation and submission for the company’s PD1 antibody, sintilimab, which was approved in late 2018 and launched in China in 2019 and led the partnership efforts with Incyte to develop three small molecule oncology assets for Greater China. Previously, Dr. Blanchard was the Senior Vice President of Lilly China Drug Development and External Innovation, where he built and led the development and medical affairs teams, who designed and implemented clinical plans for assets across all therapeutic areas. He also built and executed the company’s external partnership drug development portfolio model in China. He positioned Lilly to capitalize on the positive changes in the Chinese regulatory environment to expand the China innovation ecosystem. He built multiple successful partnerships that delivered new medicines to the China market including Innovent Biologics (sintilimab) and Chi-Med (fruquintinib). At Eli Lilly and Company he also initiated the project and led the team who delivered abemaciclib, the best in class cdk4/6 inhibitor, to the clinic.
His interests include discovering and developing medicines and the application of translational research principles to drug discovery. He was a co-founder and a member of the Board of Directors of the Asian Cancer Research Group, a not-for-profit company focused on the generation and dissemination of genetic and clinical data on cancers of importance in Asia. Dr. Blanchard received a BS degree in chemistry in 1977, a PhD in Biochemistry in 1982, and an MD in 1985 from Indiana University. He completed a residency in Internal Medicine and fellowships in Hematology and Medical Oncology at the Brigham and Women’s Hospital, the Dana Farber Cancer Institute, and Harvard Medical School in 1990. Dr. Blanchard was a Damon Runyon Fellow and a Fellow of the American Cancer Society. Prior to coming to Eli Lilly and Company in 2000, he was a tenured Professor of Medicine and Biochemistry & Molecular Biology at Louisiana State University Health Sciences Center in Shreveport, LA. He has had multiple global roles in Lilly Research Laboratories including Senior Clinical Research Physician in Program Phase Oncology, Chief Scientific Officer Cancer Discovery, Executive Director of Cancer Discovery & Lilly Systems Biology-Singapore, Chief Operating Officer/Vice-President of Discovery Research and Vice-President of Integrative Biology, and Vice-President of Tailored Therapeutics. He was a member of the board for Lilly China and Zymeworks INC and is a member of the board for The Confucius Institute in Indianapolis; he is also a member of the scientific advisory board for CBmed GmbH in Graz, Austria.

Mr. Blake Salisbury is responsible for BD activities at Innovent, where he has lead the partnering efforts for cross border deals with Lilly, Roche, Coherus, Alector, Hanmi, MD Anderson, and others. He received his MBA from Thunderbird Graduate School of Global Management. He has 29 years of experience in pharma/biotech, primarily in business development (22 years), but also in sales, marketing, and pricing. Prior to joining Innovent, Blake spent almost 24 years with Eli Lilly and Company where he closed over 50 transactions of various types.

Dr. Xian-Ping Lu founded Shenzhen Chipscreen Biosciences, the leading drug discovery and development company in China focusing on innovative small molecular therapeutics, 19 years ago with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego around 1994.
Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University.
With over 30 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 100 peer-reviewed papers in prestigious journals including Nature, Science and The Lancet Oncology. He is the lead inventor of over 100 patented inventions in areas of small molecule therapeutics.

包骏博士，英派药业总裁、首席执行官。包骏博士在药物研发、技术转让、 许可和业务拓展、风险投资、创业和公司融资方面拥有超过二十年的丰富经 验。曾任珅奥基医药公司资深副总裁兼首席商务官、跨国药企葛兰素史克全 球业务发展总监兼中国区主管，美国著名癌症医药公司Onyx企业发展和融资 规划总监，之前曾就职于ICOS公司、Cell Therapeutics公司负责肿瘤学领域 内的技术许可和业务发展。包博士拥有美国堪萨斯大学博士学位、约翰霍普 金斯博士后及芝加哥大学MBA学位。曾担任百华协会董事。

琚存祥博士 江苏集萃药康生物科技有限公司研发总监
微生物与免疫学博士；曾担任南京大学-南京生物医药研究院副院长、研发总监，拥有丰富的大小鼠品系研发项目经验，全面负责基因组编辑新技术平台的开发及人源化实验动物的创制。带领团队将CRISPR/Cas9技术用于同源重组的效率提高了10倍以上，成功开发了BALB/c、NOD等不同遗传背景来源的胚胎干细胞株，并成功开发了一系列用于抗体药物筛选的人源化动物模型，包括hPD1、hPDL1、hOX40、hCD3e、hCTLA4、hCD137、hTIGIT等单靶点及对应双靶点的模型，这些模型已经实现了市场转化，获得了良好的经济效益。

陆阳(Patrick Lu)博士是美国Sirnaomics, Inc.（圣诺制药） 创始人、董事长和CEO，苏州圣诺和广州纳泰两家分公司的董事长，国家特聘专家。陆博士自1993年以来，在诺华药业（Novartis）和代进基因公司（Digene）以及后来在中美两地的创业生涯中，一直从事分子医学研究和靶向药物研发创制，并在跨国生物医药企业创建和管理领域积累了丰富的实践经验，是国际基因治疗和纳米颗粒载体的资深专家，并是国际核酸干扰药物开发领域著名专家和连续创业者。
从作为联合创始人创立Intradigm公司开始(2000 - 2006)到创始人创立圣诺制药（2007年以来）, 陆博士参与和带领团队在美、中陆续集融资超过9000万美元。陆博士已经陆续发表了60多篇科学论文，并是50余项已授权或者正在申请的国际和中国发明专利的发明人。陆博士曾经获得美国国家健康研究院和马里兰州政府的多项研发资金支持，并在中国主导了多项包括国家“十一五”、“十二五”、“十三五”国家重大新药创制专项等国家、省、市和地方的科研基金项目，并被获得多项荣誉奖项。
陆博士早年毕业于广州中山大学并取得博士学位后赴美（1987）在马里兰大学和乔治城大学从事博士后研究。陆博士是美国华人生物医药科技协会（CBA-USA）共同创始人和第二任会长，现任广州市生物产业联盟（GZ-BIO）秘书长。

Dr. Qiu is the CEO of Qilu Regor Therapeutics, an innovative drug discovery company he founded together with a team of accomplished scientists and executives from top global pharma companies. Located in Shanghai, Boston and San Diego, Regor leverages world-class expertise in Computer Accelerated Rational Discovery (CARD) and efficient R&D ecosystems to accelerate the delivery of novel therapeutic agents with high unmet medical needs for patients in China and around the world.
Before returning to China in 2018, Dr. Qiu was Executive Director & Head of Structural & Molecular Sciences at Pfizer. He built and led a team of ~60 scientists with industry-leading expertise in structure-based drug design, computational sciences, and integrated molecular mode of action approaches. Prior to joining Pfizer in 2001, he was a member of GSK Global Target Evaluation Meeting and Novel Targets Committee. In 25 years in industry, he has contributed to 30 clinical candidates across diseases areas (inflammation & immunology, neurosciences, oncology, cardiovascular & metabolic, infectious & rare diseases) and therapeutic modalities (small molecule, ADC, biologics & vaccine). He discovered PCSK9 molecular mode of action that led to the industry-wide shift from seeking protease inhibitors to antibody therapies. He built the first cutting-edge cryo-EM lab in industry & New England, and delivered multiple clinical candidates using fragment-screening. He also served as President of New Drug Research for Qilu, one of the biggest pharmaceutical companies in China.
Dr. Qiu graduated from Peking University, obtained PhD at Michigan State, and completed executive trainings at Harvard Business School. He was an NIH Fellow and HHMI Research Associate at University of Washington in Seattle. He has trained 15 postdocs, served on expert review panels for National Institute of Health and other US funding agencies, and has been a member of Faculty of 1000 since 2004. He has >6000 citations (h-index 39) from over 60 publications, including in top journals such as Nature and Science.

MIT博士，药品制程及新药数字化战略专家，曾任职于诺华-MIT中心，麦肯锡顾问，AquaFresco创始人

Education & Academic Career:
• Postdoctoral Research Follow,
Massachusetts General Hospital, Harvard Medical School • M.D. ,Ph.D.
Shanghai Medical School, Fudan University

Industry experience:
• June,2017 to present
Sr. Vice President, LCDDMAC, Eli Lilly China
• Sep, 2010 to June, 2017
Vice President in LCDDMAC, Eli Lilly China,
• Apr 2007 to Sep 2010
Oncology Medical Director of GlaxoSmithKline China/HK
• Sep. 2001 to Mar. 2007
Oncology Chief Clinical Research Physician, Eli Lilly China

Zhengqing Li is the Vice President and Head of MSD China R&D. In this position, he is responsible for the operation and strategic direction of MSD R&D Center in Beijing. As the China R&D head, Zhengqing leads a development team whose primary mission is to bring innovative medicines and vaccines effectively and efficiently to meet unmet medical needs of Chinese patients. In addition, Zhengqing plays the leadership role in building MSD global capabilities in China, and in establishing external collaborations with research institutes, professional societies and industry partners. Under his leadership over the past 8 years, the MSD China R&D Center has been growing dramatically with more than 1000 scientists with expertise across Clinical Research, Regulatory Affairs, Clinical Trial Operations, Pharmacovigilance, Project Management, Biostatistics, Epidemiology, and Data Management, etc.
Prior to joining MSD, Zhengqing took a number of leadership roles with Bristol-Myers Squibb (BMS) including the Head of Clinical Research, China R&D and Executive Director and Head of Oncology & Neuroscience, Global Biometric Sciences. Prior to joining BMS, Zhengqing also worked with Pfizer and Procter & Gamble Pharmaceutics with increasing responsibility in drug development.
Zhengqing has authored and co-authored more than 40 scientific and clinical trial methodology papers and abstracts. He has played leadership role in the development and approval of nearly 20 drugs in China and United States. Which including famous HPV vaccine GARDASIL and GARDASIL 9, chronic HCV drug ZEPATIER and key product of immunotherapy KEYTRUDA, etc.
Zhengqing was born and grew up in China. He received his undergraduate education at University of Science and Technology of China and his PhD degree from University of Wisconsin-Madison with major in Biostatistics. Upon completion of his PhD, Zhengqing took a faculty position in the School of Public Health at State University of New York.

Dr. Chin’s career spans over 20 years of experience in medical oncology and clinical development in the pharmaceutical industry. In January 2020 he was appointed as CMO at Elpiscience Biopharma.
Prior to joining Elpiscience, Dr. Chin was a Senior Medical Director of immuno-oncology, Global Clinical Development at AstraZeneca. There, Dr. Chin provided leadership and expertise to enable new investment decisions in oncology therapeutic development, which involved the successful development of clinical strategy, determining the direction of regulatory interaction and coordination/execution of new clinical trials. Prior to his career at AstraZeneca, Dr. Chin was a Global GI Oncology Lead at Eli Lilly. He was involved in the transfer of cetuximab (Erbitux) full rights in North America from BMS to Lilly, led regulatory submission for Erbitux label updates, and fulfilled Erbitux post-marketing commitment.
Dr. Chin started his career as a medical oncologist and served as an assistant professor in the Division of Hematology/Oncology at the Medical University of South Carolina in Charleston. He was a clinical investigator with a special interest in cancer therapeutic development and correlative studies. Over his career, Dr. Chin has served as PI or Co-I in over 20 active clinical trials. He is currently a member of the executive committee for the Chinese American Hematology and Oncology Network, a non-profit organization focused on fostering exchange of medical information between United States and China in the fields of hematology and oncology.

Nanhai He is the Head of Biosciences of Adlai Nortye who has over 15 years of experiences in research / target identification, and multidisciplinary background with past experience in biochemistry, immunology and metabolism. Dr. He received his Ph.D. in Molecular and Cell Biology from University of California, Berkeley, and finished his postdoctoral training at the Salk Institute for Biological Studies. Dr. He has published more than 20 papers his research field.

Dr. Xiaoning Guo is currently the vice President, Head of R&D and Chief Medical Officer of SciClone Pharmaceuticals co., LTD. He is fully responsible for R&D of pipeline drug candidates and life cycle management of post-market products. Dr. Guo graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences with a PhD in pharmacology. Later, he went to the United States and worked as a research affiliate at Roswell Park Cancer Institute, a National Comprehensive Tumor Hospital and Cancer Center. In 2007, Dr. Guo came back to China and joined MNCs including Astrazeneca and Johnson & Johnson to in charge of translational medicine project, clinical Phase I to III project development and portfolio management. After a couple of years, Dr. Guo joined Covance as a senior Director, Clinical Drug Development Leader in Asia Pacific region, responsible for the development and implement of the global development strategy of the project. Dr. Guo has accumulated extensive experience in different stages of drug development from preclinical including biomarker research to translational medicine to clinical development. Before joining SciClone, Dr. Guo served as deputy General Manager and Chief Medical Officer of General Regeneratives, co., Ltd., responsible for clinical development and regulatory affairs department.

Previously, Dr. Zhou was Scientific Director at Amgen, Thousand Oaks, USA. His over 20-years experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, real time analytical assays, formulation and product specification for drug substances and drug products made Dr. Zhou many times as Project Process Team Leader/Project Team Leader/Cross Functional Core Investigation Teams Leaders at Amgen in the past.
Dr. Zhou has proven bio-industrial leadership in scientific innovation and technology evaluation, and is well known for implementation of membrane chromatography in mAb large-scale processing. Dr. Zhou has excellent reputation and an extended external network in the Process Development and or Process science peer community due to his extensive speaking and publication record including research articles, patents and book chapters in the Process Development and Process science field. Dr. Zhou has proven records for design space for process robustness and viral clearance in mAb production. Dr. Zhou was awarded as 2007 Amgen’s “Excellence n Science and Engineering” for his major achievement and leadership on photo-oxidation on monoclonal antibody yellowing, and selected by Amgen as a visiting professor teaching the GMP Master’s Degree Program at PKU, People’s Republic of CHINA since 2007.

Maggie Gu (Juanhong) is Vice President – R&D Shanghai Innovation Hub at Ipsen, a leading biopharmaceutical group dedicated to improving lives through innovative medicines in oncology, neuroscience and rare diseases.
Maggie has over 20 years of experience in clinical development, Medical affairs and Clinical Research operations in pharmaceutical indursry. Prior to Ipsen, she was Vice Present – Clinical research and operatnions in Junshi Bioscience, where she led and contributed to regulatory approval of the first China-developed PD-1 anti-body.
She started her career in the pharmaceutical industry as a Clinical Research Associate in Daiichi in 1997, and worked through the roles as Clinical Research Project Manager in MSD, Medical affairs manager in Fujisawa, Head of Clinical Operations and Therapeutic Area Medical Science Director at GlaxoSmithKline, as well as the Senior Director-Clinical Development in Clinical Operations at AstraZeneca.
She has successfully led development and registration activities of a series of innovative products in Oncology, Dermatology, Respiratory and other areas in China, including Tuoyi, Tagrisso, Botox, Avodart, Protopic etc. Prior to joining the pharmaceutical industry, Maggie worked in the Pediatric Research Institute,
Children’s Hospital affiliated to Shanghai Medical University. She holds a Master‘s degree in Pediatric Medicine from The Shanghai Medical University.

Dr. Zhuis an expertin antibody drug discovery and process developmentwith more than 18 yearsof industrial experience. Hehas extensive experience in antibody drug discovery, process development, and manufacture facility construction. Dr. Zhu is the CEO for both Huaota Biopharm and Huabo Biopharm (members of Huahai Pharm), leads its global biotherapeutic research.Prior to join Huahai, he worked at Boehringer Ingelheim for more than 8 years in different function areas at multiple locations (Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led andengaged inover 20 global BI biological research projects including current clinic Phase I-III projects and market products; Dr. Zhu obtained his PhDin microbiology and immunology fromtheUniversity of Illinois at Chicagoand has authored more than 20 publications in peer-reviewed journals.

彭思颖, 哈佛医学院附属免疫疾病研究所博士后。北京市省部级人才、“高聚工程”、“亦麒麟”人才,“科技新星计划”入选者，现任北京艾德摩生物技术有限公司总裁兼任首席科学家，专业擅长肿瘤转化医学及实验动物学。带领团队成功研发出免疫重建人源化动物模型构建技术, 人源化异种移植（PDX）小鼠模型构建技术以及创新型肿瘤药物临床前评价平台。

Dr. Wen Luo has over 20 years of experience in biomedical research and industry including more than 15 years of experience in applying genomic technology in drug discovery and development. Prior to founding Denovo Biopharma, Dr. Luo managed the genomic group and provided bioinformatic support to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was a senior scientist for bioinformatics at Incyte Genomics, where he managed one of the largest proteomic databases, LifePro. He was also involved in discovering novel human genes and splice variants, and was the co-inventor of patents covering hundreds of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen, which had been acquired by Pharmacia, where he worked on drug target identification and validation for a number of novel kinases discovered at Sugen. Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at the University of California, San Francisco, and received his Ph.D. in Molecular Biology and Biochemistry from Indiana University School of Medicine. Dr. Luo received pre-med training at Peking University and medical training at Peking Union Medical College.

任科，现任上海药明康德新药开发有限公司副总裁，SMO事业部津石医药总经理，在生物医药研发领域拥有19年相关经验。他在阿斯利康、PPD、西斯比亚等跨国药企、CRO、SMO工作多年，从事新药临床研究相关的战略发展，运营管理，业务拓展等专业工作，在肿瘤、呼吸、心血管、内分泌、感染、消化、神经内科等参与过上百项创新药的I-III期临床研究工作，在相关专业杂志发表十余篇文章并在药物临床试验机构联盟和DIA等多个学术机构担任学术职务。 任科领导着目前中国最大的临床研究执行团队，在全国142个城市有3000多专业的研究人员，与上千家研究中心进行了超过1000项临床研究项目的实施，在过去4年已经帮助50多个产品顺利通过药监局核查上市，通过率100%，其中包括中国首个PD-1产品的上市，中国首款宫颈癌疫苗的上市，中国研发的首个欧盟批准上市的生物类似物上市，中国首个以真实世界数据支持的医疗器械产品上市等突破性项目的成功实施。他还带领团队建立了行业里非常领先的CTMS数据中台，整合了全公司所有的项目、人员、医院信息、财务、商务、HR等板块业务流和数据流的一体化平台，积累了大量临床研究操作执行的第一手数据，为行业赋能，并因此获得上海市发改委现代服务业资助项目一等奖。

Dr. Li is the founder, Chairman and CEO of HitGen Inc., and also a Fellow of the Royal Society of Chemistry and a Guest Professor of Sichuan University, etc. Dr. Li has over 30 years biopharmaceutical experience (at Protherics, AstraZeneca, HitGen), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Dr. Li held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca, which included molecular design, synthesis and screening. Dr. Li has published more than 30 papers and 20 authorized patents.
Since its foundation in 2012, HitGen has developed into one of the most influential companies in the field of novel drug discovery research centered on DNA Encoded Chemical Libraries (DELs). HitGen has established extensive international R&D collaboration and its own new drug pipelines. HitGen (688222.SH) became a listed company on the Science and Technology Innovation Board in Shanghai Stock Exchange on April 16, 2020.

邓天敬博士，保诺科技中国区首席执行官，清华大学医学院客座教授。
美国马凯特大学（Marquette University）生物分析化学博士，曾参与了多个药物在美国FDA的申报，作为美国 FDA主导的制药行业产品质量研究院（PQRI）的 药品包装萃取物和渗透物（ extractable/leachable）专家组成员 ，为 FDA起草了全球第一份药品包装萃取物和渗透物指南性文件。作为保诺科技中国区的领导人，邓博士成功带领上海研发团队在2015年实现上海分公司业绩500%的增长。

Hequn Yin is currently CSO of Fosun Pharma. Prior to joining Fosun, Hequn was a VP of Pfizer Oncology R&D in California, USA. Before Pfizer, he spent nearly 20 years with Novartis in New Jersey, USA where he held positions of increasing responsibility from a Sr scientist to an Executive Director. Hequn also worked at Hoffmann-La Roche in New Jersey during 1997-98.
Hequn received a B.S. in chemistry from Peking (Beijing) University in 1985 and a M.S. from the Chinese Academy of Sciences in 1988. He earned a PhD degree in pharmacology from the University of Rochester, USA in 1995. Subsequently he conducted post-doctoral research in molecular biology & biochemistry at UC San Francisco, USA between 1995 and 1997. He also attend the eMBA program at Fairleigh Dickinson University in New Jersey.

Jonathan Wang is our head of business development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking. Mr. Wang received a master of business administration in healthcare management from Wharton Business School.

Dr. Feng Bian is a Senior Director and Asia Emerging Science Lead in Pfizer Asia Discovery Labs (ADL) of Pfizer’s Worldwide Research and Development. She is responsible for cultivating strong and in-depth scientific relationships with Asia Academic and Life Science Communities with a primary focus on southern China regions to access emerging sciences, promising compounds, and breakthrough technologies.
Prior to ADL, Dr. Bian was a senior investigator in China Novartis Institutes for Biomedical Research and group head of liver pharmacology since 2014 in Shanghai. At Novartis, she was a project leader and managed liver disease pharmacology platform to deliver data packages for drug discovery projects. Before Novartis, she was a key scientist participated in setting up JnJ China research labs in 2012, and Associate Director of Biology to manage CROs and academic collaborations as well as internal R&D programs. Dr. Bian began her R&D career in Parke-Davis/Warner-Lambert in US as an in vivo pharmacologist in the Neuroscience Division, and later became a principle scientist in Pfizer’s Neurodegeneration and Psychotherapeutics Unit, contributing to programs like Lyrica®, discovery programs for Alzheimer’s disease, bipolar depression and dermal fibrosis. Dr. Bian has 20 years of expertise in small molecule and biologics drug discovery and her work has enabled NMEs to reach first in human. Dr. Bian received her Doctorate degree in Biochemistry from The Ohio State University and her Bachelor of Science degree from Nankai University at Tianjin, China.

Max received his BS from Jilin University with honors and earned a CGP national scholarship sponsored by the Chinese government; he obtained his Ph.D. in organic chemistry from Purdue University in 1992, joined Gensia (later became Metabasis) as a medicinal chemist and worked until 2009 with his last position as director of medicinal chemistry. Max then joined Merck as a Senior Investigator in the External Basic Research department, and then from 2011 to 2013, he was Director of External Medicinal Chemistry, Asia Lead, based in Shanghai facilitating Merck-CRO operations; 2013-2016, he was a Principle Scientist in the exploratory chemistry department at the Kenilworth site. In 2016 he joined Eli Lilly as Asia Head, BD and External Innovation for diabetes and CV research and worked until March 2018 before joining Qilu Pharmaceutical as VP, Global Head of BD and External Innovation with responsibilities for all BD and external collaborations globally including in-license, out-license and setting strategies for drug discovery and external collaborations. In June 2019, Max joined CSPC as corporate VP, President of CSPC Shanghai Research Institute, CEO of InnovStone Therapeutics, responsible for small molecule new drug discovery efforts. Max has extensive experiences in business development globally and more than 25-years of experiences as a manager of drug discovery programs spanning from early (Target Selection and Validation, Lead Identification) to late (Lead Optimization and candidate selection) stages; led programs that advanced multiple compounds into human clinic trials (two completed Phase 2b POC studies); experiences in therapeutic areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver fibrosis, anemia, viral and bacterial infections; extensive knowledge of Structure-based Drug Design, Medicinal Chemistry, Drug Delivery, Prodrugs, Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside Chemistry; more than five years of managing drug discovery programs executed at various CROs. His research activities have led to 91 publications and 60 patents.

Dr. Zhou is Chief Executive Officer and co-founder of Eccogene. Prior to founding Eccogene, Dr. Zhou was the head of chemistry at Lilly China R&D Center, where he led project teams to achieve candidate selection milestones for diabetes and diabetic complications. Before joining Lilly in 2012, Dr. Zhou was investigator at GlaxoSmithKline working on drug discovery campaigns utilizing disruptive DEL technology. Dr. Zhou began his career at Tetraphase pharmaceutical, where he co-invented Eravacycline, an FDA approved drug for cIAI. He holds a Ph.D. in chemistry from Brandeis University and received a B.S. in life science from Fudan University.

Dr. Dadong Li is currently a BD & Licensing Manager with Roche Pharma Partnering, based in Shanghai office. He is in charge of BD efforts in China across various therapeutic areas, from preclinical to late stage, and represent both Roche and Genentech. Prior to joining Roche, Dadong was a commercial officer with UK Department for International Trade at British Embassy in Beijing, where his responsibility is to facilitate UK China investment and trade in healthcare sector. Dadong also worked as a management consultant with PwC Management Consulting on strategy for healthcare companies and he has experience with Chinese Academy of Sciences as a junior scientist.
Dadong holds a Ph.D. in Chemistry from New York University, and a Bachelor degree in Materials Chemistry from Peking University.

Dr. Wan is the founder and CEO of Lynk Pharmaceuticals, a VC supported biotech company focusing on oncology, auto-immune and inflammatory diseases. Dr. Wan earned his Ph.D. degree from Boston University, then conducted a postdoctoral research at Harvard University. Before starting Lynk Pharmaceuticals, Dr. Wan served as the Head of Chemistry at JNJ’s Asian Pacific Discovery Center with various cross-function responsibilities. He was one of the key leaders and played an instrumental role of building the Center from its earliest inception. Prior to JNJ, Dr. Wan had worked for Wyeth/later Pfizer for a dozen years and served as a group & project leader as well as a postdoc research advisor.
Dr. Wan has research experiences in multiple therapeutic areas and made significant contributions to the development a number preclinical candidates, clinical compounds and marketed products. Dr. Wan has more than 50 scientific publications in peer-reviewed journals and meeting abstracts; he also has close to 140 world and national patents. Dr. Wan won a number of awards and recognitions; he is an elected Fellow of the Royal Society of the Chemistry (2015), a winner of Young Industrial Investigators Award (ACS, 2008) and a steering committee member of Chemistry in Cancer Research of AACR (2017). Dr. Wan is a co-founder & a member of Board of Directors of Chinese BioMedical Association (CABA) and served as the President (2009- 2010). He is also a member of many prestigious professional organizations such as AACR, BayHelix and ACS.

Dr. Min Li received his PhD in Organic Chemistry from Johns Hopkins University in 1991. Following a postdoctoral research in medicinal chemistry, he had worked for several multinational pharmaceutical companies with increasing responsibilities, including Roche, Merck & Co., Inc. Schering-Plough, and Merck again. Over the years, he has led technical teams of senior-level scientists for various analytical and pharmaceutical manufacturing process investigations and troubleshooting, impurity peak identification, study of drug degradation chemistry, analytical development, and support for new drug filing. Since September 2014, he became Vice President for Analytical Operation at Huahai Pharmaceutical, a leading Chinese pharmaceutical company with operations in both China and US. He also established the Center of Excellence for Modern Analytical Technologies (CEMAT), a technical core group created for solving the most challenging technical problems from pharmaceutical R&D to scale-up and commercial production at the company.
Dr. Li is a leading expert in drug degradation chemistry and he published a single-authored book, “Organic Chemistry of Drug Degradation” (by Royal Society of Chemistry) in 2012; the Chinese translation of this book was published in September 2019. He is the first/communicating author of more than 50 publications in organic, medicinal, bioconjugate, and analytical chemistry (including mass spectrometry). He is currently a member of the expert committee (Chemical Medicines 5) at United States Pharmacopoeia (USP) and a board member of Sino-American Pharmaceutical Professional Association (SAPA).

药学研发专家，具近30年药学开发经验。领导过多个项目的研发团队，将多个新药候选药物推进至临床各个阶段和市场，包括舒尼替尼（Sutent）——由辉瑞研发的新型具重磅炸弹潜力的抗癌药物。吴振平博士于2008年起至今任职和记黄埔医药，负责组建药学和生产部门。公司已经成功将十数个研发药品推向临床研究，包括在中国和美国进行的研究。多个项目已经进入或完成三期临床研究，其中抗癌新药呋喹替尼已经上市。
吴博士曾在位于加州的药物研发公司Phenomix任药学部高级总监。在此之前，他曾担任辉瑞圣地亚哥全球研发中心（前称为Agouron医药公司）药物开发部总监，更早之前在罗氏加州研发中心（Roche Palo Alto）任资深科学家。吴博士于香港大学获得博士学位并在加州大学尔湾分校取得了MBA学位。他曾任中美生物技术和制药协会理事长和会长。2003年，他因舒尼替尼（Sutent）项目获得辉瑞杰出员工奖。他带领的索凡替尼课题组荣获2010年度和记黄埔医药优秀团队奖。

Dr. Guo has been working in the healthcare industry since 1991, including ABC Laboratories, Pfizer, Ascenta Therapeutics, and Ascentage Pharma. At Pfizer (1995-2005) with various technical and management roles, Dr. Guo participated in many NCE drug R&D projects, several of which have successfully reached commercial stages. At Ascenta (2005-2009), Dr. Guo was the founding Vice President of Pharmaceutical Sciences & Manufacturing, and also General Manager of Ascenta (Shanghai) R&D Center which engaged in NCE drug R&D in China from 2005. Dr. Guo played an important role in Ascenta’s >$600M global out-licensing deals (i.e., with Sanofi-Aventis in 2010 and with Debio in 2011). Dr. Guo co-founded Ascentage Pharma in 2009, a globally positioned China innovative NCE drug R&D company, and currently serves as President & COO. The company has quickly built up a pipeline of 8 clinical-stage NCE projects along with several IND-enabling and discovery stage projects, covering oncology and anti-aging / anti-viral therapeutic areas through its apoptosis/PPI platform. During 2002-2005, Dr. Guo served as an Overseas Advisor for Beijing Zhongguangcun Biotech Park in China. He has been an adjunct professor, a faculty and graduate student adviser for the IPEM program at Peking University during 2007-2018. Dr. Guo served as an Independent Board Director at Porton Corporation (Chongqing, China) during 2012-2016, overseeing its successful IPO at Shengzhen Exchange, China, in 2014. As a co-founder and the founding Chairman, Dr. Guo has served on Board of Directors of SABPA (www.sabpa.org). Dr. Guo received his Ph.D. degree in Organic Chemistry at the University of California at San Diego; M.Sc. in Medicinal Chemistry at Institute of Materia Medica, Chinese Academy of Sciences; and B.S. in Chemistry at Peking Normal University.

Dr. Steven Hu currently is the Senior Vice President of Everest Medicines, being responsible for CMC and supply chain. Before he was the Senior Director of CMC in Roche Pharm Research and Development (pRED) Shanghai, heading process research and synthesis, analytical, preformulation and formulation development to support Roche China portfolio. Before joining Roche, Steven was the Director of New Product Development (NPD) of GSK China R&D, overseeing the whole drug product development life cycle from formulation development and optimization, process development and scale-up to technology transfer to commercial manufacturing. Steven had worked in Merck (West Point, PA) and J&J (Spring House, PA) respectively in the United States before coming back China in 2010.
Steven obtained his Ph.D. in Chemical Engineering from Brown University, USA, and then spent about two years at MIT as a Post-doctoral Research Fellow.

肖毅博士于2018年9月加入凯莱英医药集团担任项目研发中心高级副总裁，负责工艺开发，导入提高研发水平和效率的新技术，以及工艺研发与上下游部门间的协调与整合。肖博士1991年获日本名古屋大学博士学位（师从2001年诺贝尔奖得主野依良治教授）、后在美国科罗拉多州立大学L. Hegedus教授研究室进行博士后研究。肖毅博士曾任职于美国默沙东和施贵宝的工艺部门，有超过20年的制药工艺的研发经验，并为施贵宝公司创建了催化剂研究实验室，导入高通量筛选技术和以数据库为基础的工作流程。期间参与了数十个研发项目。已经发表过50篇论文，赢得了包括绿色化学总统奖在内的多个国际大奖，在世界各地发表过40余次的学术讲演，目前是2018年制药化学反应与工艺会议的组委会成员之一，2019年美国有机反应与工艺的Gordon会议的工业界主席。

Dr. Jim Li is chief executive officer of Sundia. In this role, Dr. Li is responsible for the oversight of all business divisions across the organization as well as formulating and driving key strategies for diversifying and growing the company. Dr. Li also leads the company’s executive committee, helping to drive Sundia’s overall global strategy.
Dr. Li has led a distinguished career in the pharmaceutical industry, having spent over 18 years at various companies including Henkel, Wyeth, Pfizer and Wuxi Apptec in the area of process research and medicinal chemistry. During his career, he was involved in numerous drug discovery programs such as COPD, asthma, Rheumatoid/osteoarthritis, and diabetes. Dr. Li has co-authored more than 60 research articles and patents.
Dr. Li received his Ph.D in Organic Chemistry from University of Central Lancashire UK followed by a postdoctoral fellow at the University of Chicago with Dr. Philip Eaton.

Dr. Deepak Hegde completed his Doctorate in Biopharmaceutics and Pharmacokinetics from University of Mumbai in 1996. He also completed his Masters in Financial Management (M.F.M) from University of Mumbai in 2000.
He is currently working with EOC Pharma as Chief Technology Officer, responsible for development and manufacturing of new speciality anti cancer products for China. Prior to joining EOC, he was with GSK Shanghai, R & D China as Director, Global External Development & Supply, AsiaPacific, responsible for developing drug products for GSK global portfolio and for introduction of new products to China. Prior to this he worked with Wuxi AppTec as Vice President for Formulation Development. At WuXi Apptec, he was instrumental in setting up the Formulation Development Business as well as the formulation team, GMP facilities and systems which have since been approved by the EMA, USFDA and CFDA. While working with several multinational companies from US and Europe, he helped develop more than 150 NCE’s. He established several enabling technologies like Microdozing, Nanonization, Spray Drying, and Holt Melt Extrusion (HME) etc. at WuXi AppTec which helped customers expedite the First in Man (FIM) studies in US, Europe, Australia, Korea & China. Prior to joining WuXi AppTec in Shanghai, he has worked at several positions across Rhone Poulenc, Sandoz (A Novartis Group Company) and USV Ltd, a premier Indian Generic Company.
He has extensive experience in generic formulation development of solid and liquid oral and injectible formulations from a very early phase of development all the way to technical transfers to commercial manufacturing sites. At Sandoz, he worked on formulation development for the regulated markets like US and Europe and participated in technical transfers to commercial sites of Sandoz at Rolab in South Africa, and Novartis Bangladesh and Novartis Pakistan. Several generic products that he developed have since been registered and commercially launched in Europe, USA, South Africa and Asia. He is a life member of the Indian Pharmaceutical Association. He has two US patents, five PCT and US patent applications and several National and International publications to his credit.

Dr. Ma obtained his Ph.D. from Shanghai Jiao Tong University, and went on with organocatalyst research in NTU as a postdoctor. He has 10 more years of experience of drug R&D and management, focus on CMC. Dr. Ma joined HaiHe in mid of 2016, and set up CMC department. He oversees CMC development and DS/DP manufacturing for all HaiHe’s pipeline products

Dr. Shijie Zhang, currently serving as Chief Technology Officer at PharmaBlock, is leading initiative to extend the team’s competence in process development and manufacturing to support clients’ late phase and commercial programs. Dr. Shijie Zhang has 20 years of combined experience in medicinal chemistry, process chemistry, and API manufacturing. Before joining PharmaBlock, he led the CMC API team at Agios for the two FDA-approved therapies (Idhifa®, Tibsovo®), by managing and overseeing API development programs and manufacturing activities spanning from preclinical stage to commercial stage, and preparing API sections of regulatory filing documents, including IND, IMPD, NDA, and briefing documents.

单波博士具有超过17年在欧美，中国的新药和仿制药研发和生产经验。目前是德琪医药负责药物早期研发和生产的副总裁。单波博士曾经带领团队完成共计1个国家一类新药的申报上市，多个处于I-III期临床试验的一类新药，以及一系列临床前的项目开发。单波博士带领团队完成了一个国家一类新药生产基地从设计，土建，装修，设备采购到工艺验证和试生产的全过程，包括两条API生产线，一条固体制剂生产线，并且于2018年通过了国家注册现场和GMP动态核查。
单波博士曾先后担任歌礼药业副总裁，凯惠药业（上海）有限公司常务副总经理，上海睿智化学研究有限公司执行总监，GE Healthcare英国研发中心科学家等职务。单博士具有英国Aston大学药物化学博士学位。

1990年~1995年 沈阳药科大学 日语药学专业本科毕业
1995年~1998年 沈阳药科大学 药物分析专业硕士研究生毕业
1998年~至今 上海市食品药品检验所工作 专业职称：副主任药师
主要从事化学药品的仿制药复核、药典起草、进口药品质量标准复核、现场考核和质量标准制订等工作。
2003年8月 ~ 2004年2月
赴日本国立医药品食品卫生研究所（即国家药品检验所）药品部进修。
详细了解了发达国家对于药品的审评要点与技术要求；师从《日本药品品质再评价工程（即仿制药质量一致性评价）》“总设计师”系统学习了实施细节与技术应用，掌握了“如何采用多条特征溶出曲线评价口服固体制剂品质”方法与手段，深刻了解了溶出度试验对于仿制药的重大意义和举足轻重的作用，以及发达国家如何提高和控制药品内在品质的具体措施与手段。
截止目前，发表了80多篇药品品质评价方法的思路类文章，尤多篇溶出度和有关物质研究文章引起业内瞩目。
2007年1月 曾担任国家发改委价格司药品价格处顾问。
2008年起~至今 担任国家药品监督局高级培训学院、全国医药技术市场协会等“化学药品质量研究”授课教师。
2009年1月、在国内知名的药学网站——丁香园创立“溶出度研究”专栏，登载了撰写的10多万字相关内容。
2009年~2012年 任国家食品药品监督管理局市场监督办公室专家顾问 负责指导“全国评价性抽验工作”，并首次全面引入了“如何利用体外多条溶出曲线评价口服固体制剂内在品质”的作法，发现了部分国产上市品体外多条溶出曲线与原研品的显著性差异，从而为临床疗效和毒副作用上的差距提供了佐证，为2012年初国家推出“仿制药质量与疗效一致性评价工作”奠定了基础。
2010年 曾担任国家药品审评中心顾问，主持编译了《日本橙皮书——多条溶出曲线数据库》和《日本仿制药生物等效性试验系列指导原则》等。
2012年6月~2013年10月 担任《国家仿制药一致性评价项目》办公室专家，参与起草了《如何测定原研制剂多条特征溶出曲线指导原则》、《如何进行仿制品与原研品多条溶出曲线比较指导原则》和具体品种比较法。
2013年12月 在国内知名药学网站——丁香园创立“杂质研究与品质评价”专栏，登载了撰写的10多万字相关内容。截止目前，溶出度专栏和杂质专栏的内容已成为国内研发人员的《必读手册》。
担任《中国医药工业杂志》、《药品评价（医院药学版）杂志》编委

Shih-Ying joined Dizal at January 2019 as the CMC head for API and drug products development, Clinical manufacturing, and supply chain management. Before coming back to Shanghai, he has worked in Pharmaceutical Development in Bristol-Myers Squibb at New Brunswick New Jersey for 13 years. During the tenure in BMS, he has worked on more than 40 different new chemical entities including Brivanib and Cabozentinib in the oncology area, contributed more than 5 NDA dossiers preparation, especially as the author of the Module 3 QbD sections for Onglyza, which was approved as the first QbD-based NDA filings. Other approved NDAs that he has participated including Sprycel, Kombiglyza, Reyataz, and Daclatasvir. After coming back to Shanghai to join Hutchison MediPharma as the Executive Director of Formulation at 2015, he has contributed to Fruquintinib NDA approval in CFDA. He has also served as the CMC project lead to collaborate with AstraZeneca for the joint global development of Savolitib. In Hutchison he successfully finished two bio-equivalency studies to facilitate formulation changes during pivotal trials.

Dr. Jin She is Senior Vice President of Chemistry Manufacturing & Control department at Hua Medicine (Shanghai) Ltd. Dr. She has over 16 years’ of experience in the biotechnology and pharmaceutical industry. Prior to Hua Medicine, he worked at MSD R&D Center (China) as Director of Process Chemistry, and Roche R&D Center (China) as Head of Process Research & Synthesis. Before returning back to China from the US, he worked at Inspire Pharmaceuticals Inc. as Sr. Research Scientist and team leader of Process Research. Dr. She has also been an Industrial Advisor for Engineering Master Program at East China Science & Technology University for the last 8 years. Dr. She Received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill. He obtained his BS and MS degrees in chemistry from Beijing University.s

Dr. Feng is currently Vice President and head of CMC of Laekna Therapeutics. He oversees CMC development and manufacturing for all Laekna’s pipeline products. Dr. Feng has more than sixteen years’ experience in new drug research and development including preclinical development, early phase and late phase product development, clinical manufacturing and process validation towards commercialization. He has led the technical transfer, clinical manufacturing, and process validation of various products, including successful approval and commercial launch of Niraparib in China. Prior to Laekna, Dr. Feng has held various management roles in Zai Lab, WuXi Apptec, and Schering Plough in US. Dr. Feng received his PhD from Purdue University.

Dr. Zhixuan Wang is as project CMC operation management role in Integrated CMC New Product Program department at Sanofi China. She Holds Master degree from Peking University and Ph.D from Shenyang Pharmaceutical University. She started her career in drug product development in North China Pharmaceutical Group Corporation. In 2006 she joined in Chinese Academy of Sciences and working on transdermal drug delivery system research work. In 2007, she joined Novartis China as Senior Scientist in Chemical and Pharmaceutical Profiling, Novartis Institutes for Biomedical Research Co., Ltd, and followed GSK R&D China in 2011. Zhixuan has worked on a wide variety of Discovery & Development projects, her role includes compound developability assessment, physical form selection, formulation development, drug product manufacture and clinical supply, CTA/NDA submission and new product launch. She is also involved in Innovative drug delivery system research and development work. Dr. Wang has published ~ 30 papers and patents. Zhixuan has contributed chapters to “Liposome Technology” and “Novel technologies of microencapsulation and the application in DDS”.

胡楠 博士，毕业于浙江大学化学系。长期从事有机分析研究，对反应机理、食品及药品检测、代谢物研究等均有较深入的理解，在国外知名质谱和化学相关期刊发表论文10余篇。现为安捷伦LC-MS应用科学家，负责液质类仪器的应用技术支持。

王立坤博士在2018年创立海维医药科技，专注于药物稳定性预测、成药性研究。王博士曾先后任职于Johnson & Johnson Pharmaceutical Research & Development 比利时研发中心，恒瑞医药南京研发中心，曾经成功领导过了多个重磅小分子创新药早期开发、改良型制剂的研发工作。王博士在主持过的研究项目中申请超过20件专利、并在多个国际一流药学期刊学术会议上发表文献。